var title_f10_28_10688="Cryoretinopexy spots";
var content_f10_28_10688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryoretinopexy spots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cryoretinopexy probe is applied underneath the retinal break, freezing through the sclera, choroid, and retina. A number of cryoretinopexy spots are created in order to continuously surround the retinal break.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wilkinson CP, Rice TA. Mitchel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright &copy; Charles P Wilkinson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10688=[""].join("\n");
var outline_f10_28_10688=null;
var title_f10_28_10689="Sartorius muscle flap";
var content_f10_28_10689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sartorius muscle flap for radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sartorius muscle is sutured to the inguinal ligament and over the femoral vessels at the end of the groin node dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10689=[""].join("\n");
var outline_f10_28_10689=null;
var title_f10_28_10690="Applying upper arm brace";
var content_f10_28_10690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Applying an upper arm functional brace",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a commercially available upper arm functional brace being applied to immobilize a healing fracture of the shaft of the humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10690=[""].join("\n");
var outline_f10_28_10690=null;
var title_f10_28_10691="Mafenide: Pediatric drug information";
var content_f10_28_10691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mafenide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=see_link\">",
"    see \"Mafenide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/41/38548?source=see_link\">",
"    see \"Mafenide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sulfamylon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=see_link\">",
"      see \"Mafenide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;3 months and Adults: Topical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: Apply once or twice daily; apply to a thickness of approximately 16 mm; the burned area should be covered with cream at all times",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: Irrigate dressing every 4 hours or as needed to keep gauze moistened",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfamylon&reg;: 85 mg/g (56.7 g, 113.4 g, 453.6 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, topical, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfamylon&reg;: 50 g/packet (5s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: Apply to cleansed, debrided, burned area with a sterile-gloved hand",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: Reconstitute 50 g powder by adding to 1 liter sterile water or 1 liter NS for irrigation; mix until completely dissolved; filter solution through a 0.22 micron filter before use; cover area with gauze and the dressing wetted with mafenide solution; wound dressing may be left undisturbed for up to 5 days",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prepared topical solution is stable for 48 hours at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the treatment of second and third degree burns to prevent septicemia caused by susceptible organisms such as",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, maceration, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperchloremia, metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (following accidental ingestion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding, bone marrow suppression, DIC, eosinophilia, hemolytic anemia, porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Blisters, burning sensation, excoriation, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, hyperventilation, pCO",
"     <sub>",
"      2",
"     </sub>",
"     decreased, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mafenide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment and in patients with G-6-PD deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Superinfection with nonsusceptible organisms has occurred in burn wounds treated with mafenide; some products contain sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4302933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies using an oral preparation. Safety and efficacy have not been established in pregnant women. The manufacturer does not recommended use in women of childbearing potential unless the burn area covers &gt;20% of the total body surface or when benefits of treatment outweigh possible risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acid base balance, improvement of wound healing",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cellular metabolism and bacterial folic acid synthesis through competitive inhibition of para-aminobenzoic acid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Diffuses through devascularized areas and is rapidly absorbed from burned surface",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To para-carboxybenzene sulfonamide which is a carbonic anhydrase inhibitor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Topical: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/41/38548?source=see_link\">",
"      see \"Mafenide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if rash, blisters, or swelling appear",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12567 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10691=[""].join("\n");
var outline_f10_28_10691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190673\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048382\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048375\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190660\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190646\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048385\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048377\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048384\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190691\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048388\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048374\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048373\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299625\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190654\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190656\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302933\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048381\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048372\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048387\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048379\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=related_link\">",
"      Mafenide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/41/38548?source=related_link\">",
"      Mafenide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_28_10692="Pathogenesis of metabolic alkalosis";
var content_f10_28_10692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of metabolic alkalosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10692/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10692/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10692/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10692/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10692/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10692/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/28/10692/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic alkalosis is a relatively common clinical problem that is most often induced by diuretic therapy or the loss of gastric secretions due to vomiting (which may be surreptitious) or nasogastric suction.",
"   </p>",
"   <p>",
"    The pathogenesis of metabolic alkalosis will be reviewed here. The causes and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and subsequent maintenance of metabolic alkalosis requires two separate abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevation in the plasma bicarbonate concentration due to hydrogen loss in the urine or gastrointestinal tract, hydrogen movement into the cells, the administration of bicarbonate, or volume contraction around a relatively constant amount of extracellular bicarbonate (called a contraction alkalosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"       \"Causes of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A decrease in net renal bicarbonate excretion (due both to enhanced reabsorption and reduced secretion), since rapid excretion of the excess bicarbonate (primarily as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      ) would normally correct the alkalosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/1,4\">",
"       1,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are three major factors responsible for the rise in net bicarbonate reabsorption in metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In the absence of advanced renal failure, one or more of these factors must be present to sustain the high plasma bicarbonate concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective circulating volume depletion, including reduced tissue perfusion in edematous states such as congestive heart failure and cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"       \"Pathogenesis of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chloride depletion and hypochloremia.",
"     </li>",
"     <li>",
"      Hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Understanding the mechanism by which these factors enhance bicarbonate transport is essential for the appropriate approach to therapy. Correction of the alkalosis can usually be achieved by the administration of sodium chloride or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , thereby allowing the excess bicarbonate to be excreted in the urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTIVE VOLUME DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the fall in glomerular filtration rate and the associated sodium avidity seen with hypovolemia minimize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, the ingestion of a very low sodium diet (10",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    can raise bicarbonate reabsorptive capacity from 25 up to 29",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    even though the patient is clinically euvolemic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/6\">",
"     6",
"    </a>",
"    ]. More marked reductions in tissue perfusion can increase bicarbonate reabsorptive capacity above 35",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    thereby allowing the maintenance of a relatively severe metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental studies suggest that most of the increase in net bicarbonate reabsorption occurs in the collecting tubules, in part under the influence of secondary hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The following factors contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone directly enhances acidification by increasing the activity of the H-ATPase pumps in the luminal membrane of the intercalated cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/10\">",
"       10",
"      </a>",
"      ]. This pump promotes the secretion of hydrogen ions into the tubular lumen, thereby increasing the reabsorption of bicarbonate.",
"     </li>",
"     <li>",
"      Aldosterone-stimulated sodium reabsorption in the adjacent principal cells makes the lumen electronegative due to the loss of cationic sodium. This potential minimizes the passive back-diffusion of hydrogen ions out of the lumen, allowing the urine to become much more acid than the plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased chloride delivery diminishes bicarbonate secretion in the type B intercalated cells, which is thought to be an important component of the normal renal response to a bicarbonate load (see next section) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHLORIDE DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting and diuretic therapy are associated with both hydrogen and chloride loss. The hypochloremia can contribute to the reduction in bicarbonate excretion by increasing distal reabsorption and reducing distal secretion; this effect of chloride may be more important than the associated volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/7-9,12,13\">",
"     7-9,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bicarbonate reabsorption in the outer medullary collecting tubule and in the",
"    <strong>",
"     type A",
"    </strong>",
"    intercalated cell in the cortical collecting tubule is mediated by hydrogen secretion via H-ATPase pumps in the luminal membrane; passive cosecretion of chloride is required to maintain electroneutrality, while intracellular bicarbonate is returned to the systemic circulation via",
"    <span class=\"nowrap\">",
"     Cl/HCO3",
"    </span>",
"    exchangers in the basolateral membrane (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/14\">",
"     14",
"    </a>",
"    ]. A decline in the tubular fluid chloride concentration will promote both chloride and hydrogen secretion.",
"   </p>",
"   <p>",
"    In contrast, the",
"    <strong>",
"     type B",
"    </strong>",
"    intercalated cells in the cortical collecting tubule are able to directly",
"    <strong>",
"     secrete bicarbonate",
"    </strong>",
"    by reversing the location of the transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     Cl/HCO3",
"    </span>",
"    exchangers are now located in the luminal membrane, leading to bicarbonate secretion into the tubular lumen, and the H-ATPase pumps are now located in the basolateral membrane (",
"    <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"     figure 2",
"    </a>",
"    ). The activity of these cells is appropriately enhanced by alkalemia in an attempt to excrete the excess bicarbonate. However, the associated fall in the tubular chloride concentration will diminish the favorable inward gradient for chloride, thereby reducing bicarbonate secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HYPOKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia directly increases bicarbonate reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef82488 \" href=\"UTD.htm?42/0/43020\">",
"     figure 3",
"    </a>",
"    ). How this occurs is incompletely understood, but at least two different mechanisms may contribute. First, the fall in the plasma potassium concentration leads to a transcellular cation exchange: potassium moves out of the cells to partially replete the extracellular stores and electroneutrality is maintained in part by the entry of extracellular hydrogen into the cells (",
"    <a class=\"graphic graphic_figure graphicRef60830 \" href=\"UTD.htm?3/29/3548\">",
"     figure 4",
"    </a>",
"    ). The ensuing intracellular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/16\">",
"     16",
"    </a>",
"    ] can then stimulate hydrogen secretion and bicarbonate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/17\">",
"     17",
"    </a>",
"    ]. The movement of hydrogen into the cells also contributes to the alkalosis by raising the plasma bicarbonate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, some of distal hydrogen secretion is mediated by H-K-ATPase exchange pumps in the luminal membrane that actively reabsorb potassium as well as secreting hydrogen (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The activity of these transporters is appropriately stimulated by potassium depletion, thereby leading to a parallel increase in hydrogen secretion. The net result is that hypokalemia and aldosterone, which stimulate the H-K-ATPase and H-ATPase pumps, respectively, can have a potentiating effect on distal hydrogen secretion and therefore on the development and maintenance of metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This synergism has potential clinical importance, since the major causes of metabolic alkalosis (diuretic therapy, vomiting, and primary hyperaldosteronism) are associated with both hypokalemia and increased aldosterone release. Potassium and aldosterone are particularly important in primary hyperaldosteronism, since these patients are mildly volume expanded and therefore neither volume nor chloride depletion contributes to maintenance of the alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, severe hypokalemia (plasma potassium concentration usually below 2",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    may enhance bicarbonate reabsorption by an additional mechanism. Via an unknown mechanism, distal chloride reabsorption is diminished in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/21\">",
"     21",
"    </a>",
"    ]. As a result, sodium reabsorption is associated with a greater than usual degree of luminal negativity, since this gradient is usually dissipated in part by chloride reabsorption. The enhanced electrical gradient can promote hydrogen secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10692/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 551-558.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/2\">",
"      Galla JH. Metabolic alkalosis. J Am Soc Nephrol 2000; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/3\">",
"      Laski ME, Sabatini S. Metabolic alkalosis, bedside and bench. Semin Nephrol 2006; 26:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/4\">",
"      Sabatini S, Kurtzman NA. The maintenance of metabolic alkalosis: factors which decrease bicarbonate excretion. Kidney Int 1984; 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/5\">",
"      Berger BE, Cogan MG, Sebastian A. Reduced glomerular filtration and enhanced bicarbonate reabsorption maintain metabolic alkalosis in humans. Kidney Int 1984; 26:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/6\">",
"      Cogan MG, Carneiro AV, Tatsuno J, et al. Normal diet NaCl variation can affect the renal set-point for plasma pH-(HCO3-) maintenance. J Am Soc Nephrol 1990; 1:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/7\">",
"      Galla JH, Bonduris DN, Luke RG. Effects of chloride and extracellular fluid volume on bicarbonate reabsorption along the nephron in metabolic alkalosis in the rat. Reassessment of the classical hypothesis of the pathogenesis of metabolic alkalosis. J Clin Invest 1987; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/8\">",
"      Wesson DE. Augmented bicarbonate reabsorption by both the proximal and distal nephron maintains chloride-deplete metabolic alkalosis in rats. J Clin Invest 1989; 84:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/9\">",
"      Galla JH, Gifford JD, Luke RG, Rome L. Adaptations to chloride-depletion alkalosis. Am J Physiol 1991; 261:R771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/10\">",
"      Khadouri C, Marsy S, Barlet-Bas C, Doucet A. Short-term effect of aldosterone on NEM-sensitive ATPase in rat collecting tubule. Am J Physiol 1989; 257:F177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/11\">",
"      Harrington JT, Hulter HN, Cohen JJ, Madias NE. Mineralocorticoid-stimulated renal acidification: the critical role of dietary sodium. Kidney Int 1986; 30:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/12\">",
"      Schuster VL. Cortical collecting duct bicarbonate secretion. Kidney Int Suppl 1991; 33:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/13\">",
"      Levine DZ, Iacovitti M, Harrison V. Bicarbonate secretion in vivo by rat distal tubules during alkalosis induced by dietary chloride restriction and alkali loading. J Clin Invest 1991; 87:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/14\">",
"      Stone DK, Xie XS. Proton translocating ATPases: issues in structure and function. Kidney Int 1988; 33:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/15\">",
"      Bastani B, Purcell H, Hemken P, et al. Expression and distribution of renal vacuolar proton-translocating adenosine triphosphatase in response to chronic acid and alkali loads in the rat. J Clin Invest 1991; 88:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/16\">",
"      Adam WR, Koretsky AP, Weiner MW. 31P-NMR in vivo measurement of renal intracellular pH: effects of acidosis and K+ depletion in rats. Am J Physiol 1986; 251:F904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/17\">",
"      Capasso G, Jaeger P, Giebisch G, et al. Renal bicarbonate reabsorption in the rat. II. Distal tubule load dependence and effect of hypokalemia. J Clin Invest 1987; 80:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/18\">",
"      Wingo CS, Smolka AJ. Function and structure of H-K-ATPase in the kidney. Am J Physiol 1995; 269:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/19\">",
"      Cheval L, Barlet-Bas C, Khadouri C, et al. K(+)-ATPase-mediated Rb+ transport in rat collecting tubule: modulation during K+ deprivation. Am J Physiol 1991; 260:F800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/20\">",
"      Eiam-Ong S, Kurtzman NA, Sabatini S. Regulation of collecting tubule adenosine triphosphatases by aldosterone and potassium. J Clin Invest 1993; 91:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10692/abstract/21\">",
"      Hulter HN, Sigala JF, Sebastian A. K+ deprivation potentiates the renal alkalosis-producing effect of mineralocorticoid. Am J Physiol 1978; 235:F298.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2330 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10692=[""].join("\n");
var outline_f10_28_10692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTIVE VOLUME DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHLORIDE DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HYPOKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2330|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 1\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17917\" title=\"figure 2\">",
"      Distal HCO3 secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/0/43020\" title=\"figure 3\">",
"      HCO3 reabsorption plasma K",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/29/3548\" title=\"figure 4\">",
"      Transcellular cation exchange",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_28_10693="Negative remodeling IVUS";
var content_f10_28_10693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of negative remodeling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravascular ultrasound images of the proximal reference and lesion site are shown. The remodeling ratio (EEM area lesion/EEM area proximal reference) is 0.71. EEM, external elastic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Schoenhagen P, Ziada KM, Vince DG, et al. J Am Coll Cardiol 2001; 38:297. Copyright &copy; 2001 American College of Cardiology.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10693=[""].join("\n");
var outline_f10_28_10693=null;
var title_f10_28_10694="Meibomian gland dysfunction";
var content_f10_28_10694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78680%7EDERM%2F58040%7EDERM%2F66750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78680%7EDERM%2F58040%7EDERM%2F66750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5X61JGfl2ke9MHSnrmmIcKcBSAVMqk0ikiKRcoeKhPGK07aNXlVHYKrcE+gqk8JDyKvzBD1HpQtRS0YrAuCR2GahH3foa04Yl8ltvde9UNhCGhCvfUvzxiTSlk5ypUfpVB3LBfYAVZdx9hjHOTxxSW1vvUs3XOAPWhbD6scttmzkkx8w5pNOjJmzj5a1IY90QhHVhjFP0/TpWmmto1PnINyjue9RzaO5bjZoi1CNYYCw4NUrIFsMnart4fNtyr8OOMelQ6fGYo5CegBpJtRHJXkH2ZZYJmB561Fa2iTabM7yBXjPyr61PZs3lRxhdzyMevpRFCy3M8DgBlOMVSlbciUW0rFhEVNMtyvfr9c1ZtsQlj2wTSCP/AEFY88q1O1RPKgyCclMVla7sa3srkHg1M30zkdVrtYITIelc34OtGwzkZyMV6BZ2h2AbTUzfvMcF7pn/AGT5eKgW1Md8jn7sg2N/Suph09mA461LLpBMeCvX26Gkn0NN9Dh/B+nu0t3BsIxKa1Nd8NnU/CJCJmeEM6YHPBORXX+FdGNo9w7j5nbOa6HSbNRZDIyA7j/x41d3zc3mY20sec/Dacavon2edVa4tj5UikZJHY1pPos2iXrXNqjPYs372IDJTPce1VL6yPgnxzHfxqV0q++V/Rc/4GvUoIY7rbIMNGw4I/iFKS5XZbCjqrPoYOnRxXMSyREMh5BFcH8WvBjSwjXNPi+eMjzwo59mr1Q6CsEhlsG8tjyYz90/4VZQSCBoru1LIwKsB8ysO9XB8rJkro8U8QTLr3w+jW7UG8gKyRzdRKvQ8+vqPasbw/Pf2emf2ZNn7OHDIT/AD1/Cu8utJPhye9ia2e58O3LbyuMtAx7j/PNaSaBbS6ZBd6eFkTYcb+RIp6j61b0SiZJPqcl8TfCUM2h2N3ZbTPAm2Qr/ABDqDXmly161lBHKzs0B/cseq+1e86f4bkviiwSypbY5RzkD2qrrvgO0s7CV/OG7qqkd6FLRIfLd3PPNR15p47e6smeG+mjVLhBwpIGCfx61o6Z4Qm1DTJbmbAcjK7u5rfsfh3eTael3Eq7zyFJwa1IfDGvXASGWZkjAxgcD9Khy2SKUep5Xc6NcGVkK58vrgV0mk+E7ye2gnig3QMeqjkmvWNE8I21hC63KiaVxhifSrKeH3sd39m3bRxnnyZBvUH27ipcrvQtRsc3b2Go6Tax+WGvbcL80Q4lj/wB3+8PbrV+yu7e7tjJC4YqcOp4ZD6EdRWjNDqeNqRwMfUMRVC90Ga7mE92yRTAY8yHhiPQnv+NQapPYzdQf7Q6wW/zSk4JHam2NhHY38tseWlUToxHU9GH8j+NaFtp15pQIjiW7i/vp8sg+oPB/A02a5hlkilUkSQHLI4KsFPDDB/P8KTZSRzGq6XP4fvpdZ0eEy2knN9ZL3H/PRB6jvWb4qszcpa+LvDLiW4t1zKif8t4u4I9QOCP8K9KEeBleDXJ3ujXOkXsmoeH13QSNuu7DoH9Wj9G9u9NSD2ZQtoNM8SaZDqEEfySqRuU4ZT3RvXHvXnHivwzJ4cuEvrJpDb7shgv+rb8OldaLiHw5fnVtLJk8OXz7bu3A+a0l/vbe3+fauwuIILu0Ktsntp0z6q6noaFLk9A5FU9TyabS5dXtIta01ne4UZZgwyWXqOO9T2cUV89pc7jIkreWysclTjkH0q7dWV14IvnurRXuNEmYean8UR9ax9TdLC/i1vSXEunTyB3jB+63cEdqrWW3yEko7/P/ADMrUrL+wdfUyqzWUxyG9j1/EVs6jYPPbGNXE8ZGVLH5h6EHvWtfxWfiPSnVG56rn70be9ZHhmaQGTS77K3Vv90H+JfapbcteqNFBRdujMiTdLCbPUAY51/1crcZqS0Z2t1eM+ao4Kn7ykfzrpr6whvI/LmXI7HuKwfsUmmXe65QSWjja0ijp6E/1q1ZoGnCV+hSu0ErebCdtxHztPBYelQXASeJLm3IWVT8yHv6iulFnAx3KiMOx61lalYLbyC4hTj/AJaIO/uKcWthVEzGOx1ZAPkb5lH90+lQxszIYnHzL6+lX762Zbdbm3+eM8nHanNEl5CksfyyAZ/+tWlzmdznweMYp/CgHH1pqjmpQOOlUZpDo8Gp1X8M1EseGBWrqAeWpH3s9KTLWgiL0qLySk37sn5uoq0inPIqSNCzE46GknYco81ig5Y3KxqdoUY+tRsCJXjYcE1omwaacOnXPNTXMaW95CJE5ampoUqbTuZfk+TCHk5x0FWbJCrh5D97pWnr9mi2fnr0BGRVUxGaxikQfdGanmTin3DktL0L9jD+98zrzmnJfXOmeJ4btHKFh8r+hq7pkYmtkZBnj9al1CwW4tQGOJQcr7Vz8120+p0uKaTRm6nah5Vk53E8+9VLiMw27oF5YYrXhjlkkhSVeR+tXUtBcSFCmQKtTdryIcLvQxPD1mSVmk6LwoNM15PsmrwXS/6uTAeuoGlvEoMXT0qLU9FkvLFlYfMvzClGS5rvqW6b5LGHdL5VwUA+XORSawBJDEBWnb24uNKZnX97ANpz1xVBkNxLGFB4OK0i+phI7bwRpJbS45NuCxPau3sNPIAyo4qfw5pwg0u2jUYwgzXQ29p3xWEVfU1SsjOhtMDpVv7MvlHdj61oPCsaE4zTUtjIN0hOOwrRKxSV9SvZW+VHpVixhCWW44+8zY/4EavRRqqBVFJFCfsUYPt/Oi+grXkZWtaJDr2lyWl6AqtymByp7GsLwpc3GhTjRdYyAhxbzHoy9hmvQkiGAMfpUGoaVa6jB5d3EGHY9x9KE7qzIkru6EQArkHikyB1qtBo95ZxiO3uBJGOgkHIH1pw029mP7yUIM87aAsQ6hdW5R4JEWRZBgpjOa52z8J3EcUi2MzQWzPvWB+VH0rtbXSILcgld7+rVd2FcDAxT5rbEclzm4INQt4hElpHkcbg3BqNNClurlZtTcMAciMdBXUFe5HNNbqBg/lRcaiV0hVVCqMKOAPSgIACathB1qKZRgDHJNSykiqsfzlj37UyZOw61cC7R0pHj4560h21KLRBF4FUblfmCtnHWtlkqpcqSdoHJpFR3KDpznFZ93brI5UoHBGDkZ4rVMEjcFqPIVB059aRorI5kWJUbI55omHGM7l/I0G3ukHyyQOf9oFc/lmtq4tyzblH41WaFznPFJmll0ON1rQnvXlnijhiuJBskIbKTL6OuOfr1rjdNub/AMI3badqkT/2S7/uJc7hDntnuv8AKvXJ4tik9hWHeW0V2kkVzGssLggqw4IpOWlmUqd9VuZlyiXELI6q8Trgg8hga8u8R+G59EumuNP+ewc5aI8gexFddqEV/wCGZFFq32jSM4xJyYfQE+nvT7rUAWtluk2bnVhn5kZT15HB61UG47bEVEqis9Gjz/S5xZzrHIz2+f8AVyEZC/7Leq+/atHV4vt6xzoRb6pBzE6n5ZB6A966i60SNk32axXEB5MDnp/unt9KxrrTbd0aK1lltphy1vN0P0zWis3cy5ZJcoaFqcep27KyiO7j4li9D6j2q3PGCjI4BVhg1z13pElswu7eV0u052twWHsehqzo+pxXa7L6UpJnAHQNT5baoqNV/DIrR2htrhraOWRG5MTDkMPQ+4qZkuUcGdA2B1A4rYure2lt9qttYcq6nlT2NV7O5aUmKddk6D5vRvcU9zNpJ2OfmTyHkkt9jRvy8Of1ArPhhkWdGtuY5G27R2Ndc9m99PHFawedM52oqpkk+gpt14eeyuStxbvFcRMPNhb5SR3B9DTuYS8jzghd3yZx705BmmgVYjUAD1rVsmKJIl98VaRcVHGvtU6DmoZqkWoUV8CrlrAguXTjBAIqGwhJcMa0vK2yK/Q4xWTfQu1xY7QgkRgKKpavpryRLIpy6GtWOTnmpwQ1RzWdzXkurMyHUXGmNDKTnbkn6VZ8OxQS2JAAbBKEVc2INwCjkEVj+FmNnqF3aScZO5c094PyJcbTV+pfth/Z2oG3IIik5Un1rX+zB2Jf8KbdwR3kWG4cfdb0qC0uJIZPKuOGHRuxpN31KjHl06Ft4EhUOR8w6VNpsO5Wc9TVW4k811jU555rZtVVI1XI6UntYpWuSxR5Bq3bW4demfYU61jDn5RxW3p1iRMMj5TWbZpdHOy+GndZZLXgOPmSsKy0GQarawKhJdvmOOnNezWmnFAAfuGtC10S1SUTJH+8HINaxbtZnNNRYWFkscSqF6AVbEJDYUVeiiO0YHNWY7T+91NNaKwGVLbs8ZBPaks4AV+YE4rRuYiCsa8bu9TW9uqqMdKbL15SukO3oOKWOHMITGOP1q/5XHAp4j47Cgi1inDjGG+93FWAoxzTniB6jp3pFRsY3Clew7X1DYB0zTAQByefSpUVi5BPFSrEB2pXBqxWWRPWkd1LDOfrVkx4PAx60FeMYzTuKyKoZWYgHNIYycEHkVNJCMBlAyKeBhaLhbsQMpxzUOAZAOuKssu489Kidf3wAxgDmkxpAVyKjIKj5uvarBwFyahwHG7qaYkiJwFQselVwhZizDBPT6VPKd7BB0HJpyrkiluVayK0iBR71XdSRVyc+naoJTgZpC2KUmMc1VfoT2qeU5bAqtMuOvA60maRRTu3BG0d6y50UFsVoznqQMVRPHLDoazZvHQzZbYSKyyKGVhhlPIIrkr3SptKieGINLYl98OOTCf7v+7XfMgK7hxUTRbjlunpVR0Bxucx/ZyXdvkxC2m67ozgj8qhu9CSUhGlZ1xyJFDfka6pIxuJAqvdIoTcOtWmwstjh5/D8kZKQXWI/wC4wyP1rGvfCEksbkSQl85+UYya71wZOgOab5IBPNWpMylSjbU818jUrSNE3shAwPMXg/jSQKLyUJczNFOoyrN0H413d86kFAAR0Oaq6dY232ndJBGQevFWpI55Un0O9+FUuieE/Cr65rUayatNKY7FGXIf0ZD06/iMVsyfDm41a01LxD4ouRDLMjzk8jZxkHaOvbjiuKs7y2il0601CEz6TZTealsh2jJOScjvXWfFP4lxaxoX9maLZzNbSAec8pw4weMcnP41UbdDBwknqfIi84qxGOMdagTGKsxVTKiizH0qzDioIxViKoZrFF20l2GrwnDday0GMVet1B9Kxl3Nki0hyeKtJkqM8VBGoz1qzGPyFQywPVeaz9Rs2hu4ryEHI+8BWoFJYVZRQ3ysMg01oOUeZWIbO4jlQMDVt9ki4KhjUSWMOdygqT6Vet7ZUHAOaLis+o2x05A29xyelb1rZIf4T+NQ2seSM9K27KLOMdKTbZNkixp1qN2Aorp7GzAxkdRVGwt8MrY+tdJAgJUCmo3IlIkhQeWoHYVpW0eEyemKhtoPnIPStW1h3IABxVbMSV9RttB/Fjk1bCcdKkEZGABxUoU55GKLha5Rntw+cjn1qLyHiAIJI9K1zGAhPeqqq78hvwpmkSCDDZ4PvUypnOD+lTQw7Mk9T6VJ5IY85B9qkUrdCqyCoWwH2r1PXHarjwAnBJP41G8arjHBFDEkiNEHQCp1UEUiHIBAOKkxnpQiWiNl4xxTNgxipyOMntUExYqcHdnoBQCjchkYEMqAk+tQETKMkKQKtjKjAUgUMBtxRuXoiuCCm6qroxDyBio6gVKYAHwWbHbBqR9qrt7elCDRbFIzfKAfmcjoKjMjgcRmpFEaZYcE00ktyeKEDsJGuAd3LHk09jhc1GWC9+ahkm3cDpT2J31FPTNV5myDUsr4jxuIPqOtUJ5PekNIjbrmqd0+TtzVl3wMg1lXL/vGJNJmqRFPJzgc1GWBQmq1xKVJOeBUfn7o8Z61KRaRcLAIAKrSyEE5qNpQoXLZIqtLcDNOxaRbMowAOlVLqThqikuSQAo4qtJIW+8QKol6Csw25xzVOeZjkLzUrugHzyAD0FQNdRIMKv4mmmQyDyGb5n705AsIyetRz3eeVYCs6a4bJIY8UXJZcurgAEk8VlXV2CCAwxUNxM0h+ZvwqlIuQTmquYyZ5ulWoRzmqiVaiPIFbswiW06VYQcCq6dKsrxioZtFEyHFTxPgjpVdamWspGyRdjkOcnNWoZex61RQ9KsxnHvWbLRcWQhgcVcgfOCKoodwxirFuxU0Io0YjnHNXoFz71RiUnpV6AkAZ4+lAtDVswoAz+tdBp8fzALXO2gHmLn7p/nXT6bGRIu0gr6UGckjqNKtchSRxW2lntdNoqrpIHlqR1roLeIkqxU1pHY59biJZjYGwa04IAEBQdB0qe3i+T7tTWi/OwA4FJrqUnoRqF4xwe4NSeVuU96uiIdxmjYAflGKdmTzIpLGNvH61Abcq25Bx6CtUouTkc1EwC9BxQXGZmMdvY0qNkZFTT4JIqMAKOKDVpWEI4qGUEjKjJqR2PrxQMUhJEUa/Lk96lBxURfDbRwKC2PvD8aSdgaHSDeaibZ0I5/KnGXjg8VWldcepoFYfJIvJJzTDKpHXAqrJMqZyc1X+0DJB5PtRcrl0Lcr7uF/OqrSEHk5qKS4PfgelVJJsEnPFFxWLTMM81DJMADtwB61QlvB03ZPrVd7k854FA+VsttcjJGTk1GZ8ZJIFZs14FOVI+pqo100hwgZz6KM0rofIac95nvVZZ/Mbk5qr9mu5DkqI1/2jzT2iSFSZJCcelLmK5B13dLGvUVjzTs7HAJ+gp11f26H5VHHc1SbURJxu4+uKl1Eaqm0gmWVhhVx9arNHIvV1H41aQPN90Ek1dh0uSVflA57mkm3sJzUDBkuI0z5rMxHZRVG51WBPuxk/wC8a2tY02e1Rj5e4e1cde28hblSvtiolOS3KjJMsya23VVUVVm1k9fLQms+aNkP3R6dKpyI2eSBU+0ZT0L76zITwgFR/wBoSv1FVY7dTy74qGeRYjtjJJPQY5NaRb6mMpF5rpsdTVKbUgBgEE+tRNEzx75Tx6buPxqqQO3Iq+YxepI91I3+yP1NV5rpzlc0jkCqc0yBuW59OtCdzNnML2qxEearpU8ddjMoouJVlD0qpFjFWUPpUM2iWE+tTrVZCR1qZDWcjaKLkQyODVpFIIqhE+GFXYiWHBrPY0SLMeTViNSSOKhhU96vQ4OOxoQWL1sOB9Kvwrk8A1nQPzitO1Y5XkCmiWjQto2K4x2rptDyrKJAdw46Vh2vUV1ehR5Zev5U7GUnpY7DSokfBBANdHAjKADyO1YdkgKAAc9q2reVht3g8d6u1jKKubMB+UArhfWrIVYnyBwetQ2jBk6gj0qeQfKcGna5HWxPgUh6dKbF9wZ5oZsHtTM7ajWJ9KglZsfd4pJZQDUDzrUtnRCD3I5uuMYqFQAeSM02eXf7fWqLvtbg/iD/AEqdToWqLzMtVZ51UgEnFVpZuPvflVSSfqSQKBqNjQe5BHC4HrVdrvjjjHc1my3G4YBJxVVrh8YO3NSyklY1WvQM9SarT3mBx17CslroAnzG/KoJNQRR8ozSDlNKWYty3bmqxvcE+lUd08xz90H1pRa7m+Z3b2FK9ilC5Ze/45NUp7veeWArSi00OP8AVj8eTT1022Q/MoJ9hRzDVKxhK5Z/3SPI5744q1HYXEuDKwjX8zWuNikCGPA9qjeQIMvwT2FTzIrkZSXT7aIb5B5hHd/8KWW4jiQiPaoHTHBpt1djaTkDjuaw7y6Tj5vf1zUSqpbAqZLqOoSDhGwfTPauXu7yRnO5vm+tTanc4AbdyTjOa5+eZnb5VANc8ptmsYImlnld8KN2eBUqQzAbkyR3AqnCroclhnsMdK1Ibk7NzYzj0qYu+45uxbsby5QbQgA963bW6mK5ZtuOa5eTUNhJz+AFNOpyFApbt6V1wnynJOPN0Oh1bVA6soIOOM965W9nVjnI5pssjTHAJz6k4qhJG20sSFUcFiaiTcmEYqJTvDlm5rMnQDk/n6VfvVnQZVWUHozr1HqBWfLGGXe4Muf756fQDilYpsryyKvCyKT/ALOW/QVGCBykTse5cgU53P3QRnsBVZ3yGwSWXqccD2NWvIykSSvJt5WNR6lv/rVSad2JMQD+pH3fzp4HnYMrGRv7vRR+HephEzDAG0EcH0qkZspPE78yycf3U4H+NRmMIMRrj6VqxWhJwoJPpT/s4dGYAKBxirVzNtHnymp4jVdRUsQ5ArtZlAuxkdqmRuODVVR6GrESM7AKCT7VmzdFuMjHJ5qQegqsEdR8ysPwp6uR0NS0bRL6RnHQ1PDIyHms9ZX/ALxqdJW9c1k0apGxBOMCriShiMVhxXDD0qwt054zipKSN+Jh1rRs3G4c1yschzwx/OtG2kJOQ5pjcTu7J0IBLAV2fh8pwQ1eYabKcj5+tdzoE+0APVrc5KkWj0S1kwAf61rW8wKYIH41y1pdjaMEYFX4rwYxnmtbGC0Omsb1UG3IyKvveblwprjvtSgbgRmrEWpDAwRStY0a5tTp4r35cE8j1qGa9O7G/wDKuf8A7QyTljUEl2pPLYFSWoq9zoDcJnJaopLxFHyjJrnpNQRO+apT6scEKc8dBSKUToJ7wnOTgVnzXqg8HJ9qwpLuaToMe5NV3lkPWSpcjWMDXmveuciqr3g7kD05zVVLOaUZPyg92OKlXS8jBkP/AAEVDkaqmMk1EAYUE/Sq0l1cSnCocVq2+nRJ1Usferq268YQAfSp5i1SOaWCaRgHDEntWnZ6XlgzgZHGBWtEqKdqgZ6dOBTsYPPT8qlyNVSI0toowOOvpSjahAVdp9xUqoCMjAGPWkfO0EDk/wAqhyLUUhd25OSAaineMDcew5NR3M4VihOCOfrWbPeeYhB457Vm6liGuw6e825KkexzWfcXnOSxP1FV7k5YncB71V2O/UEmsnNsl2Q69nEqNtO0454rAmYKSrMM9ie1bk9i7x91rC1O0lhXLfMtS20EbMxryKZpCFYFT3FRogjTaSR6mpZZtoA4FZ11OcYRgfakryLeiLImU9DntmoprhhgLmqgc+hU9+KJWAAByG+vStVEybJGuCSAxJ9aR7gZAGQB1z3qOMMRgDPeiSFgm7A9vetEjJkq3QOQFK+5qSG/EBDBQT2yM4rOaGdhuSNio5PaieC5gi866jWJOAFaQB24BGFznBBHOMVcU+iIk0txdVu3uDuc59sVlTkqCRwvrmrE8hZV8t9mR8wIyRVVo4urbnP+1z+lJx11ZPNdaIhjKEMV3t7r/j2qBlYnamEj9F/xqZ5fJyR930qEuZP9Xnn86rm0sieXqyWHZFIuxQx7g9DVpYWZA/y7WJAwwyCPbr3pttB8uWUHHG3HX8a0IbR/Ld3eOIKAVQ5DPnuoxyOK0irmMnYhiiVI+VcSHlWbhCPb1qIMoEmYi0jY2sSQF9eO9Wi5RkMgEioCPLJPTr/Worme1IQRhxkfMpPU+3tVoyZ5tdPA8ubdCq+9MWoVqZeldkmTAmRuKt2t0YHVl6iqI6U9cms3sdMVfQ2G1GR+uCTULylznABqkmRUqkipbZtCCRbU5AqRDiqqMamRu1Zs1SLiFSeasJjtVCN6tRyVnK5ool+F1X7y5q5G4yNoxWWj5xVuDzD0Ump5i+VG/p8p3jmuz0i+CBQWrgLWK4JG1GrasorskYQ1pFmFSnc9Ci1EDJVzzV+DUuOv61xVrbXgAJAH41pwWt1n5mx9BWvOYOmdYmor3I/E0p1FQOGWsGHTp3I3ZP1OK17XS0Vd0kgHt3pOQ1TZL/aDE/Lk0jXErjvVlbMKwChvy4q3HaL3xj/aOKhyNVTMuNJJG5yfarUdo+elaUVuin5VAz1IHX8atLCi8scLU8xooGStjuOWbgdeatx20UXKoC3qameaNDgnJHY01Z2Y4AXn0qXI3jSYeV3PJqaPbt5/OomYLxklieKcN7BsDn0PQ1m5mypku9SMAkn0PFGWbjAA9ajaMqV3kDNKMKB3IP6Vm5lcqRJHGzFQcEepqR0VRgtyfu55qJZ0xhTxVY3gXcBlz2PapciWyeVljBIUc9ao316AAqnHv0qCe5D9GI47cVWMeW5Ynnp61DkZORVurt2bcX4HABrNnvthLHOQcYHFbFxArsV2gEdx3rMvrQ8/vPl9CKxkwjqUrm6YtwVPHqDWhpLB0BJBY9zXP3OICT0AqzpeoxxykKy8+tEHcU4nYm3GzcxGaxtWiiEDsxz6LSNe7UY+dx7GuW17WC+YlYHPoelbSldbGaWpz1zKTcMF65/AVD5QkIIzxxUluMkvICSTzVmNBztwPelBDmyjcJgEZ9wfSqDSEcbuvrW1FEz3ITeqk/3lz+lWH023ifdqlzEtm2dz21uDKPoCwBHrmt4xuYSnboYdjKCcbuPpV2SQbSAduO5pl5b+HI455dH8Q3Uskagpb3enmNpDuxgOrEDjJyQPzrOmunReVG3kblOc471ag15mTqJvt+BNLdxxv5k+ZnAwgLEKv/ARWFez+dc7sfMfSpJmeYEqQV9qqnKyrgZbpgDOazk29HsaRSWpatlIjDFuadLKFQ4AHqxqIzAr8h+YdsdKgYvNJgguzHAUd6taaIhruOsoY7m+hS5Z47Yt88gxkD154q7o0SjzkkiZy3KHIGMdeD1oFsYZDG0iSsoAHlnKjjtVpM/u8sTKT8oB6Htj3rWK5TGcrmnPpk1rO8F1E0U0bbGRhjafenXqoYo4ocSTxp8zABQME9889ufwrU1zxAdbkW6Z1inZUEof523IoXcWwOuOgzXPzXfkxPHhiZP9YwJBfvj6VrojDV7mdfylpn4VXPzbV+VQuPfnNZ0q4fc8n7vHUDv6VpyR28phmvEubWJ32rcgb425xhh1GPUZ+lUta0m7t9kkarNZy/6ueFt8bfiOh9jg1LjfUE+h5+q5qVRzSKtTxxE10tl04DVFTKM9qmjhHpUqwg9qycjrjGxCoqRVzUywHIqzFbsT90mocrG0YXKixk1KkVbNppcsuPkwPU1q22hPnqPyqbt7Giikc5Bas5wqE/hWnb6U5xvBH1FdVaaPKoG3AHqBV5NKbA3tS5e5S8jm7bRwT1JrVt9O8nnKfjWqLBI8bmf86uW8CZH3APcZNK6WxXI2U7WEnjIA9hWnDGsXJBNWooecIrN74xViKyJ68596TkHs7jrSQHH7sH3rVhhdiCSw/TFVIbUxkDAyR61eiR0+8D+dCmHsexajkiRgvLMPQZq5DI38MW33Y5P5CqcRkKndlRjgiprWM7Tulc98AUnMtUF1NSIMAXldz7MoWn74xliwHvnFZ/knAJJbHapFiVgAy8cjGOKlzLVFF9LkIMqAynvVSa7ZnAx14BBqaG3bvnbj16U42aBNy8uOcVHOy4xjF6lRMliDwOuamWJyvA69z0q4sSmEM0eGH8PepQy8Y4BHPFS5A52KnlHja2QOnHSrEBYDD5/GpIUUtz25qSZgBkEYqGzNzvoUriZQME/MOcmqc12C7An6EVHeOHbC8k+lZg3O2BkgcE+/pWXM2S5FmW78o5yQagM+5eAQfany2MjpyQvfmqE8MsONpDD1BpSbJTuWIXllbMWxsD5icEc8VqxQf6PuQ5YgduntXOxyqpAZlBrUh1BY02Dgdz2pRZElqdR/YsAtI3EiM7LnKtyPrXJauqwvIud4A4q22rlIWVZCFPHWuU8QaoqI6KyhiehOTTnJWtYVOLucxrdy3nYjbOT61Stp5eOTj1x3pZwJ2BXOCTVy3tmwAeD6YqaaZtJpIjnu7gxbWlIBHY1mnJxklvw5Nat2oU8AcenP51QuJUTHrnI+lbpGN+wsbdRg8dPSnmUjdu7dMdqZAcpkc96SXaykiRcgZOTwK0jG5hKZDPM3mFkbbnPI71lX08kqlVclTwQalvZQIi0c0bKOeHBqrE7TfdOCRzTb+yJdyqsTLkjHB5rTtW8wKSoI6FfX60NZlUDHH0zVdpGtTkAFfbtVRhykSlcvXVkghZwuCFy+wdPxrW8N+CfEWq2Q1rSNLNzbR7jFM8yRRqy5BbLMM4IPtkVylzqRaFlVzhhhl3YGOuD61nSavctZGweef7EG3iATMI1buQmcZPrXRGcdnqc8qcntoddaeBnmvTFdeLPC1pI8An3SX5Iy38BIXAb1Gfzrn7+EWM6/Y5Ybu3bPlzxxOElHcgMAevH4Vjplym7EcbHCs3A+v0rpLK/jjszaGa0dd+4SujFjheFU9hnPA7nJq4qL+yTPmW8r/cZT3F4DtSKBVxwWY8/kafLeavNuYpZFnxkY9K0RLblGjcRwhTlnYjeW7gA849qWPyZF/wBGxIcZJTGcf0pak/Mxxc6jCAz29q+TyVkOahfVL9877Lft5PlyZ4q5cQyXLKB264GABV+GSGycCBVBdPKk7jB6mkn5aA1bqc4t4zsEvRdW8DHc37slfrgVu6bJFa27NBcpJHIACqSghh7gf1qbUFnsmW2eB45pUV1DA5ZWGQR7HrWZ/ZaXMjq8CiQDPmKcFfxFUkovTczbclrscpHCTjBq1HAa0rTT2fAH8q3bHRC5GVp3bO2LSOchtHfgCtG30qVgMiusg0URr90fjWrZ6TgBnAAzSa7m0ZX2OPg0SRscCtaz0SXIIUfWu3stGBbIxjFbFtoyBOhPtUNI0UjjrPRpBt6VqWunlSAQD7AV1Q01VAHBPuas/wBnKsi7gMsOMVLkbRVzn0t2RThR9TSfZWkPOAfYV1KaYp+UZLEdxUkGnh0UbSSpxnFQ5GkYpHNW+kqxyQpPoTVtNNVB8q/vD0x2rozZpHIqx8HqRjqKR0jjB3KCw9OtS2aIx4rRmUDYe3epo7Zd20Lg5wD61soBsXaBk+1MNs3mBgwLHnAHSs7lLfUzVtnLcY2jtjmrCW7AnKnPbNav2cMSSOPbipBFs2dRwDyOlMOZFOGABCdm3PY1ItuqpuI25XkjtVjyGJZc8tyCelSQBXjyzAhRhhjjPrRcXMkVfs5xIFwD2zUkaKmFPIPUdqkaRXVsLhsdarTNgrjOTyc1EpCc7loFVBEfC9WpwGxV5HPPPpVLf1befeq8l0zsAT8ueprPmIlJlq5usHg5C4Jx6VRnvAMsep9T2/yaimfcSODjsDz+dVnywYFdwHZe5rOU2Rctx6nh/lIYDggnvS3N68seV4GeoPb6VCtiDgquD1x6VDOHTPZOh4qbyAUO8soVHAL4BOcVrWNpGFGMDHTIrFtbqOKQbscjG49fpWqsqlWAkBAGFYAjNXBaEPcuzIFIUHOeorK1cpApYLtXqcVaVwgJLfia5nxPrCNEYYvmYHH40SegLcq6zqtref2bHawCFre3EUrAAGR8nJOPr1NHmxrAPb3rHtYlwJCzbmOPY1d+xyyny1YKXBePnlsdRQnKpb+thu0dCjdXTqD0I7D0FYsyPIzGThj3NWZXdpnXI+U8kU2efbzsz+GaFG472I4AsbKeoFXvNVVHJ+YdfSsz7SGBHI447VC11j5T/OtYpIibubXlh4w3kC4Rn+cZwV965XU3SC+aKOQsgOPcc9Knnvbjy2AfAPoajsoElifKqJ0Bbd/z0HdT7jkj8vSteXnXL1MHL2fvdC1bTRGPaMAk45o8uF0cSshX0NNdV2A4zkdu9Zs8eeckD0BqleOxnJKW5UmMFsZobO2t8ykhy8SydscFgcH6VatdNt5bW1VoY7eSINvkikdWl5JG7JKg84GAOlS2tmqIHIba2ecVPIVSP69q2hOfVmE6cHsremn5GVcafcIg8u8ZsDJ3gMP6Gsi8muI/lmBPvGcfof8AGtPUrqUptReBxkd/rWBdzERMG53HB96pzV7OP6ChSb2k/wAytO7xSK0geLcNy7xjcPbt2NR/PK24jr0xTElKPkHPovYVpKtxqs81y0yxuoXeQAoPRRhRx0ArRKL2dim5w1kk/T/L/gjbFGEgXkqeCM4z7V1Gnp9maC8uI45YlcYhJ6gdQRWTAkyzJC9upBIHnx/dGT1OeldLd3jX0MkJEMUdqTE2AoKEcbOOT06fU0lBrcxlVU3ZHNXDCWYxklVOTyM/hW3p/h+O502W6lWKG3Rgg7lm68ntWFdyRxlxFyw6sTzWg3iG51u4sYL+WCCKCNYA8cAUKg7lVA3HnqeT61MZWeo5ptaEE0ccMIKtLDHuK/K358Gs9WuLh1jhHm8dAuD/APXr0K08Gm6uJroAy2cUJuFlunVN4AGP3YJPJ7Vzl1bSec8sPlRfMwZkGBjsAPQe1aSpuRhGojcMVlaabptro3nTa5PCxvvPjDFPRUJ4wB3FPa/inSCxs9Pw6kLGsIDySyHA+Y4ycntWdDqn2OzuNNsfKvIp1Xc80Y+Ujk7M9OSam8MW+qaaRq0G4q0beWykGSNcjMgB5wPX9apdFEzbtqyHT7BEwuPyFdJa26xKuEJycdKWyijB7nAGeK24YVCoqCpbR2w13K1rp4kIZ1GRyvrWra2UeDvGcHj2q9aW6oo3A7qvwWyFWY5z0wOMVi2dUZIrWtn69Mde1XrS2GCDu/CrcNuEgGfug5Iq9bQDAZRgdfrWdzVNFa2sVAwVIJ9asfZ+I2VAc9O5q5vVVIByqjP/ANapxGNquuMAAAegqHI2TM3Zggd/WhdwzgHC8EHirku0SK2ARnrmmiNWVidxYNxz2qbmia6kE0G5OVBIXIyaSGyEmAVG1qulwD69sirMbLgk0r3F7RpFBbIxRYORg9qcsYDEnBGOKlvJhs+WTOOoqi86BBnI+WplKwc7Za8r7RCEjQFgMkbuh+tRbGiEit8sj8YPQVBbXrQ4MZ56YFOM0l3MIxhpGPyj/wDXS5k1qTzNDzJlFRjhgeDVaQpHu2nAJ5B6UJDcOMojbR1JHH4Gg2E7cMxGTyMc0ndBz3IdwA+Utg8dar3Ep2kDH97NXbmIw26ptPJyzEDPtj0rOkKeY21mdDwCwAP1xWcnYafYkHmswCqQxXcckDjGc0kUE7xuyLlFPJOOD/Wi1KE4YkL2IGcmtdZbNLTYsZZ+CzO3GQcjAFKK5txNtGJNCcbgMEe2KfabPtAWcnyxgsV64z296NQukSJ1HzSfyFYTagQdyn2NJpJiV2dvEsXll0Py9fmwMVg6q8bCaQHCDp2rKbVio2sTjGcVi6rq7z5SM/KvWqcroEiJtQKSuqYZR0NT2+tTQRkMpJHFZECF2LHoQOCMCrIiO4uCPapRTsTX+u3M48uIFR6isyXLtmSQsoPQVaAUyEvtHv6VDdDcxCDOPXgCjlb1EpJaIa8ypGAH+Yc8mpn1sPbRo6COa23SRy4yAQpyPoRxWLLIA+0rg5xjPenJtZ8NjaR+daw91kzSaLNnbvM7eUQwf5iD6VFbhJLC8ju1aC7tHKEH+IHlT+I6VSiu2gj8kNhomKA+oHT9MVQvmuJ7+It8izoVZhxuZDkZ/BjW0YpJx/r+rGMpO6kxy3KyTHOSFoZXlJdOatR2dqthIkkRFyzArLvwFXnIx3JPc+lU7+KdHT7FNFFhxjdkqqk4Oe+BTpwstSalV30Kl1c7HG/g5xW/oVlI1qt8+EiBIRmHDH29TXL3ZluboIsDSSs7KjRq2yXHdMjJHfpkd66jQvEcdjAo3vDIi+WDJj5d2dxUHp9RzzVqDjO0jKdRSjeGpamtlDXMMKnZE/7vA6qeR1/EVzWqK0TZ27e2BXUS6np00EQRVFwwkjM+87ckZQkexB/Oua1rU4RABgNL0JU5DN7e1a1Ipx5kY0pNPlaKNrqBRDCflcH8hUssglikLI0ipguQeFGcDP4muXmmZ5tzZBJPAps97KF2oVyeCewqYXRpKF2a91qMNlaTRRLE5mHKNGGI9wTyD9Kz7nUbCaK3W60qJGUfM1rKyMw987hn8KytzCQty7noSKWOPEilzuYtzitlKSF7OG/5afkXLezt7hneKSeIAcCVQ2TxwSMdvatqG3DZMcTw26njaN/cdSBn8TUOntEk0H2wn7MpwVTAOPr/AFrrtb1u1n0yOKytra1iiztVByAcZ3NnLHjvVxae5z1HJbM515YmUpHKpA44PP5Vi3rpHu8stGSQSUODx6/nVzVb9r3asMJKqMBtvH4GqC2MysPOjaNsd88+nWs+t4sbWnvoeLV7lRcDzUscnzJGQkRHnAJHXjvj8K6Pwfc22h6hbaj9mtNQ27v3VynmRtkYGR3Izke4p81z5emQWn2d4LWEBnKN5iSSd3PcdcVkRRC9vHTS45XlwWPlIWVsDJyB0Hv2rRxWmmv4GPO2rXuvxPZtYmkm0iJtVmFjBJIQ+m28BEku0jCmQDGTk9OF6VxXibWrGWH7O0SMF3eVFEflgzjCDjJx1JOcn0789p11JMzW2pNOWQYijEmAO/yn6+lb1loRvNBu9X+zCW1tEJmWFcOrBfu9zyed2Kv3ntuZJxW5z2nRRteG3ulEcbH7zckdz9eK9F0zTb231qyhtkmFrfwf6lEUOIeACpLdzj05rxOS6mublVAK5ONo616HBqlytjZwSO0t5EirDcM53xheQqnPAHNOD6MmtBrVHU2yhQTkEetaduzgqduQO1UbMBYwBg8d60omjQAS4BHTmuOR2wkaUV0QcsO1XUldnyM4Pas2DJ5HAPUntWjaqEUccms2bxkXI55Mso5PpV63lkKLnIBHA9KqRAeWGLJkn7v8Qq1G4Xrg46VlJm0ZDoL2Cea5jgkEj2svkTgow2vtDYBIweGHIzVw3DlAOPqKRIZpoTMQfIj43M2Bz2Gev4VJFbNlQqs244DY+XP16VD7mqmRMz8DoPbtT7eQo5LZOefrV+6tbe1uzAW84hlDNuwOnI4//XVC+kgN3MbdAkKPhQMnj1Gaco8u+6BT5tiV5AV44PtTQ7uz+TGzhF3MUBOB6n0qql4UZgxOx8BhnkirtheGTTb2KFTHG7jPz9F6beeo60oNN+8OTa2KcjkABo5AxAYLtIyD0NQyI5hSU7AGJG09ePX866G6a3/cLG/2jy03PzjLEDjd14wOKxZEfzV3pkEHBBpyhpdCjJlKFczRrKVSPcNzc8DPPStixvrK1urq6R3kmQL5TuuAP7+1Aenpn0rn72VY2wT0JHWsxr0b8sQcdhWMZuDNHFTWp6DJciUzPG2IXZWWMsfTjimvK0qbe5bJbv8AnXLWGroqjcwz71onWYFQFX+bua1dTm1YlHl0LdyjLG5ble1cbqmoRwzuqHJo1/X5JAUhYk/WubDkSb3bdu9etYTs3oaR0NsakWUYOF7mo5NWcBgvQVmbvUjceenT61J5Qyd7cN3oSBjjczTOSxOD+lNiQqAZFIUk8+vtUbt++Xkt34pt9FMkqRspUv8AMAD0A61aptkOaRLcqFLAt8pGc4qotvkZPLAAf/Wp0jNsCgjce2c1K3yQ54A7ZPWnGNxSnYhl8pYSARvHGAP61TiuMKQe3Wn3jeXBucgKwyMccVzlzesjnapyeck9qU1Z2KhqjpPtELBg3GehNQG8+yTx+ZC99BKQi+WhZ1LHAAUctz2rmvtbu3ytxmgT3fmh47h0AYMGDYIxzmtoOy2uZVI31TsLql3F/a7IQyRq5GHBUjHYg8jHpTprliSEPyjuOlal6sWox3OravqSzanNlVt1QM0xGPmkPATPQEc8cjFYEtpLHfi1srSaaQs0clvD+8kRgCSMA84wTkcV0fV18UNU/v8AT/Luc/1npPS39X9PyLmm29zf3MotUaXaq+ZngIM4DEnhRkgZNOvrfyxZ3MjElLhUUeocEH+lU/Cmq2cOp3cN3I76fd2zxgLzmQDdEcezgfmauXeppcaLdFV+aPy2kO8cESrgAdegNVSgm7Pfb+v66E1ZNJ9tGU7++KnZGSCMiqUaySAkucHjJqK+lSe5YxRlU4Gf61ZiniitwScjHA7/AFNYJOUjaT5UdB4c1C302e2tNSDvpMk4N4gJBaM8HaeqkZY5UgnJGai8ceH30sDUNPLX/hu5ObTUUTCMCceW/dXBBGDjOPqBzc92wBdSrqy7QeoX6e9WfDPjqbRTLpmoxvqHhu4OLvTy+3f/ALSN1RgcHIxnFdkJJLknt+K81+q6nHKEk3Uhv+ZhvKzAhOcc+wxUaKWlw5Zg3U4+77itfVrO1trl5dLlefR7hnFpMRhuOfLcZ4Yfr1704aeqwI6ZkdyVKAEYPb605UnDZhCtGa0MJrYDcGOWDEY9vWqcUYld2G3apwM9PwHetRoZLmRoIUH2k5WJe7+q/X09+O9YSKxDEEqo4LkY/BRSUepopt6X1J5UAYpHktnLep+vpUlpDmZVJBJHJ/pUKtEjqNuewTPX3NXLRo4pRK212H8GOD7UCbdhT5jsAq9OQO31NWdNhWXUoIZZATM2zJOAM8VKs76lIwXZEq9QBwKdepbWUCsMm5/h9fXOfrRa2qM27rl7k4ug0YEsaReUdgAJAAHGMevrUNxd3V0zEKwB6s/JNbd5DY6nLFr0Swx/axiW0jfaIJlA3EjsrfeH1I7Vg6lqsSqEgXLdOOn/ANeqmuqehnGV+hd3WyWMazqwlC/NM8hJPoMdAMdqyJtRih3Gw82GcqVaWJypZT2OOo9aL19QtbMR3scsButsiJJHjenOGB9KZpmiXd8yiKNmz6ChtqyQ1CLV5Hban9ofQtFimfT7+CO1WV3sRteBm5IcnAaTGOhHpio/DGs/YLoNaXX7w/cnPyv6FJF5wDnqeDV6PQbnS/DyWmqqhtbj9/CElyyscDcy/QYGfWmWUGl3GkSWtxarFdIxMVyxYH/cPbB962TTSjI43C13ES08NY1iNwYYLm4dt0spwqc88evXgU3xlp03h24EE0P+kjnzjkNgjjA6c05rp9GmF5JFDcWyEjyI23PCSv3lGeQPTNWdXuINU8PxaxNfxz3bkQW9oZP3kagcyOucjJ6duaOWwKV3qdjBp8q2Gn3Et1bJHeFikSHdIuDjJX37c9q7Cw1DRvDdi72Mct1rE3Cy3EAAix3UHpznivN/DWtHTL6C/hAaeI5Xd0HBA/nRcanc3d9JcXU5keRi7EnuTzXPJpO9tV+O/wCWhvTTejPTdA0K91ueclo43X5mZjkEntxU13ZDTd0F88LTFSAkfLIcjBJx3/OuP0PXLm1k329w8e4bT5bbTitqOeOdwxP19TUKad3PVm9nfyLjogUMikY53ZqibrbI2TkVPqN/GtvsjIyPU1zy3fmSEcn3riqnZSV0djo9/bveQvdvMRGMoFIOCPrxW+uuLeSj7RCRGkimKFSAqqPX1NecLK6OCrZPX6VbTVpUHyqnGOaUajiml1LcE3dnX6nOJbyScDaGYnZ6A1jXt8FkIZgc/lWLcanPIGy+CPU1QVmkILkg+9RVqObuaQhY2/ty8qSM/SnWt71AwFz+VYrIz5YHn+VNLhfvZxnHvUJsp2Osg1RI+Mg+2cVR1DxGqyNHDjdjG4HOK5WV5FZmQnI6DOSKYlrLKC8gwDyfWq5nsg5V1LE1/JcsWYnr0xwajbeMHOC3OAKiZNmNpbjr9aVOEG7OfUmoUXc05kSKsgG4OAM4zUojLx8MxYHkZoiBkVVjBYklVHc/4VWkkkj5b5QHII7nBwcGq5XuLnQn2csd2SD0JJpyoBEcHoMA4xQrq8EYBVXkYKDnJJP/ANamXZ8h5IZMjbz9RVcllchTu7EG8+bn5icgVO0ZVFJNU9PV2fdnpyT6VLczhJ0iL/vDyBVwhcipUsRXNx9nZn3shHO4npVOPXllnmvGWZvtA2QeYu3ZCPX3Y8/TFV9edbgQWXINwcyEdViH3vz4H4mn29ob6A/ITCvy5xwnoM+tXqlZdRK17svi6ZsybRzwPpT9Qukj0i9uAfngTdsJx0IrJiuPIgeFlBkUbcnk/nWRNK11HcxA7lMbqevPBpwtGST7kzXNFtEx1pbnwtYvvzPIGJHcYJFYqO0gLnkdzmruhRW91a3ZEUcCxXDqIhnCggH645qvqFosDl4WMYI+7nqaKtL323sFCqnTVtyezUu+B1I71roPsvlyBtky7WGBjBByDz16VyNpqTWtxwNwPB960ZdcilgP2kF+2wjt9adNrqFRSZW1uaaOVmVjhjyT1pnh25tibr7YLsXKRGSzmtSA6TKRt3f9M+pPGeBjHNSwS6ZqlgbWU3Nldqx8ucsZInXBOHHUHOACOPUd6NMtXsLC6mh1Hyppv3DQRE/vYs5bcey5VeO/4VvFS5ueLuuv/BuYzcJR5JKz/rb+vUuazq0WuS3GsmGGC+jXfqMC7Yw53AebEo43YxuHOeW9cZmpzxzW093ZrhJIwQeOTlcj86q3ks6Xkd7HNsu7dlkjkAHBUgjjpjgcVn3uoXNy11LKuZZi0tyWP3mPJcemT2rqi1Vd+qt/X9b/AJ8clKiuV7O5r3BSAbeVYH5s9j6VUa4TCkMzMeuBWlqNlLqnhWz8RxSwyKkn2G5hijVBCVUeW2B97coJLEfeBzXPZyuZCRGOgHf2rncLWfT+v1OuMuZC3TbmJt/lY/eYdPyqvBaln2yA+YeQOxp8UjecQo9tvoKuvdQrKv8Ao6vECCyuSdwHbP8AhVJdxTbWkSxpcZjjkgkMnknMjgEcYGNwHY81dvL9LW9uIorr7bDjZDcpEUEijjOG5B61nS3qNbTuLdUWO3KAKfmYlx19eM1m29wZovs9xLOLORxI8cLdSoO088ZGSPxNbRatZ7HHOLu6kd+q7jZrqVbqO4gZllRt0cgJBQg5BX6Vs6/pH2nSrHX9NidbS4Jgusg7YLpRllz/ALQw4+pA+7WRaI5x5gDSeucrj2/wrr/DH+lx3OhkvIL9QYQT8q3Kg+WQOmTyn0elFcsuV7f1r/XQ0nUTSnH+kcNHEYSXbhf7x6mhmcDAO0E9M5Jq7exvBcPE6k3CMQ+4Y2HuMetRQPDEjl1LTE8bfT3qLWeprzXRc0a78jUrNyoiiEqBywzuXcM5H07Vc8Sz2X9s6g9mvmoZ5PKONo27jjjtxWSZV86N5uMMMKBzVYpPdXJCqcMxIVRReydzPlu7ksF9LAsiBleOQEMn8J/+vSrE1xLE0CPxjqehr0D4efDS+8RuzQ2rskRAfOAFz65/Hiu4fwx4csre4tbSCXUL23DJJJsKR7j047Y5Oc9qqMXNa7ESnGD93c4a4tb7W7m3fxHeyXd3b26iFBhywLbgpI6cE+9eqabpV8ujxzWgFrBbxlmtI4VWQDvz/jzWF5dv9qksr28xY2SCXz4IFEvAwpkPOM/7Oam8S+KbZNL+zteTXPnESskLBVDYwOepHTirWhg3zFuLUtC0i6ubrdFfI6rsSVPnVsc59OwxXB6pqi3VxPaxhLW1nkMjl13eWM9vwrF1zWImMbQYDqvzADArGutca8tfLhtoo/JXczgnc5z1P51HP0LUGaMs6WV8JrRnKxuGTzVxuA6E/X0rD1S8W5uJJ/lWTOQsfyhPZfQe1dH4N8IX3i7T7+8e+htbW0UM5kPzdOw71Ba6DZQX8SXl7ttSxJeJdzbQeuPU9hVRbtdbEySv5oNL1RJIwpYk+lbcM7yL8obavU15bZXbwurKSBXZaPqqyBSWw3v0rmlfZmq907ezmdArDODW7b3bKmS5HtXJzavc6hdPc3tw00znLFu/bp9KsxXjuAufoBWUl2OiD7m/JqJKnPHPpSQXC7vrzmsy2bD5bmrfmRhxt4HcVhKLOiM0bAkAjBySxpyyR4yc89qoB1+zyszbVRSxJ9hU0mzyY3D7gyqy475FTyaXLVTWxYMiE8g7QelI8wLjYcZFVNwC4DHrTo5FVxkd+OaXIVzmlNL5UaLk7m61WldjuY4wO1ZVpqQvvElyGI+yW0YUNu+87f5NaxkQt5cWWTPX2rSpDl0MqdTmvIdZgSEn+Dr060+7kO3G7HAOemM5x/KpHZI1Cn5VI7d6z7u+jeW7j8sMx8tOTwABnj86Sgle5fM2yNHaSQkEDocipJJFQYxyO9QWM6mZ8r90YCkdKpyXrz3FygcMIOqhuFohBtNhOpaSRoW96LScOvXoOKzZ7y4vFLiFAiSy/IpI6uagR/OkJXkZ7CnaTKDaNKwC7ndsZ9WNJJuP9eZbkossaLLb3OqAXd8LWGzT7QY0h8ySVmDKoUdBjnJJHUdaoXl5K1yzXLYRm+9/LNUYysk1/d7ipkl8tSDj5EGP1O41At4Mssmfm+6VPH41pLT3X/X9MiDveXc6CyuQhOCNueT0qfWJ7GDxVZPa3IaJdKEsyPgskrMV/u8Ajkck49K52QSW0YkVgyPzjPIrCTUJdS1a/wDMlZ5Znjs4z1KRovJA9h+prej7qk/L9V+lznrNNx9f0/zNeK6F/ePNFny3OxD/ALA6H8Tk/lXW6ddzJpSWT3IFmpaRYTwu7uSfWuY1q2gs3aTSYnhjA/doz7jtHQE4HP4Vj3XiQAh3XAGD5YPGff2rNxalzM05uaNkW9UugqNJcRyW86sylJPlYemR2qho195blyQQW55qn4znc+LNUVyDm6kcYUKvzHPAHGOe1RWkCyIZSdmeAV71Venas7BRlehG/VGppdrc2st/FBGzveqlxbKvWTDMhA98im6re2j6fBOWxJKm7bnkev61n6pqF9GNJKXEmLRZFiOcBTv8zj3yag8S2SW/iG6t7d1uIm2Tq8edpEiK/wD7NiumaU4t210f6P8AG33nNQfJUs/P8P8AgMyZZ2eXKZHoBWrpqLKQZsMemDV6yt7NYAzEGVe2OlMu/JhG4jAwDnFcyp6XOqVW+iNOOwiK5UbQOpqubqO0uo5JbWG5jRWVUkBAJIIDHBBJBwRnjgdqoQ60EUpnK4xluCOeoq3qUd3f2NxLo8Amgs41a6MYy0W7+M+o7Z6D2renG/w7nNOWtpbGHqupESyAkPI53buAB+A4H0FL4Ts59V1nyoJESZYZblXl6fuo2k78fw4weOaymheII0qH94Mgnkn/ADir2hStaS3EnRDbSpt7nchX+taRSclfuOrpTcVqXvDPiSTRrzUbfU2abTNaiMN8FAyhLblkUDjcrYIHTr61FrGmz6dfS2lxJGJo2Kt5bbsD1GOOax0VHU5PTqG7fX1p0l5Kbfy5JGkihGyJi2So67cenJrRvnunvv8AMwinSlo/df4EhlWIbYRlRnJ9/wCtRPOWU8/Qk0xoncZJBHr2pUjxlsZPYn+lY6HS7HS6Fphu9IlaKMtNLLhVzlmCDLcenzA1z12jRzSNCu0A4Mf9739qvWeqTW82nvYp5E1tn96jHLFjkn06YH4VWdmaaRpSVLMSSepPvVXVrGNndtkMEjFxcQxMzQ/fXGRt7g+lddomoyXOj6pfAkS2kULwuv3oSJBjB7Vzl5E1qp8qTDSqGwOjjsCKqxXt8Fvn2bknA+0DupUjDfyrSKvZHPPSV+jNDWZje3TX08nN1ulkYcEuT82fx/nWeLpEh8qBB7NjnNNhWa7h8kZOG3IB6nr/AErtPCHg69uZHaWwPyDcXnOxVH41DfM9DbSC97oYegaBNqdzD5skdvHI2DNMcKvvXuPw1+HNhbava6nbSf2pDbMHyqlQ5HU49Aap+ENJ0+4sh9viluPsbny0gh+WTPOWbrx6V2+keLtWTTZ5rSysrPTYyYgkKgEuRxwfzpKKW5lOpKZmDUrqDxDqf9k3P2HTFfzbrymGWHTgnuT6Usuu2+oTx2fhy28hDIMfL80g77jySSfWuesLpdTufs7TQ2NrEHkvL4jJ2n0Hc9gPeneH/Heg6Hq85sdLuZFR99uqyZfYo+YnPQtjPtRzXfqJxsjE+I9vqul6zJZSRyRw3G2YEdGwAMZ/2ea88utdKzJmCOVo12fMOGx0Jru/Ffi0+NNFlRRNJqIuGlWDb/q0wc/N3HtXn0OiTTMhlIyzY244oqd4mlNXXvFGaSfVjHa2duE27iSDkt7k9OK1/DugFb/Ev70AAEL0bPati48LXOmWwu5NogPCOjDDHuOua27EafcTwLazvA5AUzTuFCjbz+uaSX8w5S0tHYmn0658JwrbNNBPFOMyWkb52hlBwWHesmCOGeVGkgjEYfJizjcOvWtvGmQ+Uuj2dxf3+4HzLlwY845AjHXnuTWTPFeJcNJfW0oTftJ2lVU5/KqMkjxaO5XCjJGOtW4b0qfkbHpWJmnxuQaqVJMI1O53mjayNwWU4967aynTyTKGG0DrmvGIp9pBz0roLDxDPDaNErnngHAPX69KwVJqSXQucrK8T1CGfKbgcg96lSYZGTg9RXLaVrKSWgiiONowST1rWt5c8scmspxUtjWnO2jOi+3tbWM9yojZ4kLgSKGUkdMg8Ee1SC7mnnRrlwxkQcooUA45AA4FYOoSL/ZrIhO6XbGQfdu34VfurkLp8/DFwjbNgydx4GMdTSUNEl1NHPVsvtMjSMqkhV4J65NQX98tnY3ExJ/doWyB6Djj64rF0C4mTRIvtQk82ZzI24YI7AH8BTL/AFF5tQg0yCRh54/0n5QR5QIJHPT7o5FV7Je0s9lv8v60JVRqnfqxtnE2n6bYv5r+c58y456s3P6DArrEvVAVgRnGRjpVIWL6mwsrWJp55+EjRRuYgE4FcPp2tyqblbrMXl4Cc8nPSpdNtOo/n89i+baCO8utaUFi2Sw4FZ1rdNcTSO743PwPwFYRae6mHmOpAAYlWDdRnqO9dDY2n2YASAIHQScnnBGR+dZclzXnStYueY8Q8xWGQMrzjNUvEGg3Oj3l1NZ3CGG8t7e7V22q0iyKxJ25JHOR9AK0HaKKPfsVhtPXtS/ErSIfD9no9xHJM095p1u8wkLNtYAjgngDpx2xXVhqTmpxt9m/3NGM6n7yFu/6HK6XqxX92+UZeSCcZx3q+b3ydIsYrVHnuptqRRxqWZ3boAB1OTXL26Q6158a3MME0ETz75WCAhRnaCepPQCp/D2ratAk0VlJJHaTXNrHPcRoC0SrJuUBv4TkZ467ayp09L7q/wDwR16lr2/q5JcX7afafZ7hHjmUFHSRSrqwJByOxznOadocj3DKwy5JwF68+lZ959kk1u+Ta727zyGOaf5WK7iQSB3NbbaMNFn80Xum3KqsbpGkjP5hcZ2gAcle/oautS/euMXsyo1UqS9EJJdsFmRUPyvkZ9CKwtEeK1uLicyksZG2k8HBPP8An2q3JP8Aa70BQ0e8LHk84Oe2cDua5mGYNbRxhhwefU5OaucGoNry/UyhLnmovpc9Z8MahpWoXN9Nr63939ms3njhtAWZymOuAcKBnJPArznxBqFvdypHZw4A5Y7as6RcQWOo2l1LCz2kUqNOmceZGCCyfiARXWfGXS7DS/GQm0q0gt9KvIY7u2WBAiNG6g5AHTkGtKUfaUpx6xV/VaK3y/UV+Sr5M5n4nWeo23jrV/7ThaO5knMpU4JCsAy9CR0IrOtJwluSW+VfU/mK9B+OV3a2/wARNVZbdUbMQZcjLHykyTivNNTc/ZYLmKJU+0bjx0ABxj68VVemnO67J/gmVSn+7hF+hrWpi1bS9XMm8XFlHHc28ceMN+8CPn/gLZ49KNQRU8L6FrURLSSmeyn+8drRMCuT0HySLgf7Nc/otzJa3/mAkb0ZD75HAP4gV1+gxHVfhv4osTcGNLC4t9Xt7dQCG3Ewye/AdPyqqEVJqL6tr71p/wCTWM63uSv2s/0f4HNQ6puuYV8ssoYFsA8r3/SrF5E97YLf25YokhjkTI+T0OM5AOf0rP0/TZZpCyP5SD5WkY4AzUzwG2LxQSSNFINrk8BsHP5VitNzd2T0Ke5m+VPvHuK6v4b6ynhzxCstySbC7jazvk7GB+GPrleG/CuWYCPG0YJ6VKpbbzz7f41D8h1LSVuhq+KtJk0fXr2wui5NvIURmTbuTqrBewYEN+NZlqGkaYLGQvlnA7npz+Vbeu3b6pp2n6jIwM8SCxnckszlBlGOT/c+X/gFZECqOZCQDxjuRW0neSl31/z/ABOeMrws91oP/sW7uLKO+a3mWxaQxLchPlLgZK57npxWeI/s8zLMm5cfMw6H6+lbV3q03kJCzN5SHMcOfkQ+uPXgVlPI8zyAfOz8FiP5UrrRB7zGOrWTozEeQeVXOdn/ANanFg7ZB5Pf0+lQmGZG2qdw7qf88UttKLeU4O9TyQ3VTVOPMZKfJ6FqKMqQVG1RyWPU02YhmPl52dWc96srtjk8y9XflcpGc4ORwcis6RpLhgsakt2UDgVFrbmik5PQlmuYvIQR7vNUYJJ7VraNobag9pC021JUaaQBCxUZxyB+FdX4O+GyTW/9oeJrprKAoJIoQuZJh6D0rrtLlj0SykGlW9tdXltMHQGIuQhBBUt6YPfuKuCd7mVSSatHUwvA0Oi6dpupaPq1nJFr1v8AMkpQ5ljODGyD2P5jFd8vi2D7BA99bWsjKABbovz9MfN757V5j4vg1KVk1xbsPqViVYLE3PljkqD2xmoNO8QJFNHeSyM6TOJjKgAZhnJHsc5qpytqjKMbuzPW/BniGeztNRtJJLXTbV2Ms9xkM4BH3EX+9/KuB17xSlvdzvbsfKaMwosnzEKe49D7+9cZr3iaS/vZHjXam47VHHGc5PvT9D8Lax4lEtxDHttYV3SzSHaij6msJScnyx1OqNOy5pFO61yacNFCGVT2HermgWN8GkmRpIpJI2TcPvYIwf04rpPDvhnT7WRpr6YSCP5gFUkSH+6D2rvNP1q20uInTbC3+05+aadOgP8ACo9KmK5Xdsc2nokcp4e8LXEVoLy28oR2p3sJH2lz3/Sr9xfxG33WVr5UsaEPIq7iAfT04rahFrdpHc3mttbPux5KwFlTP6GqEupW9jfakLa5jmtpUWNtg2l178Y4zirulsybX3OeuYrK/gUpLKkxOCHPDHtz2603w/4XutT1VtLliMMy/OzMOiDvRdmxnEsttbTxsz4UCYbR6cYzVWPXr2a7Ed1eGMLH5PmMf4B/CfUUk11G07Oxf1rStP0G4ZLTVDLdrtZTDyq+xb1+lXIvFepalZR6dLdWroqsNs4Ce5+b1zVbT5re4hFq0tonmZBllXGwZ7HtXP6xaQrO4sYbmSM5ZWcY3AdSvqKuzWsTLR6SPESeMCnA8VGOtOFdBgSBsD3p8bZkU+lQZ5FORsZNFik9TStL6aK5AjbFdfpfiJVjRJY8yZ5kLHp6YrgYGw5bqTVmOYqMhqwnTvsbwkpbnrrXcMxtJVUCFpCx544HT8yKnu9Zs9PQzXNoL2L5lEBkKBmKkKSRzgHB464rzrRdZsbOGY6razXYeB0gWOYx+VIcbX6cgeneprM6jrVrdTQRF7eyCyStkBUBOBkn1PFKEG7XWt7ev9bGcpaSXQ9D0qV54oII4y7MVijRMfMx4AGfepPE2n6R4b8R3sGk3tzeTxYgnlmKgeaP9YFAHQNx+HfrVD4Y3wtoNU8SahDDcWekxbUglj3pNPICsantgHLH6VnanBsstKuYEEaT2xZ5A64Z95z8vbAIFaUYN05uW70+7Vv5aL5v5KdS1VLojqdDvpLfRNZ1x8Yt4vsdsrIW3zTBlyCOhVdzc+1cRYWkU/n/AGndHIXOAwwQBwP5V6ab9I7bwZ8P7VZYo7iWG71VgMM7ysGC8c/Kh/Ueleb+OL6K68Y6tJYyTGCS6lZHkLbipY4yTz09acaS+reekn/298K+5X+ZdOo5VXL+tCIxXWlzPvQhAAwB9CODXQ6x4gsYNRRLHzEhW3g5cYLOI13Hn/azWP4qzLfJbxzQvFBbxRu8Q4YhBnJ7nPU1R15YLvVGMBZolSNAQMEkIo/TFc/s1HVaXj+dmdEJ89mzstAvJPEs91b2sqx3MVtJcIGQuZigyUHoSMnPtXb/ALQTm507w6kTl3NhGx9wc4P6GvM/hhNLoPjnRrqFVlLTCAoTjIk+Q9v9r0r0D4zX1tpuo6RZTO9xPaabBFOFPCMpYEex4rqwMrOp3UX90rL9HYwm+WqrHj2n6XMk8rSxyPGkUkjGNS2AFPJA7ZxzXpfhiwkk8B6YiQCO3uPElvHdOf8AXORFjYoAxtG5up4NY/hiaWfw94s1bzDFEkEVhGBjDeY4d1/KNR/wKuw8F3eoT+B/BNnAI2W7155S/wA3JQr1xjHLE9c8VnSirc/+P8IN/ncVeblOz8vzOH1i1hguZ9Plt3S4R23hzynPGfeorO0kGlao888cYtLU3dvIW+cFXVcDB4zuPX0qx4j0nytd1KOW+XzPOkaSQMSHIY+uT+ZP1p3hlLC6jurTWDDFpMMLXV24z5ssaOh8sEdN33R7tVVEo4nVfa/Xb57FSk/YfIY3naOdFs1lghvJom1W4aQZ8r9y7RIevOwBvrIAeleaBJAFODgAV6Npk9xr+s+KNYvZESX+z7u5Pmu3G5fLCqRk5HmAAdOK5pxBEC8icjhEI/U0qllTsujt80rt/wDk1y6Dcakr9kYjXEmAh3cc8+leh+JPEcXiXwR4ZZoHN7pGNPu5sKN0ecxAAckBQRk9z71xF3DuUSkEtn5RjqK1vDN1DY3Ukcy+fBdoIJLfOA2WBXJ9mVT+BHesaU1CXN0s0/R6P/P5F4jWN1utS78XLuO6+JGvSQvuU3TqCX39MDr07VjasJI9A0tJmJCNJ5aDHCnBz+Jz+VO1wNqGqX19cGJXmnkdvKGFyWOdo7CseaNuE3N94Yya3qyvWd/T8LCh/Cg+1gjmRJY3XlkIbnpx7V6F8IokvPElxpUigHVLC7smUNgAmMuhH4otcEdOlhUNuRjjOB2rb8C6n/YnivTNRlYqtreQzMFOGZdwDAfh/OsFJw95bqz+a1QV0pL8PvLtuAkW1f8AloAXyOc+lUNQKRjjBc9gaueNEbTPEur2WzyRBdyxhNxYgBzjk8njHJrmWudzAcnnnmrxEFGrKK2TYUm3FSJ7Y+ZcLkDLdCelT3ZUSFVwWJyWHQUkEZnjLfKkYxznvUiCJkMjnaSSGHoaytoNy1LWjBpLPUrLd/r4fOXKg/PFlhyenG8cetZ5xtyvLDkmrOnXSwajbPt3QpICyH+Je4PtjNRjCR5Iyi5UduhrSOsfR/1+Ri3ab8ymsXVmBJ96I5djHBwf73pRczM7AHgHoB3p8MMSpvlOMfw0rFuXclRcITGSM9XPU1JYXGnQTlNQtRdWrjbJhtrgeqnsf0qCIyXkhht0Z27Kozmuq8JfD+91m/VLkNDCOXYjlRTV/skStb3jlbkD7Vts2uJdGhciOWZAHjB/vYr2T4deGDplzus9Mh1u7kiWSOVXyiA8g11dxpXhbwhpsK6VCmoyzqI5lnXcrDuCOleZxeKtX8DzXw8OOyaNdNl7Y/M1v/uE8gVpZb9TC72Wx3+v6vd4uJdblitLhUaFYETc3SvNJXuIVkEM8kUUn3lDY3fWor7W7e/tReS3bS78tuPLFj1z71jrf3GqSG3t2KD+AkdaxnPXU6KcNNCbUNV2Ao8mWxjaKi8LSDy73SnsHuf7QGLMLwY5M849fpWzovhmG2DS6rFJLdHlYzwo9z611EulXGpaIiaSixalayie1lgQCRJV5AHselKnJ31Y6kVb3ehz+ieBb+zuDNf6c7BOWST5SPfB611qWBk0t5Yru3SzA8vyS+HH/AaboWoX3iiyW6kaaWaVmSRScFXXhgfTH8qv2Hhy71J5I7KEZQfM/RAfTNLZ2SK31bDS9PQ6TDHJMyQNMAZnX93Gcevc1ryWul2Ut2uo6n9s3KFikgjD7vXjtWTBYsjSafqM6xvGd2A+5WPtj+dV30ueDF1YxyPt5bYNygfWpjfoga7sdcy2K28Rt7iW5CqUbeu0IPVR64rH+xwvOslmhnUgNgjdtbPQ/WtvTV/tKR4BZMF3bm8sfMq46fSs7XtGKSkaQLx3JwwQZ+gwOSapJy1C9tDB1m4SOaQTQS21yCAFVQFI7596qXP2G4jiaO2aNyoVyGzuYH7wz0zWpevd2Ma2GqWKyTplmEgy4U/w7gf58isy2vbCK83paO0TNg27tkrn+63/ANaq6kvbYp7FIjij+SToQc5Y57//AFqsya3fWljPpt/BFfW5UqiTkk25/vRkHg/pU9xPpzujvYXNsmwhHD7mZv7xyOnsKzrjTlvI5WsrhZHUbhCG+Y/Qd6u1ttzNu+54vS0goNdBgGaXOBSDrQaAHKcU8GoxUkLBJFY9jmkNE1yxDhM52Db/AI1tWd60Hhi5tYrmVftNwplhVRtYKp2kt1z8zcVzzMXcsepOa9Gls9G034beGtRkt55tQuryeSdtpCGJGUBATwT9B/Fz2px+OKXn+EW/0+8mTsvmjS8Tynw98OPD3h8Wvl3N8P7XuZGcEvvysQAB4wgJwf71dBfRR6p468M2fiK9tobCCxt3uhENoghSMMVfj73bv97FeV+NvFE/irxNe6vMgi8+TckQORGg4Vc+ygD8KivLyWfTpb64uma7u5PL2ZJPlqB1PpnA/Cq5dFST05Wm/NtSk/ztfyId1Z9b/wDDHeWHiS5l+Kd9rmh30fmQtc3MV1d7UXbtYA4PGdpAC/QVwE2ozPdSSzSGRmYszE9TRpO1NM1KcsQyokagLnOTzz26Vmqw3ckAdeeaVSftOaVrcz6eS0/NnTTtD5Kx0djfJPCsBk8pduW/2jU63It/mGH/ALpFcsH4p6zuMEMeOlczg7nQrI6201JxcpLHJ5UikMrg8qR0IrvPiL4pg1u30C0tCXEelwLcyuPmll+bcSe/Pf3NeNpcuAOcgV6Bp0sOo2tje38KLYaZbxecEyDMm5sJn+8x+XjoMntV0bwlJx3aa/FGNdpSi/M6TxJE2i/DrQdGhTy5b8Nq1wTw53ErGPptXNN8La7fabZeB8Khs7W6ebaXGHkaQZOAMjgAc571xuqeKJdY1O5v7xg00zlsdl9APQAYAHoKt2xV9B0RoFYMLybe7LwceWQAe/U8e9EVdez7KX5Nt/PX5GdZWcX5jtY1eW7v7mVyu93Z3PbJJPFQT3NrB4UvEm89tSvJ4gpGNiwgng55yTg8enPaqtzEgunLnKgkv24z0rL1fUPMCKAAXlXOBjAHanJv27qPuay96nyryPQdFeSDQdfa0Nsha2itmMxO5leePOwDqflHXtmqFxDFlmkPmSe1XvDeoww/D/xY88cTPJNYQRsw5U75JDj3wlcde6vlNoO0HsKzt+5Xq/yiv0Khdzl8iS+KBsx5aTofb6Uug2cY1aye9WQ2rTL5ixnD4zzjg8/gaz1ug6DPy47Dv9TVhpZHgSVCwIBbI4xj0NYqLehrOVotDQu9I5YwCudm0eo7n6067WOKB3kVmZSCCOxyKbLZOlhbvbygzjZLjPH0NaGoRyG2mjuI2hkKfMjqQwyM9K6aj5586/r+kc0HaPJf0GSuir03Y6VnXhQeVLnlG+bt8p4NSwy+baRMPmYqKatoJYpDKeCCK5o6PU3dnE3/AIixrN4ja5gMTLewQXfyPux5kSE5985zXLLbSK5K/NW5eET+HNCupJY96xS2kiIoVg0ch5bHUkOvJ+nas0yPIpEY2qK2qbp+S/BWf4oijO0EuxXaXywFxyO2e9KJASWdGG4YBzxu9fypoQPIcnJHJzVmwWK7uttzuWDaQNvXNKKHOSSEW5WCMiNcyHgk962dThhaV9kkcUTsZPLXkrlVOCenUmsm4+zRHIG0gYI96S+f7UIFso3QCJRISc5bHJq1pdGL1kmV55YoWynzv0q7pej3OpKZpTshHJqzoujpFco1wolzzhjxWrNKgnYQjYucBV6Cpt1ZTl0ib/hq3lsIlNi0EJHy+Yyjca39OvGjWZ7i4cOjENh8b64KTU/s+3zZcbegFQyaveXyNb2cbYc5Lkc0pTWwKm2dVrXiBpMRyOFSMkoAelczGb/V7jbZwSSljgHGa63QPAfnWMN/qTkxsemcmu+ttGXTI4bjS4449q5Cg5Zh61lds1VlseC6r4V1XRpUuRb+bDuzNb4xz/Sut8LpaXtssukRbiTh02/PGfRq7955UaZ9VheS2n+8BjLe1ck+k3kOrLqHhOKaLUWDCRM5juI/Rx2Pv9DVO0ttxe9HbY6nS9SSxurR7uFLoRHftZOuP4fpXUTa3pV1ctOdHks5mw0b2nLIffHFYOg63oGsW6adfC7tNRgULNHMo3xSZ+bp95fQ1076pZ6T5lvpahjwi3EhzwepIFJaaXDSWtjzubUZfDfi6U2UgkstcJ3tjaq3fPQY43A/nWkL28e3T+0GvIbDdhSh2qW7/Ws3xdpsepSTaauoQO0hEkU+SipKOVJJ6YNO0K5u9e0+K/vpm85XMDxkYVJFOGUenr+NEve1GrRdibVNPKTGfT/3sCn7+8ZH4VNHqlxou5bGdpXI+aPIaIn1x3ql4i069gKvLAyRn/VlU4YfXv8AWqulWt1LLFdWKEywsGCNyGIPTHes7NS2NHZxuyaXX5ri7uLpUitpJHyfKBAz6Ae9XbrxTrF/I0c9xbQSxqI22qsTBeBjcMZHqBSXgs5tZaXV7c6XJOf3sAQxhTjGQT1GetZfiTRY7CJ5I5Fu4QflmiyVI9R7VootX1M203sGp3l1K6RS21vbzxlirRKRkN+mOM/jXHait0r75oXVM5Em3CsfUGri3twZAiyuRj5AecelPvNdvZLMadq4aa3jOFPR056A9P0qk7rUlpxehLYaR/adqSt+sVz0WOThXX/e6fhWRrelXWkaktprEZQR/wAduVJwe4I6/nVq7v7M6eltIJk2yF45/vEKf4SM4rN1C7spWMEM/wBogxlZmi8twSOhGfWtNLamN2eSUtJRW5mKKSlFJQA4UtNFLQAo6iup1fxZcXvg7QdA8iFIdNE5WUZLv5r7iD2HTtXKmgULSSkt1+qt+TE0nuOJ4oBJ79OlNPSlHago1vtkCaClqif6S85kkfP8OAFH/oRrN30wUHrR0SGtCVT3p4aoKMn1pWLUrFkEuwRBlicV6Do+uLFFp2iWsa3FqYpY5Mpu82Zh9/HPC9F+hPevPoThJSOCF4/MCp7aR4hBJGzK6vwwOCKlLW63RNZc6sx15HJb3UkUylZFYgqRgg/Suig1K6HhaxhEmbWC7dlX0ZgucH3Ciud1di+ozOxJZjuJPc1r6W3/ABIH4UlZt4JUZBAPerlZ1L97/imKc+aEW+6Gatf+XJJbxncwYl29Tnp+FY005eSHJ6NmpNXYtqVySeTIapN95frUtamql7ljuRfrb/DcxA/vrzVS5G0fdihAHP1mPHtXJecxbLGt3WEVPAvh5lGGkmumY+pDIP5CuYJ5NFv3cV6/+lMKc935/wDAL8cryEDB298Vq29yDC0RbChSKybKV47SfYcZwOlNtJGHmYPUYNRZblSleLNn7XiNFToABzVh9QkuC0mC52jzCB0wMZJrmGkcdGNdN8M1W48caVBcIk0EsyrJHIoZXHoQeCPY0O0Lt7Gc9IqXVFazuFWJ425YMcH2NWElaQYXIxzk1HqkMcPiHUYo0CxpIwVR0ADECsy9mkQkKxAoq01GbRVOV0X5N8fmygs9vnnnhX/+uB+lLYXIvbnymfy4sfMR1qhZTSPo+pRM5MZKSY/2huwf1NZaMytlSQfanyaJkKWrR0DzQh2EfyRZ6nqaje/JbZaLz03VjwkyOquSy+hrr9Ct4gU/drzjNDiDlYrWOmSTyI07E7jXUQRQ2r3UcioACgUg542Cob4CC5KxAKuOgrMm+e7kDEkM4zz14FLa9ibuTVy3d6lDvITcz/7NTWFlfTr53kmOE9C/et7w/p9orIRAmfU81r3bE3Yj/gXgLjisb9WbJdjI07QbeH55WSW4fnMgyFru/DWk20Vv5lxHHM3QsFGFFZenQRNKCyA8962v9U5jj+VG6qOhqXK2pXKbMJs/s8kdtPGgA/j7/SsvyZ5N7rdBYV+XJbB+gp2fIurZosKTnPGaqKi3ck8lxl3ILZyRz+FRvozRaEl6rxIqF5L1AB8qIcAfWtLS7yC6sJFlnfTwjbBbxrtLjHc9awPD80p1lIvMfyypyoY+lXtehRJGK7soRtyxOM9acL6tdAl2Zq+MfC2jT6XZ3ug3U1jqsA3JcZ6H0z3z6VwNtq1wjJFqqSQ6ixIimQ4inI649G9V/Kuv1QeXY2saMwjMe7buJGfWuYhijvrbUrS7US25i83Y3Z16MPQ+4pylzWjJCUGveTE82bULwyX5aSRiATis+G3Nl4vFrC7Na6qfLAU4xOB8vHqw4rV8BTSXmg2s1yxeVpmiZ+hKg8A4/n1qh4wUR6PqLplZLciSJgcFGVxgg+ooUGvd87BKSlHmXqdRpOrT6fcta6pfzxCL5UVlEq89VwenHel0mPUY9dnjsoIBMFMgCkOhXrlef5Vta5J5c2mIkcIWQDePKX5unXiuOv8A/Q9eb7L+6AkGAvahW5dNhX5i54o8WX2rWa2+sW1tKYmIVNhWRD6561gWWsahpdpvsrplSbKy25XcrAeoPBru/HuH0SCV0jMzRKTJsG4nr1xmuJ8FqLnUpIpizRujgjcRnj1q2k2l3IUvdbsQ6zftPawXM1pCsckjNFcwJsycAFSB0x1xUOleJ7e0YwX9nHNYSn96hQOzH2J5FZ+qKLXVbi1gytuWzszkfrXPXwxcSAdAeBVq6b11REkmrGx4ufRJL+V/D3mpYzEMLeQf6v1APpmuYvLaOOQG0nZkIGVcYKn09x71uaVBFPOnmoG3DnPes3xVDHZ6tKtsojUNwBWko3jzMxUve5Uf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower eyelid with inflammation of the tarsal conjunctiva and cloudy oil and plugging at the meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expression of a cloudy meibomian gland secretion, which obscures the underlying meibomian orifices. A droplet overlies the inflamed marginal conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 255px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD/AYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDUlG0His+YAnmtCZSc1SkjYfSuo43uU3FNCn04qVxTQwxzTJZA6YNNxg1YcDHFQnrVCI2BpoFSNyKZnHFUgExxSAc0pIpQeaYAEznNV3AzxVl2wDioCM5pMFuRECjHp1p+2gLUXKG4ApQKcVpVHFK5SQiingZ6UBec08dKVw5QAwaetIKUGlzD5RaUU3IpQaOYLDh9acDgcmo91G6jmHYlBFKGqINRmlzFcpMGqQMBVYNT91LmKUSyHFPDj1qmGp6vUtlcpbDZNPDVTEh7U5JODzSuUkWw1G4d6rb6N/FTcqxa3DtSFjniq/me9J5nvSuHKWC+ByaYXyKhZ803fx70cw+UkZuKaWqMsTTS3HNK4co4sTTd3rTC9MZ+1TcfKx7Nio2cUwtzUbMc0uYtQHs9MLcc1GxNRlqlyK5B7PUbN3prHJphzUORSgSb6KiwfeilzByHeTptJqvKR5XNXLsgscdO5rOmcKCM8V6S0PLaKchHNQryTTpTzntURbA4qrisOc8VGaazZ6Um7mi4coMcVGWofk8UzPrRzD5BzMKQyYHFNPPSmEYHNHMLlHs2cUZHaoycUm6lzlcpLmjIqLdTlYY60uYfKPzSimEihWqblqJKKcp4qLPvTg2alsrlHknPFJk03d70hek5D5R+7tSq3HWod1G6lzIfsyVjmkLYqMvjrTWbilzj9mWA1Luz0NVtx7UqtxzU84+QnLc04P71X3UoNLnKUCwGpQ+OtV92DTgcilzlqBYVhTg9QClyal1CvZlgvRuqEZPapVUntUuoP2Y7djrS7qctuzcYNWYrJ2xgHFQ6yRSoNlTOTQAT2rWj03jLA1Zi05CMYNZvEJGqwkjnzkHpTGBPQV1C6dEeNpNPGlw4+7UfWivqkjkzGx7UC3fsDXV/2dED92pBZR7eFFS8RcqOGZyH2Vz2NJ9hkx3rrTaop5/lTlt1PRaj6wzZYZWOQGnSelKNMc9R+ldiLYemKQwAVnKuylh0cqmkt3Wpk0jPaulEINPEOOgqPasv2ETmv7HHpRXS+WaKPasPYxMOe45IqlLJu6moZpuarSTH1r6TnR83YdNJg81AXqKSTJpm6olIagT7qN9QF8U0uKXMX7MnZqYWpgbNJu5qXMfISg02YjHWmqeck8VHNLngU73QuR3Gl+etG7IqHdmgNzUc5XIT7hxnrTlYYqDOacrdu9S6lh8hOGyeKUHiohk+1PAY9BS9qUqY8NRupuxj2NPWFz/Can21jSNETdQTzViO0dugNW49PJ+9WcsQjVYaXYzM88UuD6Vtppw7ip109cY25rP6wjSOFkznQpPUUvluTwpxXSfYUHG2pUsk7KKh4pGn1JnNrA5HANSJaueoNdMtmo/hpfsoI4rN4k1hg0tznVs2P1p4sW6mtmW3dDkDNJAQx2sOfpWcsTbU2WEiZa2HHNO+xqvU1t+QMc1Uu4guMVl9ak9jWOEgUktE4yasJYRsBg1IbZ3iBQVJapIrBX4qHipMr6rAjFii1KlugYACryx8c1PFb7jwKX1iVhOhCJWhhUHGBzVqOAlx8taFvp28gkYratrFFUErk0KpKRlJxiY8Vg7gDZx9amh0ibJIT9a6m1t1XHy1b8kZyOa2jFyOaeItscgulzdCgBqGaylj6rge1dq0Q9MGoZrcMh49q09kTHEN7nDmPB5poC5x3rWvrTZKcDAqk0ODkdamULHVCV1crMgPQUBQD6VOVwfmppXrWTNSLAB9aNmecU4oQQV59qeg46YqGBD5foKdsqUrzQQKQyLZRUuKKAPMZHLVGx45roE8PS5/eSoo7irCaHbx/wCskL/SvdlWsfPxouRyLZzSDJ6V1UulQg/u1496VNOj/uCsJYo6I4OVjldreho8tz0U12C2MSjhBTxZpnhBWbxZqsEzjlhkI+6acLeX+4a682S9Qop0dnx04qPrZX1NnGPbzf3GxURtZs/cau7+yKDgLx9KR7dU6pT+ttj+pnDLZSn+Aip4tLmPO012CQBxwAOamjtTjgj6UniWP6nY5KPSHY85FWItIAPJrqRbdgKcbQDkisniGaRw0Uc9HpcagljwKsJp0WAdvWtoQgdQOeKeIVBwB0rN12axoRMYWEYHC0LZqD93FbXlrnFP8gEZqfayZsqUV0MdLcBxhQR3zVtYAPugEVeEAAycYpyKg6D8KnnY7IoiLZyamRMjoKtmNSORQkQXouRSbGVfKHOaEhXdxV0ICDxTfLK/dNTcCv5RPQUnlNg1bVWzxzSlcHmgCmIWPpim/ZFDbu9aQjBHApohOD3qXqFyg0ahcHrVC5UbgpB9a22hORkcVXmthuzjIqdtDSMipCibeCfpT1t90g+U4pERoZMgArnvWzbqsiqSMVD0Y5O2pBBaliBjArWgs0UDC0sUOSBV5F+XjtxVRVzmnMZFGAehGKuQ4yAM4pkaccCpYl2Hn61vTiclSVy/AR071YC8DIqnC2DmrQYkDBrtpo5JD1wHGR0oupEIyAAKZI3HNUrl8A4PNbWJitTN1D5pOOlZkgIJ4rRlwe+aqOucmsptbHbTZnzDJAxxUaIUf2q1MACM9aZkc1zSOuLIyhJPFNPB705pgCQBk0RksMsKxKFApG5A45qRvSo3UnpTAbzRTthooAyipPU5+vWmmLAqd0Ixin7TjpXQ6smYqmkVVTPanCMDtU23npTgKybuaJaEPlZpDAeoq2qjFKU4zUDTKxjwORVeWZImAOavFSRyKjNqJGGVFBVwiO9AQODTnjUqfl5qwkGxBtGamjhBGSOe9RrcltGUtsSflGKuQWeOT1rQSJR0FSCLFPVkuZT8gA9KUwZGMVeCE+gpViHQCnaxPMZTWig89etKYQB0rYW1Zj92pBZ4HIp2uT7WxgtajIPepBAOntWy1p8vSofspWrUB+2Mow9BijywOq81qmAHoKikh55FHKXGZmDh+RgVNGMng8VLJbhuCMU1Y/L47VEkXe4MgJ+lI0Y6kVLnjimsC1IYiKB2pxUY6UzGCKfkGkAxhj7vpSqCw44x2p4YZweaUIeqmkBE+D1GTTduei8VOsYOd3WhhsHy1NgTM+6QBQuOT2q/ZpsRQwwajSJpZN7DgVoRIDg5pSQSnoSIMjjtVqH6VCoxk5qaLkc1aic0nctJgnpT9vPSoo3C8HAp4dSMg5raBgyZeoFXbKESHBNZnm4YAVatLrynya6qbMJRbZZuoTHnGMVmXBJbpVu6u/MY89aoyPzzXQ2khRiU3XDHjFQykbTVmQgsTUOzcea5Zu7OqnoZkqb3B70mxhnvVuUYbgUzG7NZM6VIrCJR1HNP2CpjDgc04Qgrxx71k1qVzFU4U89aAwHWrfkDqeopGiBGBS5Q50VPMX1oqT7L70UWDnRn7MnmpAmRUgXNSKnHStLE3KzRDPNII/SrRjJ5pAvqOaOUfMQqhxzRg56cVY2k9BxSiPPaiwcxEEDAYqeOEYpVTaelTJiocSXIi2bfpmpQvNSAcYpQpNLlIuMC881Jt54GaAQCMjNTKAT3oE2NEe7rU8MQyKVVqxGuOaa1M5MlSMAUuzLU9RmpQnQ1pFGLepCYg3FQSwAc1fAxyelRzqSMjitbCUjInG3pwKgddwBq9Imcg1XeP0qWjohLQqSKAKrSEHgVblhdj17VXMBQ5NZtHRFortG3akCyAEHr71bXjmn7agrmM87+Mjn2qVImIqyIs9BipVQAUNBzlLytnNTR89aldRg/So1UtjHFTyi5iNjhuneggucAcVZSEY55OafsxwBRyhzEMCBVOOueam6HjgUnI7UjOSelCiQ3qTZGMk1JGeMVCFZl6VYjTAHFVYzkOAODjmpFOOPalUcU4KOtXFGRHnOCKGYg1Y2LtAprpkYArVaEtohOajKEnLNVpo8Cm44xiqbbBNFNlOaacjg81aKc+9NRVcHHODg1Ni1IplM800xgDirrR7e1RMuQaOUtSK4UdOtKBg4qVUxgYp/lHHSjkK5iICnCPBB/SnxxHPNWEi4pchDmVtvtRVzZRT5A5znxHz8vSl2461cEXpQYs9qaiPnKqqSOKd5XPSrSx4p3ljPSnYOcp7PSnqhqdo+eBQq4HIo5B8xH5fHNN2EGrPQdKQAEZqXELkQ4PNPABHWmsDu4FPVTj0qHELke0g1PH0HrTWUhaSNjnHSly6AWkqdCAcGq6E96mB9jQomUi1GR3qwjccVTRuOc5qeNh3rRIxkWDhvyqGYjHvUm4duaR8GtESig6kuSaidMCrzrxnHNVpBzg1LRqmVCoFV5UJ+70q3LGc5qM8dqzcTeMimEIPzVIEP4VMy57UqofSp5S3IYI6f5YxUqRk9RUgjIHSnysjmKckXB4pkcRJAxV5k7gZpY4h1P5VSgHPoRRxeoqQQg1OqYHtTsdu9V7Mz5yk1uDmqzxlJOAMVqccj0qCZPm96fsxqRFGhIzipguAKdEvy0/AzmlyClIao9qkx7UoGTxS4PamoEcwnT1oJJ6Uuwk07ZtFVyk3I3FJgntUhXJppBxRYCLHPT8aUDGePelHQ0Z9afKUhpA6dc03yweakGCRkUoAI47U1EdyAoAM9qcFx2zUuwkHgU9UP0p2ByGRoMZxTwo7U9eOKd+FHKQ2R7aKmyPSiiwXMhU9KXbTxSinylXGBKXbzUgxS0+UOYh2Z60FcDpU2KQgUrD5iHZxk9qVUBAx0NShcn2p6LjtxSaDmITCCKFj9qtbaQr2qeUOcgMWccUxotp9TU4IL7cHp1oYY9D9KnlHzjUQBacqgetAPFOpcoXFHtUi5zTFFSqAOpwapRM5D1ODTxyOaYOM+lOHAqiRD6YqN0Bb3qXHNGCSTniiwXK7oDjOaqyR/McA1pBfUUeWOeKTRSm0ZyxY61IIx6fjVwxgHgCkCA+tKxfOVghHvSleOlTlcHjmkK9+RTsLmIRHkZ5qUKOlSYJHHH1pQvenYlsjCgjPakZOhxUyL8opT7jinYLlYoAenWo3UkirLeo+lIFLHigaZEseM8U8RE/WpUU556U9Uyc9BQS2QKm0+9P257VLt29aQ9aLE3ECYFNcZ4p55oI5p2GReXioiCM1aqN16+hpWC5VPGQaTFTFCWPFOWLjmrRaZEqk9KkjjAycYqUIR0FOxxQS2RbAP60oA7HindMilJ4AApCuN20bTTulOHSmFyLFFSYooC6M7Yc4wKXZinjg07bVCbIivPFBU+lS4ppoGmR4NIeKkIprLzRYoRSKmUVCowwqwnNJoTFC8dKCPQDFSYGMUm3JqSbkW0sOM9aR0x7VYA/CmyDNJlJlfbjrTwnSnhCR2qZVAHoaQNkSR85xTyudvFSKPrmlxzQIb90/XijAzjOad6evegcsfSgBAKXHpS45zRnIz+VUkAgpcdqFGeacF5osF0NKj8aYQc5qcj2pjpgdKLCuRDp9aVQAMGnbTxRyGxj5fWnyhzCYPbpTwODilTABxzTuMd6LCuMCnbTShPrUyj5aTB/CnYLlcoRnHNLEhA5BzU20HpzShcGlYfMMCnJHQYpwBAxjmnY5oOM+9FhXGkZNN2tk7tpXtUwGRSY4p2EREYWkCkjmpmAI9qYAPWnYLjCOlNbuKmx2pu3tQO5Gq9KeV4pwUDijbnuaLBzDMH0pGBqQLikYZPFArlcjJpVBAqUr7UmzmgLjB704deOlLinKp6UAN/GipNpooEZ2AcZpwxg0ij1qTbnpQMjOM03Ge9PZfUU0AelMaEx+NKUNOUc89KUn8qCiLb7VLHwKRuOlIu7BFDAmGCefzpy56H8KjBxgHqKkVsdamwDqbtJ7UpIPTOacAMd807Eti4ANKFz9afGvHXPpmnEDuKLCuMAx24pQuBTselHOKLBcibjtk0nVun409l9KaoyeaLFJ6C+g680gUdB2qRRxxS8Z560Esao9eaeq5NCrknFOHFAhrCjIxTx0pjgsw6Ad6AGEYNN5B9qkxwATzijHNAwA4pQODTlxilx6GgQxlyFyeRS4yf1pevWnY596AGYwaNvSpMehpOM9OKAGY5PpSKpOalwuPWk2jHXHfFADcYHrSMDn2p4+mBSd/amIbt4AxmkxxwKkXlfSgDHFADNucUBc5xipQOhpqg0AMAPpSYJzgVKB1OaQ5IOOtAEZpMYHIqXHy9KVRjpzQIh20FRn3qVhTSOeKBkZXPQUu3kGpApA6UYz2oAZt96KfiigCjsz1pRGM85pwFOAp2FcjKA9jSCPjrUuKcBRYdyuUOO2aTyzjpVgjJpQOKAuV/Lz2pCpHGDVvaKay5B7igdymqHzCeeKm/SnhCGYk8HpTgvI4zilYdyMKcnntUijgmpAgIJIpQgxjpQSRjOB6Uh5YHkCpFjOT6ZpWjPrQIYeTj+XpSg44HSl8shvlA/GnbSMjAJNAEbE/jQOOKeAe45pCD+FA7iAjv0px2kZA5poB570oBHBHSgB8fApwBxTBn0p2e1AC/lSEc80gzn5eBTyegoAjYfNSYAXI60/vxg0gBKDjFAwAOMk07+E47UoHHalIG0470ANGccUdeMYpdv5U5RntQIaOBSnA60u3mkPBG0/jQIDSE45NKRg/WhsAENigA68/ypO3B/OlUbQAvSlboaAGoPlGetOJAPTj1oQZTg0IrA8tlcdKAEGccdKcVOacvTkYoHNADFGCc0cdj+VOAyT0pgVUJwuM0wEGeaeARSjpzSgZoAYenIpAPXp6VJgUhHNADB0OefShV44FO2+tC8DFACbaKdkUUAUgvHNOApaUA4qhDcUU/HrRigBhzjinAZHrSkAUoqWMaRg80YOKcfWkwW5xigCNgxGPWlA2gY5xT8Ggg0AKvSlwc8DiheBS5x25oAXqaU/SmgfrTj0oENZSWHYYNOA6d6ME9qXb65oAacr9KB09c04jpQF59qBibeu2ndDnFOxgc0cUAMPXmjAz0pWPoKVc45FADcflSbMj2pz/SlX2oAgEO2cyBiRtxsPTPrTgmQQQQfY1N3oxzkUAMVBtGM4B5zSKCN2emeKe3AyTk9aImEiblzj3GKQDQDgcUq9aMHPfFKFGQeRigQN045qNHWQkKMYOCPepCgPLc57DikUBTsUcdRQMjSRJMlchQdpBBHNLEQ6B1BwfUYpw3b28wBSDxg9RTlGcEsaYheAtNYHHTrTh9KGyTg8CkA1RgDFLt+bOaB0xTqAEOO/WkzzgDBpdoYjNJgljxjHFACjH50MuRznilUAEj8RQeA2OTQALwTmgdaADj3oA4oAQikAx1pxpCDn8KAE6jilxmhchcd6AD60wExRTvwooAq4xSr0pDnPFJzjgVQDxzRjmkHA5FOUcdMUANdWKnYQD70q+5yaUjnpQOOn51LAQ8EdeaXGOx/KlBIU5NIqBSSMjPbOaBi9aQgkU44HWkB460AJtGOTzRnnGKX6GgY9MGgBadjNIB6U4CgBAOODS444pSB2oye3FAhCBjmg8DinDrTTndjHHrQAckUuM8UKvqeadgA9aBkbD34pRwKdjNGKBCdTgDmhQe9OwDwelI/pSAUnHFNyKdjucUmD2xQAh6Z6YpV7elKRx17UmeAaAE45pRzQOnWjOPagBeg5pG+uBVG+1O3tLi2hlZjNcMVijX+I96v9ODzQAzcCASevtSgdutNJUsUTdn1x0FOVQBjJbHegBSCOefwo2jB5zn1penSjHc80Eicge1Cjt1NKVyelIp5IAwaAA8Hg0pxnikKjIPUmlOce1ACcE45o9fakHHI4pedp9aAFHXmjtSMfmpe1A0NPTFKCMdRnGabPJ5MLSEEqOw6n2qGySbDzzqEkk6IP4V9KYmWG6cUo6UjDHTpSigAooooArED05po45ORTjSEE/SqKFJzyMU7tzTF4XpjmnjpQAZFGaOM0pHSpYCDrSjrgmkbpxjr3pQcgkFTQAmckjuKQMOfX6UoHcjml7GgBOBS478UmeeKACKBjxjHWjPpTQD1pwz3FAhwpcUDpQR70gExzS45pB1pWbauf6UAL69KTnj1pfSgkAe9ACUvvTc56dqcBxz0oAQ54xinE+uKQetGe5HQ9aAAHLdMUHr7Hg/SkYndQOKADAC4A47UDGz0FGccgEmkxujw/6UEjhjuKCCcc8UAcfSkUfxdweB60DRTmsILi4triaNWntizROexNW1yFUAZ9T70g4yAPu8U8HnigTGJvDNvIPpSxk85wOe1PbBOMkD2pCM9DQAYOMk0Y6ZNCkElQc4puPm56UAKD1yKFzk9PSgDIODQD1zzk0ADdiSOKFJPXrRgAZxkelAXCKpycd6AAAZNJkdKU4PQUuD14zQA0Zz1560uc+5oAAbn0zSEY5zTAduAwMd+lIGyWAzwaF+9Sk54NACEGlFHQe1GKACiiigCt3oFHejGDzVFCj9KUUZo7cUAGe1L0pR0prYztIyOtSwA8j096FGMjJ/Kgg49aXPFAAO36UhGDk8j0oJyVOOAaPoOaAFyKCOetMAJHPPNO5z2xQMepA4yc0o60wkgc05SDkA5I60hDu/oKASSc9KYzjeoHNP3cHNAB34pcY65FNBBOM4pQRuxmgBR+NGMmjkZ5oyOhIzQSxBgE5zzTuoGM03PzcelLnIoAUdaRvuH60DpSPgg880AOJpM5pCQW298ZoJAI4xQApJAOOTTWDbOPT8jTsjBPvSg8c0ANj4T5uT3NKvOMk/X0o6cjmhSOlACseD396RcljSfwkAihg2R/SgBWyRweByfelQ55AwOwpG+XpjJ70ZOBk0AKx2jPrSEKB0OTQOuRzilZsEHFACcAH1o6Y9KXAJ6c0HtuNACNyRzxQByTz+NKeD+oo5POKAA5HIFIPcGgc+tLnnvQAD/Io78D5aBz1zSHPGOlAB1z2xThzxTGHB55peQwwRjvTANoP4044J46UnO4EEgDjFIOlAC496KKKAKo5PNKOc8YFFKtUUhFOelOo9eOlGQefbNAC5pGAb72eORijORxSg8VLAOT160ZweThaa7BACT1OKdgHGaBh0Bx3oHH3jRxn2pCCe/FAC8CkPYijbnjt6UuMcZx7UAABOTwQeOaCArZUc9Kcp5AY4z0pGO0kkZ7GgQEcjIyKec4PHSmxjLcE+tOO7JwAeaQCYLYJGT2p2AeDnrmjnHAH4UY70AIx6jNGATkgdOtG35+e4pQOOO1BI0gkjFJIQq5chV9ScU7rjnv0pGUFSW+bPbGaBodjFNcYBI5NKh3D5MZ70xiSCAce9Ax23Lg9u9IokDt5jArn5QB0FOwcjB6UOcdAfWglgmfm54zQQ2CM9BTCokicEsN3GRTIYmjXGcgcA560FEq7tuMc0DdzwacTgU1sED3oExEJGQeD159KUOMkHp60Y4wBz9aQgZPGBQIcWUc/lQDgkZ59aavHB/KnH7vTGP1oAM7fTml4Y54xTcY+bgmkUbgWxg5oAdkA8En60pINNyMAn1xUm3ByBQA0+poUkE7s7e2KGOGwPzpMkdDzQAoORn0oPU+vSk35wKAdtACjA7Up9wRSBjjFDZwCaADPftSnnpSZB+lIDgYoAcaKZI6xIzyHhVLE+wGf6VHYXcN/ZQ3Vs26GZd6NgjI+hpgT5opMGigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plugging of the Meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10694=[""].join("\n");
var outline_f10_28_10694=null;
var title_f10_28_10695="Liver biopsy - jaundice and weight loss";
var content_f10_28_10695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biopsy from a 60-year-old man with jaundice and weight loss (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The liver was cirrhotic. Portal triads are enlarged and inflamed. There is striking interface hepatitis with many necrotic hepatocytes in the periportal areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10695=[""].join("\n");
var outline_f10_28_10695=null;
var title_f10_28_10696="Chancroid";
var content_f10_28_10696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chancroid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Charles B Hicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10696/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/28/10696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chancroid is an uncommon infection in the United States and most other developed countries, but is a major cause of genital ulcer disease in many parts of the developing world [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/1\">",
"     1",
"    </a>",
"    ]. In sub-Saharan Africa, for example, chancroid is the predominant cause of genital ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2\">",
"     2",
"    </a>",
"    ]. Definitive diagnosis of chancroid requires detection of the causative organism, Hemophilus ducreyi. Chancroid may be underdiagnosed in the United States since most sexually transmitted disease (STD) clinics do not have the capability of isolating H. ducreyi and many clinicians do not have clinical experience with the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilus ducreyi is a highly infectious bacterium. Data from a human model of experimental infection demonstrates that inoculation of a single colony forming unit (cfu) results in papule formation in 50 percent of cases; inoculation of 100 cfu leads to papule formation in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/3\">",
"     3",
"    </a>",
"    ]. Organisms likely gain access to tissues via abrasions in the skin acquired during sexual activity. The likelihood that inoculation will lead to papule formation appears to be mainly influenced by inoculum dose and host factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemophilus ducreyi is a small, fastidious, gram-negative rod that requires an enriched growth medium containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    and usually serum for successful cultivation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/5\">",
"     5",
"    </a>",
"    ]. Cultures must be delivered expeditiously to the laboratory and incubated at 33&ordm; to 35&ordm;C in high humidity with CO2 enrichment. Small, heterogeneous colonies appear on culture medium after 48 to 72 hours. The gray to tan translucent colonies slide intact across the agar plate when pushed.",
"   </p>",
"   <p>",
"    When examined by Gram stain, organisms from culture often clump in long parallel strands, producing a so-called \"school of fish\" appearance. This morphology can occasionally be seen in gram-stained smears from clinical specimens, but it is not a consistent or reliable clinical finding.",
"   </p>",
"   <p>",
"    The histologic and immunophenotypic characteristics of chancroid lesions were described in a report of 11 men, five of whom were coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/6\">",
"     6",
"    </a>",
"    ]. A superficial purulent exudate was typically present in the epidermis, and a perivascular and interstitial mononuclear cell infiltrate was seen in the dermis. Neutrophils were prominent in most patients who were not HIV-infected, but were less common in those who were HIV-positive. The mononuclear cell infiltrate contains many CD4+ lymphocytes, which may explain the increased risk of HIV transmission among persons with chancroid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of chancroid is incompletely understood. The initiation of infection requires attachment of bacteria to susceptible cells, a process that appears to involve the interaction of a protein mediator (probably pili) and lipooligosaccharide with fibronectin contained in the extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/10\">",
"     10",
"    </a>",
"    ]. Bacterial adherence to cells then occurs via the elaboration of a heat shock protein (GroEL), which may also contribute to the bacterial chaining described above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cytotoxin secreted by H. ducreyi may then play an important role in epithelial cell injury and subsequent development of an ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This cytotoxin, present in the majority of strains, has been found to be similar to cytolethal distending toxins (CDTs) from other bacterial species including Escherichia coli, Shigella, Campylobacter, and Actinobacillus actinomycetemcomitans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar to other CDTs, this toxin causes distension of cultured epithelial cells and fibroblasts leading to irreversible cell-cycle arrest in the G2 phase of cell growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of chancroid in most areas remains unclear because of the difficulty of isolating H. ducreyi in the laboratory. In addition, most facilities do not test for this organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United States and developed countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;There were only 24 cases of chancroid reported to the Centers for Disease Control and Prevention (CDC) in 2010, the most recent year for which data has been compiled (",
"    <a class=\"graphic graphic_figure graphicRef56292 \" href=\"UTD.htm?35/18/36141\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/15\">",
"     15",
"    </a>",
"    ]. In 2009, a total of 28 cases of chancroid were reported from only nine states including Texas (8), North Carolina (6), Wisconsin (6), Massachusetts (3), Florida (1), California (1), Indiana (1), South Carolina (1), and Virginia (1).",
"   </p>",
"   <p>",
"    The apparent disappearance of chancroid in the United States must be considered cautiously due to underreporting and lack of testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. Many patients are not tested for chancroid as illustrated in a survey of 405 sexually transmitted disease (STD) treatment facilities published in 1996; only 32 (8 percent) tested patients for chancroid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of lack of testing was demonstrated in a study from Brooklyn, New York, which found that H. ducreyi caused 27 of 65 (42 percent) cases of genital ulcer disease in which a microbiologic diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 299 men with nonsyphilitic genital ulcer disease from New Orleans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/22\">",
"     22",
"    </a>",
"    ]. Culture revealed H. ducreyi in 39 percent and HSV in 19 percent; the culture was negative in 41 percent.",
"   </p>",
"   <p>",
"    Use of the polymerase chain reaction (PCR) also suggests that chancroid may be more common than previously believed. Assessment of an outbreak of genital ulcer disease in Jackson, Mississippi revealed that 59 percent were due to H. ducreyi using a multiplex PCR test provided by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Data obtained from the use of the multiplex PCR at STD clinics in ten cities in the United States in 1996 demonstrated that H. ducreyi tends to occur in epidemiologic clusters and may account for a substantial proportion of genital ulcer cases when present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/20\">",
"     20",
"    </a>",
"    ]. Cases of chancroid were identified in Memphis and Chicago and accounted for 12 to 20 percent of all cases of genital ulcers in these cities. Among 10 patients with chancroid in Memphis, the clinical diagnosis was made in none, and only two patients were given an appropriate antibiotic regimen recommended for chancroid.",
"   </p>",
"   <p>",
"    Given the limited capability of most STD clinics for diagnosing chancroid, the CDC has developed a case definition for definite and probable chancroid to be used for reporting purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite &mdash; Isolation of H. ducreyi from the lesion",
"     </li>",
"     <li>",
"      Probable &mdash; Clinical findings compatible with the diagnosis plus negative darkfield microscopic examination for Treponema pallidum, negative serologic test for syphilis, and negative culture for herpes simplex virus (HSV) or a clinical presentation not typical for herpes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon cases reported using these criteria, chancroid in the United States is seen primarily in minority populations (African-Americans or Hispanics), in heterosexuals, and among female prostitutes and their clients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2,5,22\">",
"     2,5,22",
"    </a>",
"    ]. Cases are more commonly reported in men, at least in part because chancroid is more easily diagnosed in males. Crack cocaine and the exchange of sex for drugs have been implicated in several outbreaks. In the United States, chancroid is most often reported from the south and from some eastern urban localities.",
"   </p>",
"   <p>",
"    A report from an STD clinic in Paris, France confirms the infrequency of chancroid as a cause of genital ulcer disease in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite an aggressive diagnostic approach, only 8 of 278 cases evaluated between 1995 and 2005 were diagnosed as being caused by H. ducreyi. No cases of chancroid were diagnosed in this STD clinic after 2002.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive epidemiologic data are not generally available since diagnosing chancroid in these countries is even more problematic than in areas with greater resources.",
"   </p>",
"   <p>",
"    It is a major cause of genital ulcer disease in sub-Saharan Africa and in many parts of Southeast Asia and Latin America [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2,24-26\">",
"     2,24-26",
"    </a>",
"    ]. However, the prevalence of chancroid has dramatically declined in some countries, such as Botswana [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/27\">",
"     27",
"    </a>",
"    ]. In a cross-sectional study, the proportion of cases of genital ulcers that were secondary to H. ducreyi declined from 25 to 1 percent over a nine-year period while the proportion of HSV-2 cases increased from 23 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/28\">",
"     28",
"    </a>",
"    ]. Similar observations have been made in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/29\">",
"     29",
"    </a>",
"    ]. One potential explanation for this observation is the prevalent use of antibiotics for empiric therapy of genital ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Coinfection with syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with T. pallidum has also been documented both in the United States and abroad [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. In one 1997 case series of 82 men and women from New York City presenting with their first episode of genital ulcers, chancroid and syphilis coinfection were more common than either infection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155538\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of chancroid is typically 4 to 10 days (range 1 to 35 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with H. ducreyi leads to an erythematous papule that rapidly evolves into a pustule, which erodes into an ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. Infected persons commonly have more than one ulcer, and the lesions are almost always confined to the genital area and its draining lymph nodes.",
"   </p>",
"   <p>",
"    A typical chancroid ulcer is about 1 to 2 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef76843 \" href=\"UTD.htm?16/5/16464\">",
"     picture 1",
"    </a>",
"    ), but the size is variable, especially in HIV-infected patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'HIV-infected patients'",
"    </a>",
"    below.) The ulcer is painful and has an erythematous base; the borders are clearly demarcated and sometimes undermined. The base of the ulcer is usually covered with a gray or yellow purulent exudate and bleeds when scraped.",
"   </p>",
"   <p>",
"    The most common sites for chancroid are the prepuce, corona, or glans penis in men, and the labia, vaginal introitus, and perianal areas in women. Some cases of chancroid may go undiagnosed, especially in asymptomatic women with vaginal or cervical lesions.",
"   </p>",
"   <p>",
"    Inguinal lymphadenitis is present in about one-half of infected men (",
"    <a class=\"graphic graphic_picture graphicRef76843 \" href=\"UTD.htm?16/5/16464\">",
"     picture 1",
"    </a>",
"    ), but is somewhat less common in women. The involved nodes may undergo liquefaction and present as fluctuant buboes. Most buboes arise one to two weeks after the appearance of the primary ulcer and are often quite painful. Untreated buboes may spontaneously rupture and discharge frank pus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coinfection with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other STDs, the presence of HIV infection may result in atypical manifestations of chancroid. Among the findings that may be seen in such patients are numerous lesions, extragenital involvement, and delayed resolution after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/28,32\">",
"     28,32",
"    </a>",
"    ]. There are no large series of cases of chancroid in HIV-infected persons to determine the true incidence or predominant clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of genital ulcer disease in sexually active persons is broad and is greatly influenced by the geographic location in which the infection was acquired. Worldwide, the main infectious causes of genital ulcer disease are HSV (genital herpes), Treponema pallidum (syphilis), Hemophilus ducreyi (chancroid), Chlamydia trachomatis (lymphogranuloma venereum), and Klebsiella granulomatis, formerly known as Calymmatobacterium granulomatis (donovanosis or granuloma inguinale) (",
"    <a class=\"graphic graphic_table graphicRef81735 \" href=\"UTD.htm?21/54/22381\">",
"     table 1",
"    </a>",
"    ). In the United States, most cases are due to HSV, followed by syphilis and chancroid, with the latter being increasingly uncommon. Noninfectious causes include drug eruptions and Beh&ccedil;et&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis based on history and physical examination alone is often inaccurate since findings such as pain, inguinal lymphadenitis, and multiple ulcers are not specific for any one diagnosis. Nonetheless, some findings are more common in certain infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic genital presentation of chancroid is with a deep, undermined, purulent ulcer that may be associated with painful inguinal lymphadenitis.",
"     </li>",
"     <li>",
"      The classic presentation of genital herpes is with multiple, shallow, tender ulcers that may be vesicular; in addition, only HSV is associated with recurrent disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The classic genital presentation of primary syphilis is with a painless, indurated, clean-based ulcer, called a chancre. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granuloma inguinale (donovanosis) usually presents as a painless, progressive ulcerative lesion without regional lymphadenopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"       30",
"      </a>",
"      ]. The lesions are highly vascular and beefy red in appearance. It is rare in the United States, but endemic in India, Papua, New Guinea, central Australia, and southern Africa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than one pathogen may be present, further complicating the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. PCR testing has shown that this phenomenon may be more common than is evident with culture-based methods in the past (17 versus 4 percent with culture in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chancroid is challenging even for well-equipped facilities. Most STD treatment centers in the United States do not have the capability of diagnosing chancroid and instead rely on clinical criteria for presumptive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with suspected chancroid should also be evaluated for other sexually transmitted diseases (syphilis, gonorrhea, HSV, HIV), since coinfection is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Furthermore, patients with HIV infection may not respond to treatment as well as those who are seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC criteria for a presumptive diagnosis of chancroid are used for reporting and often as a guide for initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/23\">",
"     23",
"    </a>",
"    ]. The diagnosis of chancroid is &ldquo;definite&rdquo; if H. ducreyi has been isolated from the lesion. A &ldquo;probable&rdquo; diagnosis is made if all the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has one or more painful genital ulcers",
"     </li>",
"     <li>",
"      The patient has no evidence of T. pallidum",
"      <em>",
"      </em>",
"      infection by darkfield examination of ulcer exudate or by serologic testing (performed at least seven days after onset of ulcers)",
"     </li>",
"     <li>",
"      The clinical presentation is typical for chancroid",
"     </li>",
"     <li>",
"      A test for HSV performed on the ulcer exudate is negative [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, when careful studies are undertaken, the usefulness of clinical criteria for diagnosing chancroid is limited. In a study from South Africa, for example, the diagnostic accuracy of clinical criteria by experienced clinicians for laboratory-confirmed cases of chancroid was only 42 percent in men and 57 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/24\">",
"     24",
"    </a>",
"    ]. In the study mentioned above from New Orleans, the diagnosis of chancroid by strict clinical criteria was surprisingly specific (94 percent); unfortunately, the sensitivity was poor (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/22\">",
"     22",
"    </a>",
"    ]. In Lesotho, chancroid was the clinical diagnosis in 80 percent of patients with genital ulcer disease, and sensitivity was correspondingly high (95 percent); once again, however, the specificity was poor (29 percent compared to culture and 41 percent compared to PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram stain of the exudate from an ulcer can show typical small gram-negative rods in a chain, the so-called \"school of fish\" (",
"    <a class=\"graphic graphic_figure graphicRef56292 \" href=\"UTD.htm?35/18/36141\">",
"     figure 1",
"    </a>",
"    ). However, the sensitivity of the Gram stain is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/28,33\">",
"     28,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of chancroid requires identification of H. ducreyi on special culture media that is not widely available from commercial sources. Technical refinements in culture media over the past 20 years have improved the yield [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. However, the relative inexperience of most laboratories in culturing and identifying H. ducreyi has limited the consistency of microbiologic diagnosis. Culture sensitivity for H. ducreyi of approximately 75 percent has been reported from both Lesotho and New Orleans when compared to PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/25,34\">",
"     25,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonculture methods for the diagnosis of H. ducreyi, particularly PCR, may lead to improvements in the diagnosis of chancroid. Multiplex PCR has been associated with a sensitivity for H. ducreyi of 95 percent in Lesotho and 98.4 percent in New Orleans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/25,34\">",
"     25,34",
"    </a>",
"    ]; the specificity was 99.6 percent in the series from New Orleans. PCR offers similar advantages for the diagnosis of HSV and syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No FDA-approved PCR test for H. ducreyi is available in the United States, but such testing can be performed by commercial laboratories that have developed their own PCR test if the performance of the test has been validated by a CLIA validation study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. Unfortunately, PCR may not be a practical diagnostic tool for most STD clinics because of the cost and complexity of the test. Furthermore, PCR technology is not yet adapted for rapid availability of results.",
"   </p>",
"   <p>",
"    The lack of availability of a rapid and reliable diagnostic test for chancroid prevents clinicians from basing treatment decisions on microbiologic testing in most instances. Since treatment of chancroid is relatively easy, usually consisting of single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , therapy is typically given to patients in whom the diagnosis is suspected on clinical grounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for chancroid can be considered if the clinical manifestations and epidemiology are strongly suggestive of this diagnosis. Patients with suspected chancroid should also be empirically treated for possible coinfection with T. pallidum, the causative agent of syphilis, due to frequent coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.) Laboratory testing for both infections is important to accurately determine the diagnosis and the response to therapy. Clinicians should also be aware that diagnostic testing for syphilis can be falsely negative in early stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of agents have been used in the treatment of chancroid including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . For the treatment of chancroid and other sexually transmitted diseases, directly observed single-dose therapy is highly desirable. We suggest that patients with proven or suspected chancroid be treated with one dose of either azithromycin (1 g PO) or ceftriaxone (250 mg IM) (",
"    <a class=\"graphic graphic_table graphicRef66035 \" href=\"UTD.htm?5/45/5851\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30,35\">",
"     30,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      given as a single 1000 mg dose was evaluated as treatment for chancroid in two study sites in Africa [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/27,36\">",
"       27,36",
"      </a>",
"      ]. At the first site in Kenya, 127 culture-positive patients were treated with either azithromycin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      . Cure rates were approximately 90 percent with both drugs; treatment failure in both groups was significantly associated with HIV infection or lack of circumcision. At the second study site in South Africa, patients were treated in a noncomparative trial. Azithromycin cured 89 percent of patients with culture-positive H. ducreyi infection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      given as a single 250 mg intramuscular injection has been associated with cure rates as high as 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/37\">",
"       37",
"      </a>",
"      ]. However, limited data suggest that this regimen may not be as effective in Kenya where failure rates as high as 35 percent have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/38\">",
"       38",
"      </a>",
"      ]. Failure was more common among persons coinfected with HIV.",
"     </li>",
"     <li>",
"      Single dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      was compared to treatment with single dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      in a randomized, prospective, unblinded trial of 65 culture-positive patients in New Orleans [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/39\">",
"       39",
"      </a>",
"      ]. Clinical cure or improvement was seen in all patients.",
"     </li>",
"     <li>",
"      A single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg) has been associated with cure rates above 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Fleroxacin given as a single 400 mg dose cured 35 of 36 patients with chancroid in a small trial in Kenya compared to a 30 percent failure rate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/42\">",
"       42",
"      </a>",
"      ]. Fleroxacin is not available in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    still appears to be effective. However, we hardly ever use this drug for three reasons: proper administration requires multiple doses over several days; there is an appreciable incidence of gastrointestinal side effects; and there is a risk of sudden cardiac death due to QT interval prolongation that is even higher when other drugs metabolized by CYP3A4 are taken concurrently. Other drugs are as effective, more convenient to use, and less toxic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with many bacteria, H. ducreyi has developed increasing resistance to some of the antimicrobials that were previously effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/40,43,44\">",
"     40,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with proven or suspected chancroid should be treated with one dose of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 g PO) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg IM) (",
"    <a class=\"graphic graphic_table graphicRef66035 \" href=\"UTD.htm?5/45/5851\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. A multiple dose regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg PO twice daily for three days) is an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/40\">",
"     40",
"    </a>",
"    ], but the requirement for multiple doses makes it less desirable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30,35\">",
"     30,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, we no longer use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    because of toxicity and the requirement for multiple doses. However, it may still be an appropriate choice when cost is an issue. The usual dose is 500 mg four times daily for seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar approach is recommended in HIV-infected patients. However, such patients may be at higher risk for treatment failure and must be followed carefully after the initiation of therapy. Some experts recommend multiple dose regimens with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , but this approach has not been studied prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    as the preferred regimen for the treatment of pregnant women with chancroid.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is contraindicated during pregnancy and lactation; the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    in this patient population has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. If ceftriaxone cannot be used,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is the best alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Buboes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the era before effective antimicrobial therapy was available suggest that failure to aspirate fluctuant buboes is associated with the development of draining fistulas or secondary ulcers at the site of spontaneous rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, fluctuant lymphadenitis should be drained by needle aspiration through normal skin (",
"    <a class=\"graphic graphic_picture graphicRef59577 \" href=\"UTD.htm?11/61/12241\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In comparison to needle aspiration, incision and drainage of buboes associated with chancroid was not recommended in the past because of possible delayed healing and formation of fistulas. However, more recent data suggest that these concerns may be unfounded. In a small study performed during a chancroid epidemic in New Orleans, 27 patients with inguinal buboes were randomly assigned to either needle aspiration or incision and drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/46\">",
"     46",
"    </a>",
"    ]. Both groups ultimately did well without any adverse events during the period of follow-up, but the patients managed with needle aspiration often required repeated aspirations. Thus, either modality can be used to treat fluctuant lymphadenitis associated with chancroid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sex partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex partners of patients with chancroid should be examined and treated if they have had sexual contact with the patient within ten days of symptom presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]. This recommendation is not dependent on the presence of symptoms or signs of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical improvement usually occurs promptly after treatment is initiated. Relief of pain is noted by most patients within 48 hours and objective improvement in the ulcers is usually evident within 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/47\">",
"     47",
"    </a>",
"    ]. If no clinical improvement is evident after seven days, then the clinician should consider the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis may be incorrect",
"     </li>",
"     <li>",
"      The patient is coinfected with another STD (especially syphilis)",
"     </li>",
"     <li>",
"      The patient is coinfected with HIV",
"     </li>",
"     <li>",
"      The patient was not adherent with medications (if a multiple dose regimen was prescribed)",
"     </li>",
"     <li>",
"      The H. ducreyi strain is drug-resistant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response of chancroid-associated lymphadenitis may occur more slowly. In one study, for example, 8 of 35 patients with inguinal lymphadenitis developed fluctuance that required needle aspiration despite successful treatment of the genital ulcer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/48\">",
"     48",
"    </a>",
"    ]. In advanced cases, scarring may result despite eradication of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27229079\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chancroid is an uncommon infection in the United States, but is a major cause of genital ulcer disease in parts of the developing world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causative agent, Hemophilus ducreyi, is a small, fastidious, gram-negative rod that requires an enriched growth medium for successful culture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The true incidence of chancroid in most areas remains unclear because of the difficulty of isolating H. ducreyi in the laboratory. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period of chancroid is typically 4 to 10 days (range 1 to 35 days). (See",
"      <a class=\"local\" href=\"#H155538\">",
"       'Incubation period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection generally leads to multiple painful genital ulcers, which may be associated with lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive diagnosis of chancroid is based mainly on clinical symptoms since special culture media for the diagnosis of Hemophilus ducreyi is not widely available. Testing for herpes simplex virus and syphilis should also be performed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with proven or suspected chancroid be treated with one dose of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1 gram orally) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (250 mg intramuscularly). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/1\">",
"      Hope-Rapp E, Anyfantakis V, Fou&eacute;r&eacute; S, et al. Etiology of genital ulcer disease. A prospective study of 278 cases seen in an STD clinic in Paris. Sex Transm Dis 2010; 37:153.",
"     </a>",
"    </li>",
"    <li>",
"     Marrazzo JM, Handsfield HH. Chancroid: New developments in an old disease. In: Current Clinical Topics in Infectious Diseases, Remington JS, Swartz MN (Eds), Blackwell Science, Cambridge, MA 1995. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/3\">",
"      Al-Tawfiq JA, Harezlak J, Katz BP, Spinola SM. Cumulative experience with Haemophilus ducreyi 35000 in the human model of experimental infection. Sex Transm Dis 2000; 27:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/4\">",
"      Janowicz DM, Ofner S, Katz BP, Spinola SM. Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience. J Infect Dis 2009; 199:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/5\">",
"      Trees DL, Morse SA. Chancroid and Haemophilus ducreyi: an update. Clin Microbiol Rev 1995; 8:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/6\">",
"      Magro CM, Crowson AN, Alfa M, et al. A morphological study of penile chancroid lesions in human immunodeficiency virus (HIV)-positive and -negative African men with a hypothesis concerning the role of chancroid in HIV transmission. Hum Pathol 1996; 27:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/7\">",
"      Spinola SM, Orazi A, Arno JN, et al. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. J Infect Dis 1996; 173:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/8\">",
"      King R, Gough J, Ronald A, et al. An immunohistochemical analysis of naturally occurring chancroid. J Infect Dis 1996; 174:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/9\">",
"      Gelfanova V, Humphreys TL, Spinola SM. Characterization of Haemophilus ducreyi-specific T-cell lines from lesions of experimentally infected human subjects. Infect Immun 2001; 69:4224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/10\">",
"      Alfa MJ, DeGagne P. Attachment of Haemophilus ducreyi to human foreskin fibroblasts involves LOS and fibronectin. Microb Pathog 1997; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/11\">",
"      Parsons LM, Limberger RJ, Shayegani M. Alterations in levels of DnaK and GroEL result in diminished survival and adherence of stressed Haemophilus ducreyi. Infect Immun 1997; 65:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/12\">",
"      Cope LD, Lumbley S, Latimer JL, et al. A diffusible cytotoxin of Haemophilus ducreyi. Proc Natl Acad Sci U S A 1997; 94:4056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/13\">",
"      Purv&eacute;n M, Frisk A, L&ouml;nnroth I, Lagergard T. Purification and identification of Haemophilus ducreyi cytotoxin by use of a neutralizing monoclonal antibody. Infect Immun 1997; 65:3496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/14\">",
"      Cortes-Bratti X, Chaves-Olarte E, Lagerg&aring;rd T, Thelestam M. The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase. J Clin Invest 1999; 103:107.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention, Division of Sexually Transmitted Diseases. Sexually Transmitted Diseases Surveillance, Other Sexually Transmitted Diseases, 2009 National Report. file://www.cdc.gov/std/stats07/other.htm (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/16\">",
"      Beck-Sague CM, Cordts JR, Brown K, et al. Laboratory diagnosis of sexually transmitted diseases in facilities within the United States. Results of a national survey. Sex Transm Dis 1996; 23:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/17\">",
"      Dillon SM, Cummings M, Rajagopalan S, McCormack WC. Prospective analysis of genital ulcer disease in Brooklyn, New York. Clin Infect Dis 1997; 24:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Chancroid detected by polymerase chain reaction--Jackson, Mississippi, 1994-1995. MMWR Morb Mortal Wkly Rep 1995; 44:567, 573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/19\">",
"      Mertz KJ, Weiss JB, Webb RM, et al. An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis 1998; 178:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/20\">",
"      Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/21\">",
"      Risi JB Jr, Centers for Disease Control (CDC). Using surveillance data for decision making in public health. MMWR Morb Mortal Wkly Rep 1992; 41 Suppl:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/22\">",
"      DiCarlo RP, Armentor BS, Martin DH. Chancroid epidemiology in New Orleans men. J Infect Dis 1995; 172:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/23\">",
"      Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/24\">",
"      O'Farrell N, Hoosen AA, Coetzee KD, van den Ende J. Genital ulcer disease: accuracy of clinical diagnosis and strategies to improve control in Durban, South Africa. Genitourin Med 1994; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/25\">",
"      Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997; 175:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/26\">",
"      Totten PA, Kuypers JM, Chen CY, et al. Etiology of genital ulcer disease in Dakar, Senegal, and comparison of PCR and serologic assays for detection of Haemophilus ducreyi. J Clin Microbiol 2000; 38:268.",
"     </a>",
"    </li>",
"    <li>",
"     2007 National Guidelines for the management of chancroid. Clinical Effectiveness Group (British Association for Sexual Health and HIV, BASSH). www.bashh.org/guidelines (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/28\">",
"      Morse SA. Chancroid and Haemophilus ducreyi. Clin Microbiol Rev 1989; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/29\">",
"      Riedner G, Todd J, Rusizoka M, et al. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania. Sex Transm Infect 2007; 83:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/30\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/31\">",
"      DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/32\">",
"      Quale J, Teplitz E, Augenbraun M. Atypical presentation of chancroid in a patient infected with the human immunodeficiency virus. Am J Med 1990; 88:43N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/33\">",
"      Joseph AK, Rosen T. Laboratory techniques used in the diagnosis of chancroid, granuloma inguinale, and lymphogranuloma venereum. Dermatol Clin 1994; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/34\">",
"      Orle KA, Gates CA, Martin DH, et al. Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers. J Clin Microbiol 1996; 34:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/35\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/36\">",
"      Ballard RC, Ye H, Matta A, et al. Treatment of chancroid with azithromycin. Int J STD AIDS 1996; 7 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/37\">",
"      Bowmer MI, Nsanze H, D'Costa LJ, et al. Single-dose ceftriaxone for chancroid. Antimicrob Agents Chemother 1987; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/38\">",
"      Tyndall M, Malisa M, Plummer FA, et al. Ceftriaxone no longer predictably cures chancroid in Kenya. J Infect Dis 1993; 167:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/39\">",
"      Martin DH, Sargent SJ, Wendel GD Jr, et al. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin Infect Dis 1995; 21:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/40\">",
"      Naamara W, Plummer FA, Greenblatt RM, et al. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. Am J Med 1987; 82:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/41\">",
"      Malonza IM, Tyndall MW, Ndinya-Achola JO, et al. A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. J Infect Dis 1999; 180:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/42\">",
"      Plourde PJ, D'Costa LJ, Agoki E, et al. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid. J Infect Dis 1992; 165:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/43\">",
"      Abeck D, Johnson AP, Dangor Y, Ballard RC. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. J Antimicrob Chemother 1988; 22:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/44\">",
"      Knapp JS, Back AF, Babst AF, et al. In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid. Antimicrob Agents Chemother 1993; 37:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/45\">",
"      Sullivan, M. Chancroid. Am J Syphilis Gonorrhea Venereal Dis 1940; 24:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/46\">",
"      Ernst AA, Marvez-Valls E, Martin DH. Incision and drainage versus aspiration of fluctuant buboes in the emergency department during an epidemic of chancroid. Sex Transm Dis 1995; 22:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/47\">",
"      Schmid GP. The treatment of chancroid. JAMA 1986; 255:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10696/abstract/48\">",
"      Plummer FA, D'Costa LJ, Nsanze H, et al. Antimicrobial therapy of chancroid: effectiveness of erythromycin. J Infect Dis 1983; 148:726.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7582 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10696=[""].join("\n");
var outline_f10_28_10696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27229079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States and developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Developing countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Coinfection with syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155538\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coinfection with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Buboes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sex partners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27229079\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7582|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/18/36141\" title=\"figure 1\">",
"      US reported cases of chancroid 2009",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7582|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/5/16464\" title=\"picture 1\">",
"      Penile ulcer due to chancroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/61/12241\" title=\"picture 2\">",
"      Aspiration of chancroid bubo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/54/22381\" title=\"table 1\">",
"      GUD clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/45/5851\" title=\"table 2\">",
"      Rx chancroid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_28_10697="Omeprazole and sodium bicarbonate: Drug information";
var content_f10_28_10697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omeprazole and sodium bicarbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/27/27061?source=see_link\">",
"    see \"Omeprazole and sodium bicarbonate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/47/38648?source=see_link\">",
"    see \"Omeprazole and sodium bicarbonate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2874244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zegerid OTC&trade; [OTC];",
"     </li>",
"     <li>",
"      Zegerid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2874247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2874285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Both strengths of Zegerid&reg; capsule and powder for oral suspension have identical sodium bicarbonate content, respectively. Do not substitute two 20 mg capsules/packets for one 40 mg dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Active duodenal ulcer:",
"     </b>",
"     Oral: 20 mg once daily for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric ulcers:",
"     </b>",
"     Oral: 40 mg once daily for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heartburn (OTC labeling):",
"     </b>",
"     Oral: 20 mg once daily for 14 days. Do not take for &gt;14 days or more often than every 4 months, unless instructed by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic GERD:",
"     </b>",
"     Oral: 20 mg once daily for up to 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erosive esophagitis:",
"     </b>",
"     Oral: 20 mg once daily for 4-8 weeks; maintenance of healing: 20 mg once daily  for up to 12 months total therapy (including treatment period of 4-8 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Risk reduction of upper GI bleeding in critically-ill patients",
"     </b>",
"     (Zegerid&reg; powder for oral suspension): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: Day 1: 40 mg every 6-8 hours for two doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 40 mg daily for up to 14 days; therapy &gt;14 days has not been evaluated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2874286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2874287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2874288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.  However, based on increased bioavailability, a dosage reduction should be considered, especially for maintenance of healing of erosive esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2874302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg; omeprazole 40 mg [immediate release] and sodium bicarbonate 1100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 40 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid OTC&trade;: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 303 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 20 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 40 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2874245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15664179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zegerid&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328349.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328349.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2874290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Both strengths of Zegerid&reg; capsule and powder for oral suspension have identical sodium bicarbonate content, respectively. Do not substitute two 20 mg capsules/packets for one 40 mg dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Should be swallowed whole with water (do not use other liquids); do not chew or crush. Capsules should",
"     <b>",
"      not",
"     </b>",
"     be opened, sprinkled on food, or administered via NG. Best if taken at least 1 hour before breakfast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for oral suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Administer 1 hour before a meal. Mix with 15-30 mL of water; stir well and drink immediately. Rinse cup with water and drink. Do not use other liquids or sprinkle on food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasogastric/orogastric tube: Mix well with 20 mL of water (do not use other liquids) and administer immediately; flush tube with an additional 20 mL of water. Suspend enteral feeding for 3 hours before and 1 hour after administering.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2874250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (4-8 weeks) treatment of active duodenal ulcer or active benign gastric ulcer; treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD); short-term (4-8 weeks) treatment of endoscopically-diagnosed erosive esophagitis; maintenance healing of erosive esophagitis; reduction of risk of upper gastrointestinal bleeding in critically-ill patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     OTC labeling: Short-term (2 weeks) treatment of frequent (2 days/week), uncomplicated heartburn",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zegerid&reg; may be confused with Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2874260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percentages of adverse events reported from a controlled clinical trial of 359 critically-ill patients receiving the oral powder for suspension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (12%), hyperglycemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nosocomial pneumonia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (10%), hypertension (8%), atrial fibrillation (6%), ventricular tachycardia (5%), bradycardia (4%), tachycardia (3%), supraventricular tachycardia (3%), edema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hyperpyrexia (5%), agitation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatological: Rash (6%), decubitus ulcer (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia (10%), hypocalcemia (6%), hypophosphatemia (6%), fluid overload (5%), hypoglycemia (3%), hyponatremia (4%), hypernatremia (2%), hyperkalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (5%), diarrhea (4%), hypomotility (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematological: Thrombocytopenia (10%), anemia (8%), anemia increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: ARDS (3%), respiratory failure (2%), pneumothorax (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (5%), oral candidiasis (4%), candidal infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Agranulocytosis, allergic reactions, alopecia, anaphylaxis, angina, angioedema, anorexia, atrophic gastritis, benign gastric polyps, bronchospasm,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), creatinine increased, depression, erythema multiforme, esophageal candidiasis, fracture, glycosuria, gynecomastia, hallucinations, hematuria, hemifacial dysesthesia, hemolytic anemia, hepatic encephalopathy, hepatic failure, hepatic necrosis interstitial nephritis, hypersensitivity, leukocytosis, leukopenia, liver disease (hepatocellular, cholestatic, mixed), metabolic alkalosis, microscopic pyuria, microscopic colitis, mucosal atrophy (tongue), neutropenia, optic neuritis, optic neuropathy, osteoporosis-related fracture, pancreatitis, pancytopenia, photosensitivity, pneumonia (CAP), proteinuria, psychiatric disturbance, purpura, seizure, Stevens-Johnson syndrome, taste perversion, tinnitus, toxic epidermal necrolysis, vertigo, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2874255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to omeprazole, substituted benzimidazole proton pump inhibitors, sodium bicarbonate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2874256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Atrophic gastritis (observed on biopsy) has been reported with long-term use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter.  Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of omeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bartter&rsquo;s syndrome: Use with caution in patients with Bartter&rsquo;s syndrome; contains sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Bioavailability may be increased in patients with hepatic dysfunction; consider dosage reductions, especially for maintenance of healing of erosive esophagitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with hypocalcemia; contains sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; contains sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory alkalosis: Use with caution in patients with respiratory alkalosis; contains sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole).  In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel  (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of omeprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ethnicity: Bioavailability may be increased in patients of Asian descent; consider dosage reductions, especially for maintenance of healing of erosive esophagitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bioavailability may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium-restricted diets: Use with caution in patients on sodium-restricted diets; contains sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should contact healthcare provider if they have heartburn for &gt;3 months, heartburn with dizziness, lightheadedness, or sweating, MI symptoms, frequent chest pain, frequent wheezing (especially with heartburn), unexplained weight loss, nausea/vomiting, stomach pain, on a sodium-restricted diet, or are taking antifungals, HIV antivirals, diazepam, digoxin, tacrolimus, warfarin or other prescription medications. Patients should stop use and consult a healthcare provider if heartburn continues or worsens, or if they need to take for &gt;14 days or more often than every 4 months. Patients should be informed that it may take 1-4 days for full effect to be seen. OTC use is not approved for children &lt;18 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2874267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2874266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Omeprazole may enhance the adverse/toxic effect of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol. Omeprazole may increase the serum concentration of  OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased effects of cilostazol when coadministered with omeprazole. Consider a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Omeprazole may increase the serum concentration of Escitalopram.  Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Escitalopram dosing recommendations may differ between international labelings in regards to concomitant use of omeprazole. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Sodium Bicarbonate may diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Proton Pump Inhibitors may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Bicarbonate may increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Sodium Bicarbonate may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Proton Pump Inhibitors may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2874270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food delays absorption. When given 1 hour after a meal, absorption is reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease omeprazole levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2874251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2874252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies with omeprazole. Based on data collected by the Teratogen Information System (TERIS), it was concluded that therapeutic doses used during pregnancy would be unlikely to pose a substantial teratogenic risk (quantity/quality of data: fair). Because the possibility of harm still exists, the manufacturer recommends use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus. Chronic use of sodium bicarbonate-containing products may lead to systemic alkalosis, edema, and weight gain; metabolic alkalosis and fluid overload may occur in mother and fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2874254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10903170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following administration of omeprazole 20 mg, peak concentrations detected in the breast milk were &lt;7% of the maternal serum concentration.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2874289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Take 1 hour before a meal. Contains sodium; use with caution in patients on sodium-restricted diets.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Omeprazole-Sodium Bicarbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-1100 mg (30): $341.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-1100 mg (30): $341.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zegerid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-1100 mg (30): $380.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-1100 mg (30): $380.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zegerid OTC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-1100 mg (14): $9.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Zegerid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-1680 mg (30): $380.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-1680 mg (30): $380.16",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zegacid (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2874273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric basal and stimulated acid secretion by inhibiting the parietal cell H+/K+ ATP pump",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2874275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antisecretory: ~1 hour; Peak antisecretory effect:  2 hours; Full therapeutic effect: 1-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~30% to 40%; Hepatic dysfunction: ~100%; Asians: AUC increased up to 4 times compared to Caucasians",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1 hour (range: 0.4-3.2 hours); Hepatic dysfunction:  ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (77% as metabolites, very small amount as unchanged drug); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andersson T, &ldquo;Omeprazole Drug Interaction Studies,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 21(3):195-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/1764870/pubmed\" id=\"1764870\" target=\"_blank\">",
"        1764870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balian JD, Sukhova N, Harris JW, et al, &ldquo;The Hydroxylation of Omeprazole Correlates With S-Mephenytoin Metabolism: A Population Study,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(6):662-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/7781266/pubmed\" id=\"7781266\" target=\"_blank\">",
"        7781266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berardi RR and Dunn-Kucharski VA, &ldquo;Omeprazole: Defining Its Role in Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Hosp Formul",
"      </i>",
"      , 1995, 30:216-25.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beutler M, Hartmann K, Kuhn M, et al, &ldquo;Arthralgias on Omeprazole,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1994, 309(6969):1620.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CN and Richter JE, &ldquo;Treating Gastro-oesophageal Reflux Disease During Pregnancy and Lactation: What Are the Safest Therapy Options?&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1998, 19(4):325-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/9804446/pubmed\" id=\"9804446\" target=\"_blank\">",
"        9804446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carvajal A and Martin Arias LH, &ldquo;Gynecomastia and Sexual Disorders After the Administration of Omeprazole,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1995, 90(6):1028-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1999, 141(1):173-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/10417548/pubmed\" id=\"10417548\" target=\"_blank\">",
"        10417548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2012, 36(10):941-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/23034135/pubmed\" id=\"23034135\" target=\"_blank\">",
"        23034135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epelde Gonzalo FD, Boada Montagut L, and Tomas Vecina S, &ldquo;Exfoliative Dermatitis Related to Omeprazole,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(1):82-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunasekaran TS and Hassall EG, &ldquo;Efficacy and Safety of Omeprazole for Severe Gastroesophageal Reflux in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(1):148-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/8320610/pubmed\" id=\"8320610\" target=\"_blank\">",
"        8320610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane DL, &ldquo;Administration of Omeprazole (Prilosec&reg;) in the Atypical Patient,&rdquo;",
"      <i>",
"       Int J Pharm Compounding",
"      </i>",
"      , 1997, 1(1):13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kato S, Ebina K, Fujii K, et al, &ldquo;Effect of Omeprazole in the Treatment of Refractory Acid-Related Diseases in Childhood: Endoscopic Healing and Twenty-Four Hour Intragastric Acidity,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(3):415-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/8774516/pubmed\" id=\"8774516\" target=\"_blank\">",
"        8774516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus A and Flores-Suarez LF, &ldquo;Acute Gout Associated With Omeprazole,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8947):461-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larner AJ and Lendrum R, &ldquo;Oesophageal Candidiasis After Omeprazole Therapy,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1992, 33(6):860-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/1624174/pubmed\" id=\"1624174\" target=\"_blank\">",
"        1624174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau JY, Sung JJ, Lee KK, et al, &ldquo;Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(5):310-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/10922420/pubmed\" id=\"10922420\" target=\"_blank\">",
"        10922420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindquist M and Edwards IR, &ldquo;Endocrine Adverse Effects of Omeprazole,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1992, 305(6851):451-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(4):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/10772433/pubmed\" id=\"10772433\" target=\"_blank\">",
"        10772433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottervanger JP, Stricker BH, Kappelle JW, et al, &ldquo;Omeprazole-Associated Agranulocytosis,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 1995, 54(4):279-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/7789474/pubmed\" id=\"7789474\" target=\"_blank\">",
"        7789474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soll AH, Weinstein WM, Kurata J, et al, &ldquo;Nonsteroidal Anti-inflammatory Drugs and Peptic Ulcer Disease,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 114(4):307-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/28/10697/abstract-text/1987878/pubmed\" id=\"1987878\" target=\"_blank\">",
"        1987878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000, 118(2 Suppl 1):9-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woods DJ and McClintock AD, &ldquo;Omeprazole Administration,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(5):651.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10322 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10697=[""].join("\n");
var outline_f10_28_10697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874247\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874285\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874286\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874287\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874288\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874302\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874245\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15664179\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874260\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874255\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874256\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874270\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874251\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874252\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874254\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903170\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874289\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422180\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961926\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874273\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874275\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/27/27061?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/47/38648?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_28_10698="Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides";
var content_f10_28_10698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Tamas R Peredy, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/28/10698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/28/10698/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/28/10698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26667326\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amatoxins are found in a variety of poisonous mushrooms (eg, Amanita phalloides, Amanita virosa, and Galerina autumnalis) and are responsible for more than 90 percent of fatalities caused by mushroom poisoning worldwide. Ingestion of one or more amatoxin-containing mushrooms is a life-threatening emergency. Treatment should be initiated expeditiously when a presumptive identification is made or clinical manifestations of amatoxin poisoning develop. Orthotopic liver transplantation has greatly reduced the mortality due to this poisoning. (See",
"    <a class=\"local\" href=\"#H26667347\">",
"     'Evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26667361\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical manifestations, and management of amatoxin-containing mushroom poisoning will be reviewed here. Clinical manifestations, evaluation, and management of poisoning caused by other types of mushroom toxins are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42615?source=see_link\">",
"     \"Management of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36759?source=see_link\">",
"     \"Amanita smithiana mushroom poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26038133\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are over 10,000 species of mushrooms worldwide. Of these, only 50 to 100 are potentially toxic. In the United States, approximately 6000 toxic mushroom exposures occur annually. Most of these patients experience no toxic effects or only mild or moderate symptoms. Over half of toxic mushroom ingestions occur in children less than six years of age and are usually limited to a partial or single bite of nontoxic or minimally toxic mushrooms (",
"    <a class=\"graphic graphic_picture graphicRef76207 \" href=\"UTD.htm?8/16/8453\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68114 \" href=\"UTD.htm?12/19/12592\">",
"     picture 2",
"    </a>",
"    ). Even in the uncommon cases of amatoxin-containing mushroom exposures (",
"    <a class=\"graphic graphic_picture graphicRef73705 \" href=\"UTD.htm?6/63/7152\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52731 \" href=\"UTD.htm?17/35/17974\">",
"     picture 4",
"    </a>",
"    ), children do well because of the limited amount of toxins available in the small amount of mushroom typically ingested. In the United States, no pediatric fatalities due to ingestion of a single mushroom have occurred in over 25 years of National Poison Data System surveillance.",
"   </p>",
"   <p>",
"    When serious toxicity or mortality due to mushroom ingestion does occur, it typically results from consumption of misidentified mushrooms by foraging adults and others who shared the meal. A common scenario involves amateur mushroom hunters or recent immigrants who mistake a toxic mushroom for an edible variety with similar morphologic features (eg, Amanita species (",
"    <a class=\"graphic graphic_picture graphicRef73705 \" href=\"UTD.htm?6/63/7152\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52731 \" href=\"UTD.htm?17/35/17974\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67262 \" href=\"UTD.htm?33/55/34675\">",
"     figure 1",
"    </a>",
"    ) mistaken for Agaricus species). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617122#H21617122\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 35 mushroom species in three genera (Amanita, Galerina, and Lepiota) contain amatoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. Amatoxin-containing mushroom species (eg, Amanita phalloides (",
"    <a class=\"graphic graphic_picture graphicRef73705 \" href=\"UTD.htm?6/63/7152\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67262 \" href=\"UTD.htm?33/55/34675\">",
"     figure 1",
"    </a>",
"    ), A. virosa, A. bisporigera (",
"    <a class=\"graphic graphic_picture graphicRef52731 \" href=\"UTD.htm?17/35/17974\">",
"     picture 4",
"    </a>",
"    ), Galerina autumnalis) cause approximately 50 deaths annually in Europe and Asia compared with two deaths annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This difference in frequency of lethal exposures probably reflects the relative popularity of mushroom foraging in Europe and Asia rather than significant variance in intrinsic toxicity or prevalence of harmful mushroom species among the regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11350766\">",
"    <span class=\"h1\">",
"     MUSHROOM APPEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mushroom identification is usually not readily available during the acute phase of care, and most mushrooms causing toxicity are never correctly identified. However, if possible, determination of the specific type of mushroom ingested can be helpful for treatment recommendations and prognosis. Consultation with a medical toxicologist and professional mycologist is strongly advised when attempting mushroom identification (US regional poison control center: 1-800-222-1222 or access the World Health Organization's list of international poison centers [",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ]). In any case where ingestion of an amatoxin-containing mushroom species is highly suspected, either by expert mushroom identification or clinical manifestations, aggressive therapy is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26667361\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The &ldquo;deadly white Amanitas&rdquo; (eg, A. phalloides (",
"    <a class=\"graphic graphic_picture graphicRef73705 \" href=\"UTD.htm?6/63/7152\">",
"     picture 3",
"    </a>",
"    ), A. bisporigera (",
"    <a class=\"graphic graphic_picture graphicRef52731 \" href=\"UTD.htm?17/35/17974\">",
"     picture 4",
"    </a>",
"    ), A. virosa, A. ocreata, and A. verna) are most commonly involved in human exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/3\">",
"     3",
"    </a>",
"    ]. Physical characteristics of these mushrooms include a symmetric cap (pileus) and stem (stipe) with a bulbous base (volva) and free gills (",
"    <a class=\"graphic graphic_figure graphicRef67262 \" href=\"UTD.htm?33/55/34675\">",
"     figure 1",
"    </a>",
"    ). They have no offensive taste or odor, most often growing singly from the ground in moist, hardwood chestnut or oak forests. They mature throughout the mid-summer and fall in temperate regions. White spores may be detected if the cap is left on colored filter paper for one hour. Immature amatoxin-containing Amanita mushrooms are egg-shaped &ldquo;buttons&rdquo; that reveal developing structures when bisected. Not all Amanita mushrooms contain amatoxin, including several edible types.",
"   </p>",
"   <p>",
"    Lepiota, including L. josserandii, are similar in appearance to the deadly white Amanitas and also have high-amatoxin content [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. They are far less prevalent and are implicated in human exposures less often. Their caps are more pointy (umbonate) and more heavily covered in concentrically ringed scales.",
"   </p>",
"   <p>",
"    Galerina mushrooms (eg, G. autumnalis, G. marginata, G. venenata) are smaller and have much lower concentrations of amatoxin. Galerina are brown and grow in groups directly from decaying wood. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667340\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND TOXICOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amatoxins are cyclic octapeptides t [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the multiple amatoxins, alpha-amanitin appears to be most responsible for human toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/6\">",
"     6",
"    </a>",
"    ]. Other cyclopeptide toxins (eg, phallotoxins, verotoxins) are felt to play a lesser role, if any, in human toxicity. Amatoxins are insoluble in water, so &ldquo;parboiling&rdquo; does not make cyclopeptide-containing mushrooms safe. The lethal dose of amanitin or alpha-amatoxin can be as low as 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in humans or approximately two mushroom caps. [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amatoxins are absorbed by the gastrointestinal tract and then transported to the liver through the portal circulation. Active transport by the hepatocyte membrane proteins organic anion transporting polypeptide (OATP) 1B3 and sodium taurocholate co-transporter (NTCP) concentrates the toxin within the liver cell [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Once inside the cell, amatoxins bind to DNA-dependent RNA polymerase type II and halt intracellular protein synthesis, ultimately resulting apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In addition to the liver, other organ systems with rapid cellular turnover (eg, gastrointestinal tract, proximal convoluted renal tubules) may also be affected. Amatoxins do not appear to cross the placenta based upon observation of normal neonatal outcomes in poisoned pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/15\">",
"     15",
"    </a>",
"    ]. Compounds such as silibinin dihemisuccinate, cyclosporin A,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    inhibit amanitin uptake into human hepatocytes in vitro and may mitigate toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited observations following human poisoning and animal models suggest that amatoxins are incompletely absorbed from the gastrointestinal tract, have a low volume of distribution (0.3",
"    <span class=\"nowrap\">",
"     L/kg),",
"    </span>",
"    and very low protein binding (0.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. They can be detected in blood and urine up to 48 hours after mushroom consumption. Most amatoxins are excreted in the urine. Biliary excretion and enterohepatic recirculation also occur with high levels of amatoxins measured in gastroduodenal fluid in poisoned patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/2,3,16\">",
"     2,3,16",
"    </a>",
"    ]. Thus, interrupting biliary circulation has been a strategy of reduction of ongoing exposure in amatoxin ingestion. In severe human cases, synchronous centrilobular (zone 1) hepatocyte necrosis leads to fulminant hepatic failure and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667347\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should provide prompt support of airway, breathing, and circulation, as needed. A regional poison control center should be contacted to discuss likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. Most poison control centers maintain active call lists of mycologists who are knowledgeable concerning local prevalence of mushroom genera and species and can assist in mushroom identification. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The table provides a description of the various mushroom poisoning syndromes (",
"    <a class=\"graphic graphic_table graphicRef77875 \" href=\"UTD.htm?11/28/11727\">",
"     table 1",
"    </a>",
"    ). A discussion of the clinical recognition and management of poisoning by other mushroom species is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42615?source=see_link\">",
"     \"Management of mushroom poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of amatoxin-containing mushroom poisoning typically depends upon recognition of the clinical presentation and laboratory abnormalities that indicate hepatotoxicity. The clinical diagnosis should be confirmed, when possible, by amatoxin detection in the urine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mushroom identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393811\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed onset of signs and symptoms more than six hours after mushroom consumption suggests a serious toxic mushroom ingestion. However, early onset of poisoning symptoms less than six hours after mushroom ingestion does not exclude such poisoning if multiple species of mushroom were ingested.",
"   </p>",
"   <p>",
"    Clinical manifestations of amatoxin-containing mushroom poisoning may be categorized into three phases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gastroenteritis",
"      </strong>",
"      &ndash; Patients develop epigastric abdominal pain, vomiting, and severe, cholera-like diarrhea that may contain blood and mucous and typically starts between 6 and 24 hours after mushroom ingestion. Hepatomegaly may also be present, but liver enzymes and bilirubin are usually normal. Electrolyte abnormalities consistent with a secretory diarrhea (eg, hypokalemia and metabolic acidosis) may also occur. Earlier onset of gastroenteritis between 6 and 9 hours after mushroom consumption may correlate with severe hepatotoxicity evidenced by elevations of liver enzymes at 24 to 36 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/20\">",
"       20",
"      </a>",
"      ]. Profound GI fluid losses may lead to dehydration, acute renal failure, and circulatory shock. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Apparent recovery",
"      </strong>",
"      &ndash; With appropriate supportive care of the delayed gastroenteritis, patients appear to improve between approximately 24 to 36 hours after mushroom consumption. Elevations in the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are typically detectable between 24 and 36 hours after mushroom ingestion and typically peak by approximately 60 to 72 hours post-ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/20\">",
"       20",
"      </a>",
"      ]. In patients with severe poisoning, the patient may go directly from severe gastroenteritis into fulminant organ failure with hyperbilirubinemia, dramatic elevations in liver enzymes over 1000 to 2000",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      prolongation of the prothrombin time, renal insufficiency, and disseminated intravascular coagulopathy. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Fulminant hepatic and multisystem organ failure",
"      </strong>",
"      &ndash; Approximately two to four days after mushroom consumption, severely poisoned patients develop hepatic failure, often complicated by acute renal failure. Massive simultaneous hepatocyte cell death disrupts hepatic venous and biliary flow. Peak transaminase elevations are typically seen between 48 and 72 hours post-ingestion and may be greater than 2000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/20\">",
"       20",
"      </a>",
"      ]. Direct nephrotoxic effects are seen in the proximal and distal convoluted renal tubules. Pancreatitis occurs in half of all severe cases. Loss of hepatic function over the following days causes hypoglycemia, coagulopathy, encephalopathy, and fluid shifts with progression to multi-organ failure. In up to 30 percent of patients, death occurs, typically within one to two weeks of mushroom ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393990\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with ingestion of amatoxin-containing mushrooms should undergo baseline assessment of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes, calcium, and phosphate",
"     </li>",
"     <li>",
"      Liver studies (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total protein, albumin, total and direct bilirubin)",
"     </li>",
"     <li>",
"      Prothrombin time (PT), partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      Complete blood count with platelets",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic patients should undergo testing as described above. In addition, they may warrant other studies based upon their clinical findings as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fulminant hepatic failure &ndash; blood gas determination; blood ammonia; serum glucose, lactate, lactate dehydrogenase (LDH), and lipase",
"     </li>",
"     <li>",
"      Altered mental status &ndash; blood gas determination, serum glucose, and if hepatic encephalopathy or signs of increased intracranial pressure, neuroimaging (eg, computed tomography of the brain)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667354\">",
"    <span class=\"h2\">",
"     Amatoxin detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest laboratory confirmation of amatoxin poisoning when testing is available. However, treatment should not wait for these results. Urine is the preferred specimen, although amatoxins can also be detected in blood or gastric aspirates. Detection methods include polymerase chain reaction, high-performance liquid",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrophotometry, enzyme-linked immunoassay (ELISA) or radioimmunoassay. Of these, ELISA testing for amanitin in the urine is the least technically challenging and has good sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/21\">",
"     21",
"    </a>",
"    ]. ELISA testing for amatoxins is most reliable within 36 hours of mushroom ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Amatoxins are typically not detectable in the blood or urine more than four days after mushroom consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Meixner bedside test is unreliable and should not be performed. Specific laboratory testing for mycotoxins is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394028\">",
"    <span class=\"h2\">",
"     Mushroom identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, samples of all ingested mushrooms should be obtained. Whole mushrooms are preferred, but identification can be made on parts of the mushroom, especially the cap. Further storage is facilitated by wrapping the mushrooms in wax paper, placing them in a paper bag, and refrigerating the sample. Storage in plastic bags should be avoided. Unfortunately, patients often ingest multiple mushrooms and have cooked, or otherwise damaged the fungi they have ingested, making direct identification difficult or impossible. In these situations, a centrifuged gastric aspirate may be obtained for microscopic evaluation of spores by a professional mycologist although identification of the ingested mushroom or mushrooms is rarely possible from such specimens. Mushroom identification is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667361\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for care of children and adults with amatoxin-containing mushroom poisoning are primarily derived from observational studies, including case series and reports. In addition, to careful assessment and support of airway, breathing, and circulation as needed, treatment of amatoxin-containing mushroom poisoning consists of the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform gastrointestinal decontamination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"     </li>",
"     <li>",
"      Prevent enterohepatic circulation of amatoxins by administering multiple dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (MDAC)",
"     </li>",
"     <li>",
"      Aggressively manage fluid losses caused by vomiting and diarrhea",
"     </li>",
"     <li>",
"      Disrupt hepatocellular uptake of amatoxins with silibinin dihemisuccinate or if silibinin is not available, high-dose, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"     </li>",
"     <li>",
"      Provide antioxidant therapy with intravenous N-acetylcysteine",
"     </li>",
"     <li>",
"      Anticipate and provide supportive care of fulminant hepatic failure, including intensive care in an institution with liver transplant capability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the optimal timing for the administration of MDAC, silibinin dihemisuccinate or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    , and N-acetylcysteine is within 24 hours of amatoxin-containing mushroom ingestion, these therapies should still be initiated in patients with suspected amatoxin-containing mushroom poisoning who present for treatment after 24 hours.",
"   </p>",
"   <p>",
"    Certain therapies are associated with no benefit or worsening outcomes in animal models or clinical reports of amatoxin-containing mushroom poisoning and should be avoided including glucocorticoids, insulin in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    or growth hormone, vitamin E,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    , and amatoxin-specific Fab fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241672\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates of approximately 50 percent seen in series of amatoxin-containing mushroom poisoning can be reduced to below 10 percent with appropriate supportive care alone, primarily adequate fluid resuscitation, and administration of multiple dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with significant amatoxin-containing mushroom poisoning typically require aggressive fluid resuscitation to manage losses from severe vomiting and diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive supportive care of liver toxicity includes treatment of hypoglycemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    administration for hyperammonemia, vitamin K replacement, and infusions of fresh frozen plasma for significant coagulopathy. Other common comorbidities include acute renal failure, sepsis, metabolic disturbances, hepatic encephalopathy, and cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667368\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that alert patients with a suspected amatoxin-containing mushroom ingestion receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC).&nbsp;Because of adverse effects, such as vomiting, diarrhea, and volume depletion, patients with mushroom poisoning should not receive a cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ). Amatoxins bind well to AC in vitro. In patients with amatoxin-containing mushroom poisoning, multiple doses of AC are associated with improved survival compared with supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The recommendation for AC also derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other poisonous substances. (See",
"    <a class=\"local\" href=\"#H394148\">",
"     'Elimination enhancement'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993761#H18993761\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    We recommend that patients who ingest an amatoxin-containing mushroom",
"    <strong>",
"     not",
"    </strong>",
"    undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department. This recommendation is based upon randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. Syrup of ipecac administered in remote locations far from medical treatment soon after pediatric ingestion may prevent toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H3#H3\">",
"     \"Decontamination of poisoned children\", section on 'Syrup of ipecac'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993776#H18993776\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasogastric aspiration in alert patients to obtain a sample for spore analysis may be appropriate in selected instances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394148\">",
"    <span class=\"h2\">",
"     Elimination enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients who ingest amatoxin-containing mushrooms receive multiple dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC). The dose is 0.5",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    (maximum dose 50 g) every four hours and should be continued until four days after mushroom consumption. Because amatoxin-containing mushroom ingestion usually is associated with severe diarrhea, co-administration of cathartics with MDAC should be avoided. Optimum benefit is expected if MDAC is started within 24 hours of mushroom ingestion. This recommendation is based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amatoxins are excreted in the bile and recirculated in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/16\">",
"       16",
"      </a>",
"      ]. The duration of biliary excretion may be up to five days after mushroom consumption.",
"     </li>",
"     <li>",
"      MDAC administration permits binding of amatoxins and elimination in the feces [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one case series, MDAC administration alone without other specific therapies was associated with 9 percent mortality (2 out of 22 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a critical review of 2100 cases of amatoxin-containing mushroom poisoning, detoxification procedures alone, including MDAC, were associated with a mortality rate of 10 percent versus 47 percent when supportive care alone was provided [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The charcoal dosing regimen actually delivered is often dictated by patient tolerance. In patients with vomiting, smaller, more frequent doses or slow continuous nasogastric infusion may be better tolerated and effective. Antiemetics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 8 mg) may also be helpful. MDAC should not be used in patients with gastrointestinal ileus, perforation, obstruction, or in patients with depressed mental status and an unprotected airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link&amp;anchor=H2#H2\">",
"     \"Enhanced elimination of poisons\", section on 'Multiple-dose activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continuous nasojejunal suction or other biliary drainage techniques (eg, nasobiliary catheter placed endoscopically, biliary stent) have been proposed by some experts, especially in patients who present for medical care within 24 hours of ingestion of definitively identified amatoxin-containing mushrooms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there are no published reports of outcomes following biliary drainage in patients with mushroom poisoning and no evidence to suggest that biliary drainage is additive to or better than MDAC alone. &nbsp;",
"   </p>",
"   <p>",
"    Extracorporeal elimination has not been shown to improve survival nor has there been pharmacokinetic evidence of benefit in studies of hemodialysis, hemoperfusion, or plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/18,28-31\">",
"     18,28-31",
"    </a>",
"    ]. In particular, hemodialysis and hemoperfusion are ineffective at removing significant amounts of amatoxins in patients with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2843563\">",
"    <span class=\"h2\">",
"     Amatoxin uptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several compounds have been shown to decrease amatoxin uptake by animal and human hepatocytes in experimental models [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"     12",
"    </a>",
"    ]. Of these, silibinin dihemisuccinate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    have been used the most in human poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394132\">",
"    <span class=\"h3\">",
"     Silibinin dihemisuccinate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silibinin is an extract of the Mediterranean milk thistle (Silybum marianum) and inhibits amatoxin uptake by organic anion transporting polypeptide (OATP) 1B3 and sodium taurocholate co-transporter (NTCP) located in hepatocyte membranes. It improves cellular survival in human hepatocytes exposed to alpha-amanitin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. Intracellular effects also include stimulation of RNA polymerase type I, antioxidant effects, and enhanced amatoxin excretion into the bile [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that patients with amatoxin-containing mushroom poisoning receive intravenous silibinin dihemisuccinate, if available. Silibinin is administered as an initial IV loading dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by a continuous IV infusion at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for six days or until the patient shows clinical signs of recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/34\">",
"     34",
"    </a>",
"    ]. In the United States, silibinin (Legalon&reg; SIL) is available directly from the principle investigator of an open NIH clinical trial (NCT00915681) by calling 1-866-520-4412 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. Each vial contains the equivalent of 350 mg of silibinin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This recommendation for silibinin is supported by the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of treatments given to 2100 patients with amatoxin-containing mushroom poisoning found that 624 patients who received silibinin had a mortality rate of 5.9 percent which was significantly lower than the average mortality rate of 11.6 percent among all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 118 patients who received silibinin alone found that 5 percent died or underwent liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/36\">",
"       36",
"      </a>",
"      ]. A higher frequency of death or organ transplantation occurred in patients who received silibinin more than 24 hours after mushroom ingestion (OR 3.0, 95% CI 0.96-9.2).",
"     </li>",
"     <li>",
"      Silibinin infusion appears to be well tolerated in humans with skin flushing being the most common adverse reaction reported by the manufacturer. Nausea, stomach and joint pains, headache, and itching have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/37\">",
"       37",
"      </a>",
"      ]. Anaphylactic reactions are rare [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/38\">",
"       38",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that IV silibinin therapy is safe and may have a significant impact on mortality in patients with amatoxin-containing mushroom poisoning, especially if initiated within 24 hours of mushroom consumption. Thus, all efforts should be made to obtain the parenteral form of silibinin in patients with serious amatoxin-containing mushroom poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H790516\">",
"    <span class=\"h3\">",
"     Silymarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silymarin is an extract of the Mediterranean milk thistle (Silybum marianum) that contains several flavonolignans, including silybin (the natural form of the drug, silibinin dihemisuccinate). Silymarin capsules are available in 100, 150, and 300 mg concentrations online and at a variety of stores in the US that stock health food and complementary medicine items. It is not typically available from US hospital pharmacies. Because manufacture of these formulations is not regulated in the US, the concentration of silybin in various formulations varies. However, most silymarin capsules contain approximately 50 percent silybin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/39\">",
"     39",
"    </a>",
"    ]. Oral absorption is approximately 20 to 40 percent in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/40\">",
"     40",
"    </a>",
"    ] and administration of silymarin capsules to healthy volunteers resulted in peak plasma levels of silybin at three to five hours with an elimination half life of approximately six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that intravenous silibinin dihemisuccinate is superior to oral formulations and should be obtained if at all possible. We suggest that, if intravenous silibinin dihemisuccinate is not available, patients with amatoxin-containing mushroom poisoning receive oral silymarin capsules in addition to intravenous penicillin and N-acetylcysteine.",
"   </p>",
"   <p>",
"    No clear guidance for oral dosing of silymarin for amatoxin-containing mushroom poisoning is available. Given the 50 percent concentration of silybin in most silymarin extracts and the low absorption, oral dosing of approximately 10 grams of silymarin capsules daily would be required to achieve plasma concentrations equivalent to the typical intravenous dose of silibinin (20",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    This dose is much higher than the usual silymarin dose of 150 to 360 mg three times daily that is used for other liver diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/41\">",
"     41",
"    </a>",
"    ]. High doses of silymarin may produce significant diarrhea and may complicate management in some patients. Thus, the clinician may initially start with a trial dose of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum single dose: 2 grams) of oral silymarin in capsule form every eight hours and if tolerated, increase to a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum single dose; 3 grams) for a duration of six days or until the patient shows signs of clinical improvement. In patients who do not tolerate the trial dose, lower doses may be attempted, but may not provide hepatic protection. Successful oral administration may require aggressive treatment of vomiting with antiemetics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum dose; 16 mg) and replacement of fluid losses caused by diarrhea.",
"   </p>",
"   <p>",
"    Evidence for the benefit of oral administration derives indirectly from the potential benefit of intravenous administration of silibinin (see",
"    <a class=\"local\" href=\"#H394132\">",
"     'Silibinin dihemisuccinate'",
"    </a>",
"    above). Although silymarin has not been studied in a controlled fashion in humans, it has shown a protective effect in animal models of Amanita phalloides poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Silymarin may cause nausea, abdominal pain, and diarrhea, but no serious toxic effects at doses less than 1.5 grams per day have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/40\">",
"     40",
"    </a>",
"    ]. Toxicity at higher doses has not been studied. Silymarin should not be given to patients with allergy to thistle, kiwi, artichoke, or other members of the Asteraceae family [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilute liquid formulations of silymarin are sold as liver tonics in health food stores, but these formulations are of no value in amatoxin-containing mushroom poisoning because they contain low doses of silybin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2843571\">",
"    <span class=\"h3\">",
"     Penicillin G",
"    </span>",
"    &nbsp;&mdash;&nbsp;In human and animal models of amatoxin toxicity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    may inhibit amatoxin uptake by organic anion transporting polypeptide (OATP) 1B3 located in hepatocyte membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"     12",
"    </a>",
"    ], may prevent cellular toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/32\">",
"     32",
"    </a>",
"    ], and in canine experiments, appears to have a time and dose-dependent effect on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Penicillin G is a much weaker inhibitor of human hepatocyte amatoxin uptake than silibinin in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We recommend that, when intravenous silibinin is not readily available, patients with amatoxin-containing mushroom poisoning receive a continuous intravenous infusion of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    . Recommended dosing varies from 300,000 to 1,000,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day (maximum dose: 40 million units) given as a continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. Penicillin G should not be given to patients with a known penicillin allergy. Limited data suggest that IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    4.5 grams every two hours may be an alternative for such patients. (See",
"    <a class=\"local\" href=\"#H241120\">",
"     'Other agents'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link&amp;anchor=H8#H8\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\", section on 'Algorithm for management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This recommendation is based upon the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series of amatoxin-mushroom poisoning, mortality was 2 percent for 111 patients who received a continuous IV infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      in a dose of 1,000,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      for 24 hours followed by 500,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      for two days. In addition to aggressive supportive care, all patients also received multiple dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and glutathione.",
"     </li>",
"     <li>",
"      A systematic review of treatments given to 2100 patients with amatoxin-containing mushroom poisoning found that 1411 patients who received benzylpenicillin had a mortality rate of 10.7 percent that was only slightly lower than the average mortality rate of 11.6 percent among all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of patients with amatoxin-containing mushroom poisoning, death or organ transplantation occurred in 9 percent of 249 patients who received both silibinin and high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      infusions compared to 5 percent of 118 patients who received silibinin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/36\">",
"       36",
"      </a>",
"      ]. Although mortality was not significantly different between these regimens, these findings suggest that continuous penicillin G infusion may not provide additional benefit to patients who receive IV silibinin. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the available evidence suggests that continuous infusion of high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    may be beneficial for the treatment of amatoxin-containing mushroom poisoning, but the potential risk of this therapy is higher than for silibinin infusion. High-dose penicillin G infusion may be associated with coma, seizures, electrolyte imbalance (hyperkalemia or hypernatremia, depending upon excipient), severe granulocytopenia, acute interstitial nephritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal tubular damage, although the frequency of these adverse effects are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     \"Penicillin G (parenteral): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241120\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    administration has been proposed as an alternative beta-lactam antibiotic that may have hepatoprotective effects. Ceftazidime administration in combination with silibinin has been reported in 12 patients with amatoxin-containing mushroom poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"     23",
"    </a>",
"    ]. Although the impact on mortality appears favorable, the low number of patients treated and the co-administration of silibinin in all patients do not allow for firm conclusions regarding efficacy. The use of other antibiotics, such as aminoglycosides (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ), macrolides (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , has not been shown to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental studies in isolated human hepatocytes indicate that cyclosporin A,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    are significant inhibitors of amatoxin uptake into liver cells, but their use in human mushroom poisoning has not been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2844065\">",
"    <span class=\"h2\">",
"     Antioxidant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amatoxins are known to enhance lipid peroxidation that contributes to membrane instability and cell death. A number of antioxidants have been used in the treatment of amatoxin poisoning including N-acetylcysteine, ascorbic acid (vitamin C),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , and thioctic acid. Thioctic acid is no longer recommended because it is associated with hypoglycemia and does not improve clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394155\">",
"    <span class=\"h3\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with amatoxin-containing mushroom poisoning receive intravenous N-acetylcysteine (NAC). When administering NAC for this indication, the author typically uses a continuous infusion over 20 to 21 hours which is the same as IV administration for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H6#H6\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on '20 hour IV protocol'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Administer an initial loading dose of 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV over 15 to 60 minutes (we recommend 60 minutes).",
"     </li>",
"     <li>",
"      Next, administer a 4 hour infusion at 12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour IV.",
"     </li>",
"     <li>",
"      Finally, administer a 16 hour infusion at 6.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour IV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This treatment protocol provides a total of 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 20 to 21 hours. Weight-based dilution should be performed in children who weigh less than 40 kg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H36#H36\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This recommendation for NAC is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of treatments given to 2100 patients with amatoxin-containing mushroom poisoning found that 192 patients who received N-acetylcysteine had a mortality rate of 6.8 percent which was significantly lower than the average mortality rate of 11.6 percent among all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IV NAC is generally well-tolerated although anaphylactoid reactions have been described. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H15#H15\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2844099\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plant-derived iridoid glycosides, such as aucubin, have shown benefit in animal studies of alpha-amanitin toxicity, but clinical utility in humans is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. L-ascorbic acid (vitamin C) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    have antioxidant and cytoprotective effects in animal models of amatoxin-containing mushroom poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. However, use in cases of human poisoning has been limited and beneficial effects on outcome have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"     23",
"    </a>",
"    ]. Some experts still recommend their use in combination with silibinin and N-acetylcysteine in the following doses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       Cimetidine",
"      </a>",
"      : 300 mg IV every eight hours until clinical improvement",
"     </li>",
"     <li>",
"      Vitamin C: 3 grams IV daily until clinical improvement &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394357\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should contact a medical toxicologist and a liver transplant center early on when managing patients with suspected amatoxin-containing mushroom poisoning. Transfer to a tertiary care center capable of performing liver transplantation or other bridging liver failure therapies (eg, molecular absorbent recirculating system [MARS], extracorporeal albumen dialysis) should occur if clinical signs of improvement are not evident by four days post-ingestion or, depending upon consultant&rsquo;s advice, sooner.",
"   </p>",
"   <p>",
"    For consultation with a medical toxicologist in the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Liver transplant centers in the United States may be found using the United Network for Organ Sharing directory at",
"    <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/members/search.asp\">",
"     optn.transplant.hrsa.gov/members/search.asp",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In a critical review of treatment for amatoxin-containing mushroom poisoning in 2100 patients, liver transplantation was performed in approximately 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ]. The decision to perform liver transplantation or provide other advanced supportive therapies to allow for liver regeneration in such patients is complex and the criteria for liver transplantation after amatoxin-containing mushroom poisoning may not correspond with that used for other liver diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. For example, encephalopathy may not represent an appropriate prerequisite for transplantation in poisoned patients. Liver transplantation may occur without any danger of toxicity to the transplanted liver four days post-ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports describe full recovery despite severe poisoning by employment of bridging liver failure therapies (eg, molecular absorbent regenerating system [MARS], extracorporeal albumin dialysis) or auxiliary partial liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/28/10698/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667418\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt consultation with a regional or international poison control center is advised to assist with disposition decisions. (See",
"    <a class=\"local\" href=\"#H26667425\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients with suspected or confirmed ingestion of a significant amount of amatoxin-containing mushrooms (eg, one to two whole mushrooms) based upon clinical findings, amatoxin detection, or mushroom identification warrant hospital admission with initiation of gastrointestinal decontamination, multiple dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , inhibition of amatoxin uptake (eg, IV silibinin dihemisuccinate), antioxidant therapy (IV N-acetylcysteine), and supportive care. (See",
"    <a class=\"local\" href=\"#H26667347\">",
"     'Evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26667361\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children who are asymptomatic and ingested a small amount (eg, one bite) of a mushroom may receive a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    and be discharged to home if follow-up within 24 hours is assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667425\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct consultation with knowledgeable poison specialists, medical toxicologists, and mycologists is available through regional poison control centers. In the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ). We do",
"    <strong>",
"     not",
"    </strong>",
"    endorse the use of the internet for identification of toxic mushroom species without expert consultation.",
"   </p>",
"   <p>",
"    The toxicology section of the North American Mycological Association website provides lists of emergency identification volunteers available in North America, an overview of mushroom poisoning syndromes with pictures, and archived toxicology reports that describe specifics of poisoning cases in which NAMA mycologists provided assistance (",
"    <a class=\"external\" href=\"file://www.namyco.org/toxicology/index.html\">",
"     www.namyco.org/toxicology/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26667478\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When amatoxin-containing mushroom ingestion is suspected, a regional poison control center should be contacted to assist with identification of any mushroom specimen available, likelihood of amatoxin mushroom ingestion based upon clinical findings, and to provide treatment recommendations and resources. To obtain emergent consultation with a local medical toxicologist, call the United States Poison Control Network at 1-800-222-1222 (online at",
"      <a class=\"external\" href=\"file://www.aapcc.org/dnn/AAPCC/FindLocalPoisonCenters.aspx\">",
"       file://www.aapcc.org/dnn/AAPCC/FindLocalPoisonCenters.aspx",
"      </a>",
"      ) , or access the World Health Organization's list of international poison centers (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26667425\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amatoxins are found in a variety of Amanita and non-Amanita species mushrooms (eg, Amanita phalloides (",
"      <a class=\"graphic graphic_picture graphicRef73705 \" href=\"UTD.htm?6/63/7152\">",
"       picture 3",
"      </a>",
"      ), A. bisporigera (",
"      <a class=\"graphic graphic_picture graphicRef52731 \" href=\"UTD.htm?17/35/17974\">",
"       picture 4",
"      </a>",
"      ), A. virosa, Galerina autumnalis). Amatoxins are historically responsible for more than 90 percent of fatalities caused by mushroom poisoning worldwide. (See",
"      <a class=\"local\" href=\"#H26038133\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26667340\">",
"       'Pathophysiology and toxicokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of signs and symptoms &gt;6 hours after mushroom consumption should increase suspicion for amatoxin-containing mushroom poisoning. Caution should be exercised however if several different mushrooms have been consumed, resulting in a mixed clinical picture. The natural history of amatoxin-poisoning has been grouped into three phases along a timeline (see",
"      <a class=\"local\" href=\"#H393811\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gastrointestinal illness (6 to 24 hours post-ingestion)",
"     </li>",
"     <li>",
"      Latency (24 to 36 hours post-ingestion)",
"     </li>",
"     <li>",
"      Fulminant hepatic failure (starting 48 to 72 hours post-ingestion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of amatoxin-containing mushroom poisoning typically depends upon recognition of the clinical presentation and laboratory abnormalities that indicate hepatotoxicity. The clinical diagnosis should be confirmed, when possible, by amatoxin detection in the urine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mushroom identification. (See",
"      <a class=\"local\" href=\"#H26667347\">",
"       'Evaluation'",
"      </a>",
"      above.)All patients with strongly suspected or confirmed ingestion of a significant amount of amatoxin-containing mushrooms (eg, one to two whole mushrooms) based upon clinical findings, amatoxin detection, or mushroom identification warrant hospital admission. (See",
"      <a class=\"local\" href=\"#H26667418\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are asymptomatic and have recently ingested a small amount (eg, one bite) of a mushroom may receive a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      and be discharged to home if follow-up within 24 hours is assured.",
"     </li>",
"     <li>",
"      Supportive care of amatoxin-containing mushroom poisoning includes management of fluid losses caused by vomiting and diarrhea and anticipation of hepatotoxicity and multisystem organ failure. (See",
"      <a class=\"local\" href=\"#H241672\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who ingest an amatoxin-containing mushroom",
"      <strong>",
"       not",
"      </strong>",
"      undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In remote settings, if syrup of ipecac is immediately available after ingestion, administration prior to transport to a health care facility may be warranted. (See",
"      <a class=\"local\" href=\"#H26667368\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that alert patients with a suspected amatoxin-containing mushroom ingestion receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26667368\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who ingest amatoxin-containing mushrooms receive multiple dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (MDAC) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H394148\">",
"       'Elimination enhancement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with amatoxin-containing mushroom poisoning receive intravenous silibinin dihemisuccinate, if available (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H394132\">",
"       'Silibinin dihemisuccinate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If intravenous silibinin dihemisuccinate is not available for patients with amatoxin-containing mushroom poisoning:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that they receive a continuous intravenous infusion of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2843571\">",
"       'Penicillin G'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to a continuous infusion of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      , we suggest that they also receive oral silymarin capsules not typically stocked by hospital pharmacies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the United States, silymarin capsules contain small amounts of active ingredients and must be obtained from health food stores. (See",
"      <a class=\"local\" href=\"#H790516\">",
"       'Silymarin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to amatoxin uptake inhibitor therapy such as intravenous silibinin or continuous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      with oral silymarin, we recommend that patients with evidence of hepatocellular injury due to amatoxin-containing mushroom poisoning receive intravenous N-acetylcysteine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H394155\">",
"       'N-acetylcysteine'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The clinician should contact a liver transplant center early on when managing patients with suspected amatoxin-containing mushroom poisoning. (See",
"      <a class=\"local\" href=\"#H394357\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/1\">",
"      Enjalbert F, Rapior S, Nouguier-Soul&eacute; J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/2\">",
"      Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med 2005; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/3\">",
"      Broussard CN, Aggarwal A, Lacey SR, et al. Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol 2001; 96:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/4\">",
"      Chaiear K, Limpaiboon R, Meechai C, Poovorawan Y. Fatal mushroom poisoning caused by Amanita virosa in Thailand. Southeast Asian J Trop Med Public Health 1999; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/5\">",
"      Iliev Y, Andonova S, Akabaliev V. Our experience in the treatment of acute Amanita phalloides poisoning. Folia Med (Plovdiv) 1999; 41:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/6\">",
"      Wieland T, Faulstich H. Amatoxins, phallotoxins, phallolysin, and antamanide: the biologically active components of poisonous Amanita mushrooms. CRC Crit Rev Biochem 1978; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/7\">",
"      Paydas S, Kocak R, Erturk F, et al. Poisoning due to amatoxin-containing Lepiota species. Br J Clin Pract 1990; 44:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/8\">",
"      Schneider SM, Vanscoy G, Michelson EA. Failure of cimetidine to affect phalloidin toxicity. Vet Hum Toxicol 1991; 33:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/9\">",
"      Faulstich H. New aspects of amanita poisoning. Klin Wochenschr 1979; 57:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/10\">",
"      Gundala S, Wells LD, Milliano MT, et al. The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin alpha-amanitin. Arch Toxicol 2004; 78:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/11\">",
"      Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/12\">",
"      Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006; 91:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/13\">",
"      Magdalan J, Ostrowska A, Piotrowska A, et al. alpha-Amanitin induced apoptosis in primary cultured dog hepatocytes. Folia Histochem Cytobiol 2010; 48:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/14\">",
"      Vetter J. Toxins of Amanita phalloides. Toxicon 1998; 36:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/15\">",
"      Boyer JC, Hernandez F, Estorc J, et al. Management of maternal Amanita phallo&iuml;des poisoning during the first trimester of pregnancy: a case report and review of the literature. Clin Chem 2001; 47:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/16\">",
"      Jaeger A, Jehl F, Flesch F, et al. Kinetics of amatoxins in human poisoning: therapeutic implications. J Toxicol Clin Toxicol 1993; 31:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/17\">",
"      Feinfeld DA, Rosenberg JW, Winchester JF. Three controversial issues in extracorporeal toxin removal. Semin Dial 2006; 19:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/18\">",
"      Pond SM, Olson KR, Woo OF, et al. Amatoxin poisoning in northern California, 1982-1983. West J Med 1986; 145:204.",
"     </a>",
"    </li>",
"    <li>",
"     Goldfrank, LR. Mushrooms. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson, LS, Lewin, NA, Howland, MA, et al. (Eds), McGraw-Hill, New York 2011. p.1522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/20\">",
"      Giannini L, Vannacci A, Missanelli A, et al. Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of 105 patients. Clin Toxicol (Phila) 2007; 45:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/21\">",
"      Parant F, Peltier L, Lardet G, et al. [Phalloidin syndrome: role of Elisa-based assay for the detection of alpha- and gamma-amanitins in urine. Preliminary results]. Acta Clin Belg Suppl 2006; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/22\">",
"      Butera R, Locatelli C, Coccini T, Manzo L. Diagnostic accuracy of urinary amanitin in suspected mushroom poisoning: a pilot study. J Toxicol Clin Toxicol 2004; 42:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/23\">",
"      Poucheret P, Fons F, Dor&eacute; JC, et al. Amatoxin poisoning treatment decision-making: pharmaco-therapeutic clinical strategy assessment using multidimensional multivariate statistic analysis. Toxicon 2010; 55:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/24\">",
"      Wills BK, Haller NA, Peter D, White LJ. Use of amifostine, a novel cytoprotective, in alpha-amanitin poisoning. Clin Toxicol (Phila) 2005; 43:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/25\">",
"      Faulstich H, Kirchner K, Derenzini M. Strongly enhanced toxicity of the mushroom toxin alpha-amanitin by an amatoxin-specific Fab or monoclonal antibody. Toxicon 1988; 26:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/26\">",
"      Beuhler MC, Sasser HC, Watson WA. The Outcome of North American Pediatric Unintentional Mushroom Ingestions with Various Decontamination Treatments: An Analysis of 14 Years of TESS Data. Toxicon 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/27\">",
"      Floersheim GL. Treatment of human amatoxin mushroom poisoning. Myths and advances in therapy. Med Toxicol 1987; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/28\">",
"      K&ouml;ppel C. Clinical symptomatology and management of mushroom poisoning. Toxicon 1993; 31:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/29\">",
"      Piqueras J, Duran-Suarez JR, Massuet L, Hernandez-Sanchez JM. Mushroom poisoning: therapeutic apheresis or forced diuresis. Transfusion 1987; 27:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/30\">",
"      Vesconi S, Langer M, Iapichino G, et al. Therapy of cytotoxic mushroom intoxication. Crit Care Med 1985; 13:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/31\">",
"      Wauters JP, Rossel C, Farquet JJ. Amanita phalloides poisoning treated by early charcoal haemoperfusion. Br Med J 1978; 2:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/32\">",
"      Magdalan J, Ostrowska A, Piotrowska A, et al. Benzylpenicillin, acetylcysteine and silibinin as antidotes in human hepatocytes intoxicated with alpha-amanitin. Exp Toxicol Pathol 2010; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/33\">",
"      Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/34\">",
"      Mitchell, ST. New Comprehensive Amatoxin Mushroom Poisoning (AMP) Treatment Protocol. Clin Tox 2010; 48:628.",
"     </a>",
"    </li>",
"    <li>",
"     Manufacturer package insert file://sites.google.com/site/legalonsil/ (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/36\">",
"      Ganzert M, Felgenhauer N, Schuster T, et al. [Amanita poisoning--comparison of silibinin with a combination of silibinin and penicillin]. Dtsch Med Wochenschr 2008; 133:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/37\">",
"      Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/38\">",
"      Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/39\">",
"      Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/40\">",
"      Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006; 124:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/41\">",
"      Rainone F. Milk thistle. Am Fam Physician 2005; 72:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/42\">",
"      Desplaces A, Choppin J, Vogel G, Trost W. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 1975; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/43\">",
"      Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982; 17:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/44\">",
"      Magdalan J, Ostrowska A, Piotrowska A, et al. Failure of benzylpenicillin, N-acetylcysteine and silibinin to reduce alpha-amanitin hepatotoxicity. In Vivo 2009; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/45\">",
"      Floersheim GL, Eberhard M, Tschumi P, Duckert F. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharmacol 1978; 46:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/46\">",
"      Floersheim GL, Schneeberger J, Bucher K. Curative potencies of penicillin in experimental Amanita phalloides poisoning. Agents Actions 1971; 2:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/47\">",
"      Chang LM, Yun HS, Kim YS, Ahn JW. Aucubin: potential antidote for alpha-amanitin poisoning. J Toxicol Clin Toxicol 1984; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/48\">",
"      Chang IM. Liver-protective activities of aucubin derived from traditional oriental medicine. Res Commun Mol Pathol Pharmacol 1998; 102:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/49\">",
"      Ganzert M, Felgenhauer N, Zilker T. Indication of liver transplantation following amatoxin intoxication. J Hepatol 2005; 42:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/50\">",
"      Escudi&eacute; L, Francoz C, Vinel JP, et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol 2007; 46:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/51\">",
"      Faybik P, Hetz H, Baker A, et al. Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int 2003; 23 Suppl 3:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/52\">",
"      Covic A, Goldsmith DJ, Gusbeth-Tatomir P, et al. Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Int 2003; 23 Suppl 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/53\">",
"      Shi Y, He J, Chen S, et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning--a case report. Liver 2002; 22 Suppl 2:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/28/10698/abstract/54\">",
"      Faraj W, Dar F, Bartlett A, et al. Auxiliary liver transplantation for acute liver failure in children. Ann Surg 2010; 251:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13893 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10698=[""].join("\n");
var outline_f10_28_10698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26667478\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667326\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26038133\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11350766\">",
"      MUSHROOM APPEARANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667340\">",
"      PATHOPHYSIOLOGY AND TOXICOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667347\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H393811\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H393990\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26667354\">",
"      Amatoxin detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394028\">",
"      Mushroom identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667361\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H241672\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26667368\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394148\">",
"      Elimination enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2843563\">",
"      Amatoxin uptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H394132\">",
"      - Silibinin dihemisuccinate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H790516\">",
"      - Silymarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2843571\">",
"      - Penicillin G",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H241120\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2844065\">",
"      Antioxidant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H394155\">",
"      - N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2844099\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394357\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667418\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667425\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26667478\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13893|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/55/34675\" title=\"figure 1\">",
"      Anatomic features Amanita species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13893|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/16/8453\" title=\"picture 1\">",
"      Little brown mushrooms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/19/12592\" title=\"picture 2\">",
"      Nontoxic mushroom ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/63/7152\" title=\"picture 3\">",
"      Amanita phalloides-Death cap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/35/17974\" title=\"picture 4\">",
"      Amanita bisporigera-Destroying angel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/28/11727\" title=\"table 1\">",
"      Mushroom poisoning syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36759?source=related_link\">",
"      Amanita smithiana mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1786?source=related_link\">",
"      Clinical manifestations and evaluation of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42615?source=related_link\">",
"      Management of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=related_link\">",
"      Penicillin G (parenteral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_28_10699="Aerosol delivery ventilator";
var content_f10_28_10699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors affecting aerosol delivery during mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nebulizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Position of nebulizer placement in the circuit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type of nebulizer and fill volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duty cycle (I:E ratio)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilator brand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        MDI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type of actuator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timing of actuation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nebulizer and MDI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endotracheal tube size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humidification of the inspired gas",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10699=[""].join("\n");
var outline_f10_28_10699=null;
var title_f10_28_10700="Heart rate control of MAT in COPD";
var content_f10_28_10700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic agents for acute heart rate control in patients with multifocal atrial tachycardia and chronic obstructive pulmonary disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subsequent doses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maintenance dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Verapamil*",
"        <sup>",
"         &bull;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1 mg IV",
"       </td>",
"       <td>",
"        1 to 2 minutes",
"       </td>",
"       <td>",
"        4 mg over 5 minutes; then 5 mg over 5 minutes up to 3 additional doses",
"       </td>",
"       <td>",
"        120 to 480 mg daily",
"       </td>",
"       <td>",
"        Hypotension, heart block, heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoprolol",
"        <sup>",
"         &Delta;&bull;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        5 mg IV over 5 minutes",
"       </td>",
"       <td>",
"        5 minutes",
"       </td>",
"       <td>",
"        5 mg IV over 5 minutes at 10 minute intervals for 2 to 3 additional doses",
"       </td>",
"       <td>",
"        50 to 100 mg orally twice daily",
"       </td>",
"       <td>",
"        Hypotension, heart block, bradycardia, heart failure, bronchoconstriction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MAT: multifocal atrial tachycardia.",
"     <br/>",
"     * For all patients with COPD and MAT and a rapid ventricular response, correction of hypoxemia, acidosis, and other metabolic disturbances is recommended. Theophylline can increase the ventricular response, so dosing should be regulated to keep the serum level in the range of 8 to 12 mg/mL; discontinuation of the medication should be considered.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Verapamil is preferred over metoprolol for heart rate control of MAT in patients with COPD due to concerns about exacerbating bronchoconstriction.",
"     <br/>",
"     &Delta; Representative of the type of selective beta-1 blockers that could be used, but similar drugs could be given in appropriate doses.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Verapamil and beta blockers should not be given to patients with sinus node dysfunction or preexisting second- or third-degree block unless a temporary or permanent pacemaker has been implanted. Verapamil and beta blockers should be administered cautiously in patients with decompensated heart failure or hypotension to avoid worsening these conditions.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10700=[""].join("\n");
var outline_f10_28_10700=null;
var title_f10_28_10701="ACE inhibitor moderate HF";
var content_f10_28_10701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in moderate HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enalapril, compared to placebo, decreases patient mortality in NYHA class II and III heart failure (p = 0.0036).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SOLVD Investigators, N Engl J Med 1991; 325:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10701=[""].join("\n");
var outline_f10_28_10701=null;
var title_f10_28_10702="Approach to calcipenic rickets";
var content_f10_28_10702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to calcipenic (hypocalcemic) rickets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Calcipenic rickets is sometimes termed \"hypocalcemic rickets,\" but this term is not completely accurate because serum calcium is not always low in this disorder. Calcipenic rickets is most commonly caused by vitamin D deficiency. Calcipenic rickets also may be caused by a mixed deficiency of vitamin D and calcium.",
"    <div class=\"footnotes\">",
"     * Vitamin D dependent rickets type I (VDDR-I), also called pseudo-vitamin D deficiency, is caused by defective conversion of 25-hydroxyvitamin D to 1,25 dihydroxyvitamin D.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Hereditary vitamin D resistant rickets (HVDRR) has also been called vitamin D dependent rickets type II. It is a rare disorder characterized by end-organ resistance to vitamin D, usually caused by a defect in the vitamin D receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10702=[""].join("\n");
var outline_f10_28_10702=null;
var title_f10_28_10703="Pattern analysis";
var content_f10_28_10703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pattern analysis (modified)",
"    <sup>",
"     [1-6]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Global features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pattern",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pigment distribution/variant",
"       </td>",
"       <td class=\"subtitle2\">",
"        Diagnostic associations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Reticular pattern",
"        </strong>",
"       </td>",
"       <td>",
"        <ol>",
"         <li>",
"          Diffuse",
"         </li>",
"         <li>",
"          Patchy",
"         </li>",
"         <li>",
"          Central hyperpigmentation",
"         </li>",
"         <li>",
"          Central hypopigmentation",
"         </li>",
"         <li>",
"          Central globules",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        Acquired melanocytic nevus or congenital melanocytic nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Globular pattern",
"        </strong>",
"       </td>",
"       <td>",
"        Cobblestone pattern",
"       </td>",
"       <td>",
"        Usually congenital melanocytic nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Homogeneous pattern",
"        </strong>",
"       </td>",
"       <td>",
"        Gray-blue",
"       </td>",
"       <td>",
"        Blue nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown",
"       </td>",
"       <td>",
"        Usually congenital melanocytic nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tan-pink",
"       </td>",
"       <td>",
"        Nevi in fair skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Starburst pattern",
"        </strong>",
"       </td>",
"       <td>",
"        Peripheral globules",
"       </td>",
"       <td>",
"        Spitz/Reed nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Two component pattern",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Acquired of congenital melanocytic nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Multicomponent pattern",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Melanoma",
"        </p>",
"        <p>",
"         Congenital nevi or acquired dysplastic nevi",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Parallel pattern",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Nevi on volar skin",
"        </p>",
"        <p>",
"         Melanoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Non-specific pattern",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Melanoma must be ruled out",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Local features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle2\">",
"        Variants",
"       </td>",
"       <td class=\"subtitle2\">",
"        Diagnostic associations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Pigment network",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Typical",
"        </em>",
"        <br/>",
"        Light to dark-brown network with uniformly pigmented lines and hypopigmented holes. Network tends to fade at the periphery.",
"       </td>",
"       <td>",
"        Benign melanocytic lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Atypical",
"        </em>",
"        <br/>",
"        Increased variability in the width of the network lines, their color and distribution. The holes sizes also have increased variability. May end abruptly at the periphery.",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Dysplastic nevi",
"        </p>",
"        <p>",
"         Melanoma/Spitz",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Negative network",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Symmetrically located within the lesion.",
"       </td>",
"       <td>",
"        CMN, Spitz nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Diffuse throughout the lesion or focally located.",
"       </td>",
"       <td>",
"        Melanoma/Spitz",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Dots",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Located on top of the pigmented network or at the center of the lesion.",
"       </td>",
"       <td>",
"        Benign melanocytic lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Not associated with the pigmented network or located at the periphery of the lesion.",
"       </td>",
"       <td>",
"        Melanoma/Spitz",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Globules",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Multiple globules regularly distributed within the lesion or symmetrically located in the center or around the entire periphery.",
"       </td>",
"       <td>",
"        Benign melanocytic lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Multiple globules of different size, shape, and color. Asymmetrically and/or focally distributed within the lesion.",
"       </td>",
"       <td>",
"        Melanoma/Spitz",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Streaks",
"        </strong>",
"        (pseudopods and radial streaming)",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Radial projections at the periphery of the lesion, distributed around the entire perimeter of the lesion, extending from the tumor toward the surrounding normal skin.",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        Spitz/Reed nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Radial projections at the periphery of the lesion; irregularly, asymmetric and focally distributed.",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        Melanoma/Spitz",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Blue-white veil over papular areas",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Tend to be centrally located or homogeneous throughout the lesion.",
"       </td>",
"       <td>",
"        Blue nevi/Spitz",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Tends to be asymmetrically located or diffuse throughout the lesion, but with different hues.",
"       </td>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Regression structures",
"        </strong>",
"        (consists of granularity and scar-like areas. When both are present together, it gives the appearance of a blue-white veil over macular areas)",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Tend to be symmetrically located and cover less than 10 percent of the lesion.",
"       </td>",
"       <td>",
"        Nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Tends to be asymmetrically located and often involves more than 50 percent of the lesion.",
"       </td>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Hypopigmented areas",
"        </strong>",
"        (structureless/homogeneous)",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Centrally located with peripheral network.",
"       </td>",
"       <td>",
"        Nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Structureless light brown area, located at the periphery of the lesion, larger than 10 percent of a lesion",
"        <sup>",
"         [10]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Blotch",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        One blotch located in the center of the lesion.",
"       </td>",
"       <td>",
"        Acquired melanocytic nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Irregular",
"        </em>",
"        <br/>",
"        Asymmetrically and/or focally located at the periphery. Eccentric peripheral hyperpigmentation is often found in melanoma.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Vascular structures",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        <em>",
"         Regular",
"        </em>",
"        <br/>",
"        Comma vessels.",
"       </td>",
"       <td>",
"        <p>",
"         Dermal nevi",
"        </p>",
"        <p>",
"         Congenital melanocytic nevi",
"         <sup>",
"          [11]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <em>",
"          Irregular",
"         </em>",
"         <br/>",
"         Dotted vessels: over milky-red background suggests melanoma/Spitz. Over tan background suggest Clark nevi.",
"        </p>",
"        <p>",
"         Serpentine (linear irregular) vessels.",
"        </p>",
"        <p>",
"         Polymorphous vessels.",
"        </p>",
"        <p>",
"         Corkscrew vessels: usually seen in nodular melanoma, desmoplastic melanoma or melanoma metastases.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Melanoma/Spitz",
"        </p>",
"        <p>",
"         Dysplastic or Clark nevus",
"         <sup>",
"          [11,12]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Crystalline structures",
"        </strong>",
"        (also known as chrysalis or shiny white streaks)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Melanoma",
"         <sup>",
"          [13,14]",
"         </sup>",
"        </p>",
"        <p>",
"         Spitz nevi",
"         <sup>",
"          [13,14]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The presence of a given vessel morphology is not exclusive to a particular diagnosis. For example, dotted vessels can be seen in melanocytic tumors and also in nonmelanocytic lesions such as squamous cell carcinoma",
"     <sup>",
"      [12]",
"     </sup>",
"     , basal cell carcinoma",
"     <sup>",
"      [15]",
"     </sup>",
"     , porokeratosis",
"     <sup>",
"      [16]",
"     </sup>",
"     , or clear cell acanthoma",
"     <sup>",
"      [17]",
"     </sup>",
"     . Polymorphous vessels are commonly associated with melanoma, but they can also be seen in BCC",
"     <sup>",
"      [15]",
"     </sup>",
"     or stasis dermatitis.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571.",
"      </li>",
"      <li>",
"       Malvehy J, Puig S, Argenziano G, et al. Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. J Am Acad Dermatol 2007; 57:84.",
"      </li>",
"      <li>",
"       Argenziano G, Chimenti S, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"      </li>",
"      <li>",
"       Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol 2001; 137:1575.",
"      </li>",
"      <li>",
"       Marghoob AA, Korzenko AJ, Changchien L, et al. The beauty and the beast sign in dermoscopy. Dermatol Surg 2007; 33:1388.",
"      </li>",
"      <li>",
"       Salopek TG, Kopf AW, Stefanato CM, et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001; 19:337.",
"      </li>",
"      <li>",
"       Xu J, Stoecker WV, Krishnamurthy Y, et al. Analysis of globule types in malignant melanoma. Arch Dermatol 2009; 145:1245.",
"      </li>",
"      <li>",
"       Pizzichetta MA, Stanganelli I, Bono R, et al. Dermoscopic features of difficult melanoma. Dermatol Surg 2007; 33:91.",
"      </li>",
"      <li>",
"       Braun RP, Gaide O, Oliviero M, et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007; 157:907.",
"      </li>",
"      <li>",
"       Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759.",
"      </li>",
"      <li>",
"       Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.",
"      </li>",
"      <li>",
"       Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.",
"      </li>",
"      <li>",
"       Di Stefani A, Campbell TM, Malvehy J, et al. Shiny white streaks: An additional dermoscopic finding in melanomas viewed using contact polarised dermoscopy. Australas J Dermatol 2010; 51:295.",
"      </li>",
"      <li>",
"       Balagula Y, Braun RP, Rabinovitz HS, et al.The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2011. Epub ahead of print.",
"      </li>",
"      <li>",
"       Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67.",
"      </li>",
"      <li>",
"       Pizzichetta MA, Canzonieri V, Massone C, Soyer HP. Clinical and dermoscopic features of porokeratosis of Mibelli. Arch Dermatol 2009; 145:91.",
"      </li>",
"      <li>",
"       Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy: Part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_28_10703=[""].join("\n");
var outline_f10_28_10703=null;
